



PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS

Approved Formulary File Submission ID: 00025489

This formulary was updated on 10/23//2024. For more recent information or other questions, please contact Alterwood Advantage at 1-866-267-3144 (TTY users should call 711), 24 hours a day, 7 days a week, or visit www.AlterwoodAdvantage.com.

Alterwood Advantage Choice Plus (HMO) 2025 Formulary (List of Covered Drugs)

Alterwood Advantage Choice Plus

2025 Formulary

(List of Covered Drugs)

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN**

HPMS Approved Formulary File Submission ID 00025489

This formulary was updated on 10/23/2024. For more recent information or other questions, please contact Alterwood Advantage Member Service at 1-866-267-3144 (TTY users should call 711), 24 hours a day, 7 days a week, or visit www.AlterwoodAdvantage.com

Note to existing members: This Formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this Drug List (Formulary) refers to “we,” “us”, or “our,” it means Alterwood Advantage, Inc. When it refers to “plan” or “our plan,” it means Alterwood Advantage Choice Plus.

This document includes Drug List (formulary) for our plan which is current as of 10/23/2024. For an updated Drug List (formulary), please contact us. Our contact information, along with the date we last updated the Drug List (formulary), appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2025, and from time to time during the year.

What is the Alterwood Advantage Choice Plus formulary?

In this document, we use the terms Drug List and formulary to mean the same thing. A formulary is a list of covered drugs selected by Alterwood Advantage Choice Plus in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Alterwood Advantage Choice Plus will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a Alterwood Advantage Choice Plus network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

January 2025

H9306_25_DRS_001_002_OE_C

For a complete listing of all prescription drugs covered by Alterwood Advantage Choice Plus, please visit our website or call us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

Can the formulary change?

Most changes in drug coverage happen on January 1, but Alterwood Advantage Choice Plus may add or remove drugs on the formulary during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow the Medicare rules in making these changes. Updates to the formulary are posted monthly to our website here: www.AlterwoodAdvantage.com/find-a-medication/

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **Immediate substitutions of certain new versions of brand name drugs and original biological products.** We may immediately remove a drug from our formulary if we are replacing it with a certain new version of that drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. When we add a new version of a drug to our formulary, we may decide to keep the brand name drug or original biological product on our formulary, but immediately move it to a different cost-sharing tier or add new restrictions.

We can make these immediate changes only if we are adding a new generic version of a brand name drug, or adding certain new biosimilar versions of an original biological product, that was already on the formulary (for example, adding an interchangeable biosimilar that can be substituted for an original biological product by a pharmacy without a new prescription).

If you are currently taking the brand name drug or original biological product, we may not tell you in advance before we make an immediate change, but we will later provide you with information about the specific change(s) we have made.

If we make such a change, you or your prescriber can ask us to make an exception and continue to cover for you the drug that is being changed. For more information, see the section below titled “How do I request an exception to the Alterwood Advantage Choice Plus’s Formulary?”

Some of these drug types may be new to you. For more information, see the section below titled “What are original biological products and how are they related to biosimilars?”

- **Drugs removed from the market.** If a drug is withdrawn from sale by the manufacturer or the Food and Drug Administration (FDA) determines to be withdrawn for safety or effectiveness reasons, we may immediately remove the drug from our formulary and later provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a new generic drug to replace a brand-name drug currently on the formulary, or add a new biosimilar to replace an original biological product currently on the formulary, or add new restrictions or move a drug we are keeping on the formulary to a higher cost-sharing tier or both after we add a corresponding drug. We may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, we must notify affected members of the change at least 30 days before the change becomes effective. Alternatively, when a member requests a refill of the drug, they may receive a 30-day supply of the drug and notice of the change.

If we make these other changes, you or your prescriber can ask us to make an exception for you and continue to cover the drug you have been taking. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Alterwood Advantage Choice Plus’s Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2025 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2025 coverage year except as described above. This means these drugs will remain available at the same cost sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the formulary for the new benefit year for any changes to drugs.

The enclosed formulary is current as of 10/23/2024. To get updated information about the drugs covered by Alterwood Advantage Choice Plus please contact us. Our contact information appears on the front and back cover pages

How do I use the Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 14. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs

January 2025

H9306_25_DRS_001_002_OE_C

used to treat a heart condition are listed under the category, **CARDIOVASCULAR AGENTS**. If you know what your drug is used for, look for the category name in the list that begins on page 12. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 107. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Alterwood Advantage Choice Plus covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs work just as well as and usually cost less than brand name drugs. There are generic drug substitutes available for many brand name drugs. Generic drugs usually can be substituted for the brand name drug at the pharmacy without needing a new prescription, depending on state laws.

What are original biological products and how are they related to biosimilars?

On the formulary, when we refer to drugs, this could mean a drug or a biological product. Biological products are drugs that are more complex than typical drugs. Since biological products are more complex than typical drugs, instead of having a generic form, they have alternatives that are called biosimilars. Generally, biosimilars work just as well as the original biological product and may cost less. There are biosimilar alternatives for some original biological products. Some biosimilars are interchangeable biosimilars and, depending on state laws, may be substituted for the original biological product at the pharmacy without needing a new prescription, just like generic drugs can be substituted for brand name drugs.

- For discussion of drug types, please see the Evidence of Coverage, Chapter 5, Section 3.1, “The ‘Drug List’ tells which Part D drugs are covered.”

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** Alterwood Advantage Choice Plus requires you [or your prescriber] to get prior authorization for certain drugs. This means that you will need to get approval from Alterwood Advantage Choice Plus before you fill your prescriptions. If you don’t get approval, Alterwood Advantage Choice Plus may not cover the drug.

January 2025

H9306_25_DRS_001_002_OE_C

- **Quantity Limits:** For certain drugs, Alterwood Advantage Choice Plus limits the amount of the drug that Alterwood Advantage Choice Plus will cover. For example, Alterwood Advantage Choice Plus provides 90 tablets per prescription for *valsartan tablet 80mg*. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, Alterwood Advantage Choice Plus requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, Alterwood Advantage Choice Plus may not cover Drug B unless you try Drug A first. If Drug A does not work for you, Alterwood Advantage Choice Plus will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 14. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask Alterwood Advantage Choice Plus to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, “How do I request an exception to the Alterwood Advantage Choice Plus’s formulary?” on page 5 for information about how to request an exception.

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered.

If you learn that Alterwood Advantage Choice Plus does not cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that are covered by Alterwood Advantage Choice Plus. When you receive the list, show it to your doctor and ask them to prescribe a similar drug that is covered by Alterwood Advantage Choice Plus.
- You can ask Alterwood Advantage Choice Plus to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Alterwood Advantage Choice Plus’s Formulary?

You can ask Alterwood Advantage Choice Plus to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to waive a coverage restriction including prior authorization, step therapy, or a quantity limit on your drug. For example, for certain drugs, Alterwood Advantage Choice Plus limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.
- You can ask us to cover a formulary drug at a lower cost-sharing level. If approved, this would lower the amount you must pay for your drug.

Generally, Alterwood Advantage Choice Plus will only approve your request for an exception if the alternative drugs included on the plan's formulary, [the lower cost-sharing drug,] or applying the restriction would not be as effective for you and/or would cause you to have adverse effects.

You or your prescriber should contact us to ask for a tiering or formulary exception, including an exception to a coverage restriction. **When you request an exception, your prescriber will need to explain the medical reasons why you need the exception.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can ask for an expedited (fast) decision if you believe, and we agree, that your health could be seriously harmed by waiting up to 72 hours for a decision. If we agree, or if your prescriber asks for a fast decision, we must give you a decision no later than 24 hours after we get your prescriber's supporting statement.

What can I do if my drug is not on the formulary or has a restriction?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but has a coverage restriction, such as prior authorization. You should talk to your prescriber about requesting a coverage decision to show that you meet the criteria for approval, switching to an alternative drug that we cover, or requesting a formulary exception so that we will cover the drug you take. While you and your doctor determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or has a coverage restriction, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30-day supply of medication. If coverage is not approved, after your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

January 2025

H9306_25_DRS_001_002_OE_C

If you experience a level of care change such as a move from a hospital to a home setting or a move from a skilled nursing facility to a home setting, we may cover a one-time temporary supply of drug(s) not on our formulary when filled at a network pharmacy. This temporary one-time supply must be for up to a 30-day supply (or up to a 31-day supply if you reside in a long-term care facility).

You and your provider will receive a letter in the mail indicating that you have received a temporary supply. Please discuss with your provider the drugs listed in the Alterwood Advantage Choice Plus. You or your provider may request continuation of coverage for the temporary drug supply through the plan's exception process before you run out of medication(s).

For more information

For more detailed information about your Alterwood Advantage Choice Plus prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about Alterwood Advantage Choice Plus, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048. Or, visit <http://www.medicare.gov>.

Alterwood Advantage Choice Plus Formulary

The formulary provides coverage information about the drugs covered by Alterwood Advantage Choice Plus. If you have trouble finding your drug in the list, turn to the Index that begins on page 107.

The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., DIGITEK ORAL TABLET 125 MCG) and generic drugs are listed in lower-case italics (e.g., *digoxin oral tablet 125 mcg*).

The information in the Requirements/Limits column tells you if [*Insert <plan/sponsor name>*] has any special requirements for coverage of your drug.

You can find information on what the symbols and abbreviations on this table mean by going to page 11.

Important Message About What You Pay for Vaccines - Our plan covers most Part D vaccines at no cost to you, even if you haven't paid your deductible. Call Member Services for more information.

Important Message About What You Pay for Insulin - You won't pay more than \$35 for a one-month supply of each insulin product covered by our plan, no matter what cost-sharing tier it's on, even if you haven't paid your deductible.

Your 2025 **Alterwood Advantage Choice Plus** Part D copays, co-insurance, and the Alterwood Advantage Choice Plus formulary tiers are described below.

| Formulary Tier | Retail (up to a 30 day supply) | Retail (up to a 60 day supply) | Retail (up to a 90 day supply) | Mail Order (up to a 30 day supply) | Mail Order (up to a 60 day supply) | Mail Order (up to a 90 day supply) | Long-Term Care (LTC) (up to a 31 day supply) | Out-of-Network (up to a 10 day supply) |
|---|--------------------------------|--------------------------------|--------------------------------|------------------------------------|------------------------------------|------------------------------------|--|--|
| Tier 1 <i>Preferred Generic</i> | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| Tier 2 <i>Generic</i> | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| Tier 3 <i>Preferred Brand</i> | \$47 | \$94 | \$141 | \$47 | \$94 | \$141 | \$47 | \$47 |
| Tier 4 <i>Non-Preferred Drug</i> | \$100 | \$200 | \$300 | \$100 | \$200 | \$300 | \$100 | \$100 |
| Tier 5 <i>Specialty</i> | 33% | Not Covered | Not Covered | 33% | Not Covered | Not Covered | 33% | 33% |
| Tier 6 [^] <i>Generic Erectile Dysfunction (ED) Drugs</i> | \$10 | \$20 | \$30 | \$10 | \$20 | \$30 | \$10 | \$10 |

Note: LTC drugs greater than a 31-day supply and out-of-network (OON) drugs greater than a 10-day supply are not covered.

[^]This prescription drug is not normally covered in a Medicare Prescription Drug Plan. The amount you pay when you fill a prescription for this drug does not count towards your total drug costs (that is, the amount you pay does not help you qualify for catastrophic coverage). In addition, if you are receiving extra help to pay for your prescriptions, you will not get any extra help to pay for this drug. Coverage is limited to generic ED drugs. There is also a quality limit of four (4) units every 30 days.

If you receive “Extra Help,” your copay will vary by the type of drug and the allowed days supply will vary depending on where you get your medication(s). Please refer to your Evidence of Coverage for more information regarding your copay and network pharmacy

The following abbreviations can be found in the Alterwood Advantage Choice Plus formulary:

| Abbreviation/Symbol | Definition |
|---------------------|---|
| PA BvD | Part B vs. Part D - This prescription drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination. |
| PA | Prior Authorization - You (or your physician) are required to get prior authorization before you fill your prescription for this drug. Without prior approval, we may not cover this drug. |
| PA NSO | A member new to drug therapy. The first time a member has taken a specific drug with utilization management (UM). You (or your physician) are required to get prior authorization before you fill your prescription for this drug. Without prior approval, we may not cover this drug. |
| QL | Quantity Limit - There is a limit on the amount of this drug that is covered per prescription, or within a specific time frame. |
| ST | Step Therapy - In some cases, you may be required to first try certain drugs to treat your medical condition before we will cover another drug for that condition. |
| EX | Excluded Drug - This prescription drug is not normally covered in a Medicare Prescription Drug Plan and is considered enhanced coverage. The amount you pay when you fill a prescription for this drug does not count toward your total drug costs (that is, the amount you pay does not help you qualify for catastrophic coverage). In addition, if you are receiving extra help to pay for your prescriptions, you will not get any extra help to pay for this drug. Quantity limits apply and this drug will not be covered during the gap period per individual plan design. |
| NDS | Plans can elect to limit specific drugs to a 30 day supply. |

**2025 Alterwood Advantage Choice Plus Formulary
(List of Covered Drugs)**

List of Drugs by Medical Condition

| | |
|--|----|
| ANALGESICS | 14 |
| ANESTHETICS | 16 |
| ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS | 16 |
| ANTI-ANXIETY AGENTS | 17 |
| ANTIBACTERIALS | 18 |
| ANTICANCER AGENTS | 23 |
| ANTICONVULSANTS | 35 |
| ANTIDEMENTIA AGENTS | 39 |
| ANTIDEPRESSANTS | 39 |
| ANTIDIABETIC AGENTS | 42 |
| ANTIFUNGALS | 45 |
| ANTIGOUT AGENTS | 47 |
| ANTIHISTAMINES | 47 |
| ANTI-INFECTIVES (SKIN AND MUCOUS MEMBRANE) | 47 |
| ANTIMIGRAINE AGENTS | 47 |
| ANTIMYCOBACTERIALS | 48 |
| ANTINAUSEA AGENTS | 49 |
| ANTIPARASITE AGENTS | 49 |
| ANTIPARKINSONIAN AGENTS | 50 |
| ANTIPSYCHOTIC AGENTS | 51 |
| ANTIVIRALS (SYSTEMIC) | 55 |
| BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS | 60 |
| CALORIC AGENTS | 62 |
| CARDIOVASCULAR AGENTS | 62 |
| CENTRAL NERVOUS SYSTEM AGENTS | 69 |
| CONTRACEPTIVES | 72 |
| DENTAL AND ORAL AGENTS | 77 |

| | |
|---|-----|
| DERMATOLOGICAL AGENTS | 77 |
| DEVICES | 80 |
| ENZYME COFACTORS/CHAPERONES | 81 |
| ENZYME REPLACEMENT/MODIFIERS | 81 |
| EYE, EAR, NOSE, THROAT AGENTS | 81 |
| GASTROINTESTINAL AGENTS | 84 |
| GENITOURINARY AGENTS | 86 |
| HEAVY METAL ANTAGONISTS | 87 |
| HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING | 87 |
| IMMUNOLOGICAL AGENTS | 90 |
| INFLAMMATORY BOWEL DISEASE AGENTS | 98 |
| METABOLIC BONE DISEASE AGENTS | 98 |
| MISCELLANEOUS THERAPEUTIC AGENTS | 99 |
| OPHTHALMIC AGENTS | 100 |
| REPLACEMENT PREPARATIONS | 101 |
| RESPIRATORY TRACT AGENTS | 101 |
| SKELETAL MUSCLE RELAXANTS | 104 |
| SLEEP DISORDER AGENTS | 105 |
| VASODILATING AGENTS | 105 |
| VITAMINS AND MINERALS | 106 |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| ANALGESICS | | |
| <i>Analgesics, Miscellaneous</i> | | |
| <i>acetaminophen-codeine oral solution 120-12 mg/5ml</i> | 1 | QL (4500 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg</i> | 2 | QL (360 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i> | 2 | QL (180 per 30 days) |
| <i>buprenorphine transdermal patch weekly 10 mcg/hr, 15 mcg/hr, 20 mcg/hr, 5 mcg/hr, 7.5 mcg/hr</i> | 2 | QL (4 per 28 days) |
| <i>butalbital-apap-caff-cod oral capsule 50-325-40-30 mg</i> | 2 | QL (180 per 30 days) |
| <i>butalbital-apap-caffeine oral capsule 50-300-40 mg, 50-325-40 mg</i> | 4 | QL (180 per 30 days) |
| <i>butalbital-apap-caffeine oral tablet 50-325-40 mg</i> | 2 | QL (180 per 30 days) |
| <i>endocet oral tablet 10-325 mg</i> | 2 | QL (180 per 30 days) |
| <i>endocet oral tablet 2.5-325 mg, 5-325 mg</i> | 2 | QL (360 per 30 days) |
| <i>endocet oral tablet 7.5-325 mg</i> | 2 | QL (240 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1200 mcg, 1600 mcg, 400 mcg, 600 mcg, 800 mcg</i> | 5 | PA; NDS; QL (120 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg</i> | 2 | PA; QL (120 per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | 2 | QL (10 per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 10-325 mg/15ml, 7.5-325 mg/15ml</i> | 2 | QL (2700 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 7.5-325 mg</i> | 2 | QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 5-325 mg</i> | 2 | QL (240 per 30 days) |
| <i>hydromorphone hcl oral tablet 2 mg, 4 mg, 8 mg</i> | 2 | QL (180 per 30 days) |
| <i>methadone hcl oral tablet 10 mg</i> | 2 | QL (120 per 30 days) |
| <i>methadone hcl oral tablet 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>morphine sulfate (concentrate) oral solution 100 mg/5ml</i> | 2 | PA; QL (180 per 30 days) |
| <i>morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg</i> | 2 | QL (60 per 30 days) |
| <i>morphine sulfate er oral tablet extended release 15 mg, 30 mg</i> | 2 | QL (90 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| MORPHINE SULFATE ORAL SOLUTION 10 MG/5ML | 2 | QL (700 per 30 days) |
| MORPHINE SULFATE ORAL SOLUTION 20 MG/5ML | 2 | QL (300 per 30 days) |
| MORPHINE SULFATE ORAL TABLET 15 MG | 4 | QL (180 per 30 days) |
| MORPHINE SULFATE ORAL TABLET 30 MG | 4 | QL (120 per 30 days) |
| <i>oxycodone hcl oral capsule 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>oxycodone hcl oral tablet 10 mg, 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>oxycodone hcl oral tablet 15 mg, 20 mg, 30 mg</i> | 2 | QL (120 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i> | 2 | QL (180 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg</i> | 2 | QL (360 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 7.5-325 mg</i> | 2 | QL (240 per 30 days) |
| <i>tramadol hcl oral tablet 50 mg</i> | 1 | QL (240 per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 2 | QL (300 per 30 days) |
| <i>Nonsteroidal Anti-Inflammatory Agents</i> | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> | 2 | QL (60 per 30 days) |
| <i>diclofenac potassium oral tablet 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium er oral tablet extended release 24 hour 100 mg</i> | 2 | |
| <i>diclofenac sodium external gel 1 %</i> | 2 | QL (1000 per 30 days) |
| <i>diclofenac sodium external solution 1.5 %</i> | 2 | QL (300 per 30 days) |
| <i>diclofenac sodium external solution 2 %</i> | 5 | PA; NDS; QL (224 per 28 days) |
| <i>diclofenac sodium oral tablet delayed release 25 mg</i> | 2 | |
| <i>diclofenac sodium oral tablet delayed release 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet delayed release 75 mg</i> | 2 | QL (60 per 30 days) |
| <i>diclofenac-misoprostol oral tablet delayed release 50-0.2 mg, 75-0.2 mg</i> | 2 | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 2 | |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | 2 | |
| <i>flurbiprofen oral tablet 100 mg</i> | 2 | |
| FLURBIPROFEN ORAL TABLET 50 MG | 2 | |
| <i>ibu oral tablet 400 mg</i> | 1 | QL (240 per 30 days) |
| <i>ibu oral tablet 600 mg, 800 mg</i> | 1 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ibuprofen oral tablet 400 mg</i> | 1 | QL (240 per 30 days) |
| <i>ibuprofen oral tablet 600 mg, 800 mg</i> | 1 | |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | 2 | |
| <i>ketorolac tromethamine oral tablet 10 mg</i> | 2 | QL (20 per 30 days) |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 1 | |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | 1 | |
| <i>naproxen oral tablet delayed release 375 mg</i> | 2 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 2 | |
| ANESTHETICS | | |
| Local Anesthetics | | |
| <i>glydo external prefilled syringe 2 %</i> | 2 | QL (30 per 30 days) |
| <i>lidocaine external ointment 5 %</i> | 2 | PA; QL (240 per 30 days) |
| <i>lidocaine external patch 5 %</i> | 2 | PA; QL (90 per 30 days) |
| <i>lidocaine hcl urethral/mucosal external prefilled syringe 2 %</i> | 2 | QL (30 per 30 days) |
| <i>lidocaine viscous hcl mouth/throat solution 2 %</i> | 2 | |
| <i>lidocaine-prilocaine external cream 2.5-2.5 %</i> | 2 | PA; QL (30 per 30 days) |
| <i>lidocan external patch 5 %</i> | 2 | PA; QL (90 per 30 days) |
| ZTLIDO EXTERNAL PATCH 1.8 % | 3 | PA; QL (90 per 30 days) |
| ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS | | |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| <i>acamprosate calcium oral tablet delayed release 333 mg</i> | 2 | |
| <i>buprenorphine hcl sublingual tablet sublingual 2 mg, 8 mg</i> | 2 | QL (90 per 30 days) |
| <i>buprenorphine hcl-naloxone hcl sublingual film 12-3 mg</i> | 4 | QL (60 per 30 days) |
| <i>buprenorphine hcl-naloxone hcl sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg</i> | 4 | QL (90 per 30 days) |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg, 8-2 mg</i> | 2 | QL (90 per 30 days) |
| <i>bupropion hcl er (smoking det) oral tablet extended release 12 hour 150 mg</i> | 2 | |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------|
| KLOXXADO NASAL LIQUID 8 MG/0.1ML | 3 | QL (4 per 30 days) |
| <i>naloxone hcl injection solution 0.4 mg/ml, 4 mg/10ml</i> | 2 | |
| <i>naloxone hcl injection solution cartridge 0.4 mg/ml</i> | 2 | |
| <i>naloxone hcl injection solution prefilled syringe 0.4 mg/ml, 2 mg/2ml</i> | 2 | |
| <i>naloxone hcl nasal liquid 4 mg/0.1ml</i> | 2 | QL (4 per 30 days) |
| <i>naltrexone hcl oral tablet 50 mg</i> | 2 | |
| NICOTROL NS NASAL SOLUTION 10 MG/ML | 4 | QL (240 per 180 days) |
| <i>varenicline tartrate (starter) oral tablet therapy pack 0.5 mg x 11 & 1 mg x 42</i> | 2 | |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg (56 pack)</i> | 2 | QL (336 per 365 days) |
| VARENICLINE TARTRATE ORAL TABLET 1 MG | 2 | QL (336 per 365 days) |

ANTI-ANXIETY AGENTS

Benzodiazepines

| | | |
|---|---|-----------------------|
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg</i> | 1 | QL (120 per 30 days) |
| <i>alprazolam oral tablet 2 mg</i> | 1 | QL (150 per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 1 | QL (120 per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> | 1 | QL (90 per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> | 1 | QL (300 per 30 days) |
| <i>clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 2 | QL (90 per 30 days) |
| <i>clonazepam oral tablet dispersible 2 mg</i> | 2 | QL (300 per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 4 | QL (180 per 30 days) |
| <i>diazepam injection solution 5 mg/ml</i> | 2 | QL (10 per 28 days) |
| <i>diazepam intensol oral concentrate 5 mg/ml</i> | 2 | QL (1200 per 30 days) |
| <i>diazepam oral solution 5 mg/5ml</i> | 2 | QL (1200 per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> | 1 | QL (120 per 30 days) |
| <i>lorazepam injection solution 2 mg/ml</i> | 1 | QL (2 per 30 days) |
| <i>lorazepam injection solution 4 mg/ml</i> | 4 | QL (2 per 30 days) |
| <i>lorazepam intensol oral concentrate 2 mg/ml</i> | 2 | QL (150 per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> | 1 | QL (90 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| <i>lorazepam oral tablet 2 mg</i> | 1 | QL (150 per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> | 1 | QL (30 per 30 days) |
| <i>temazepam oral capsule 22.5 mg</i> | 2 | QL (30 per 30 days) |
| <i>temazepam oral capsule 7.5 mg</i> | 2 | QL (120 per 30 days) |
| <i>triazolam oral tablet 0.125 mg</i> | 2 | QL (120 per 30 days) |
| <i>triazolam oral tablet 0.25 mg</i> | 2 | QL (60 per 30 days) |
| ANTIBACTERIALS | | |
| Aminoglycosides | | |
| <i>amikacin sulfate injection solution 500 mg/2ml</i> | 2 | |
| ARIKAYCE INHALATION SUSPENSION 590 MG/8.4ML | 5 | PA; NDS; QL (235.2 per 28 days) |
| <i>gentamicin sulfate injection solution 10 mg/ml, 40 mg/ml</i> | 2 | |
| <i>neomycin sulfate oral tablet 500 mg</i> | 2 | |
| <i>streptomycin sulfate intramuscular solution reconstituted 1 gm</i> | 5 | NDS |
| TOBI PODHALER INHALATION CAPSULE 28 MG | 5 | NDS; QL (224 per 28 days) |
| <i>tobramycin inhalation nebulization solution 300 mg/5ml</i> | 5 | PA BvD; NDS |
| <i>tobramycin pak inhalation nebulization solution 300 mg/5ml</i> | 5 | PA BvD; NDS |
| <i>tobramycin sulfate injection solution 10 mg/ml, 80 mg/2ml</i> | 2 | |
| Antibacterials, Miscellaneous | | |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i> | 2 | |
| <i>clindamycin phosphate injection solution 300 mg/2ml, 600 mg/4ml, 900 mg/6ml, 9000 mg/60ml</i> | 2 | |
| <i>colistimethate sodium (cba) injection solution reconstituted 150 mg</i> | 5 | NDS |
| DAPTOMYCIN INTRAVENOUS SOLUTION RECONSTITUTED 350 MG | 5 | NDS |
| <i>daptomycin intravenous solution reconstituted 500 mg</i> | 5 | NDS |
| <i>linezolid intravenous solution 600 mg/300ml</i> | 2 | |
| <i>linezolid oral suspension reconstituted 100 mg/5ml</i> | 5 | NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>linezolid oral tablet 600 mg</i> | 2 | |
| <i>methenamine hippurate oral tablet 1 gm</i> | 2 | |
| <i>metronidazole intravenous solution 500 mg/100ml</i> | 2 | |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>nitrofurantoin monohyd macro oral capsule 100 mg</i> | 2 | QL (60 per 30 days) |
| <i>trimethoprim oral tablet 100 mg</i> | 2 | |
| <i>vancomycin hcl intravenous solution reconstituted 1 gm, 10 gm, 5 gm, 500 mg, 750 mg</i> | 2 | |
| VANCOMYCIN HCL INTRAVENOUS SOLUTION RECONSTITUTED 1.25 GM | 2 | |
| <i>vancomycin hcl oral capsule 125 mg</i> | 2 | QL (56 per 14 days) |
| <i>vancomycin hcl oral capsule 250 mg</i> | 2 | QL (112 per 14 days) |
| XIFAXAN ORAL TABLET 200 MG | 3 | PA; QL (9 per 30 days) |
| XIFAXAN ORAL TABLET 550 MG | 5 | PA; NDS; QL (90 per 30 days) |
| <i>Cephalosporins</i> | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>cefadroxil oral capsule 500 mg</i> | 2 | |
| <i>cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml</i> | 2 | |
| <i>cefazolin sodium injection solution reconstituted 1 gm, 10 gm, 500 mg</i> | 2 | |
| <i>cefdinir oral capsule 300 mg</i> | 2 | |
| <i>cefdinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | |
| <i>cefepime hcl injection solution reconstituted 1 gm</i> | 2 | |
| <i>cefepime hcl intravenous solution reconstituted 2 gm</i> | 2 | |
| <i>cefixime oral capsule 400 mg</i> | 4 | |
| <i>cefoxitin sodium intravenous solution reconstituted 1 gm, 10 gm, 2 gm</i> | 2 | |
| <i>cefpodoxime proxetil oral tablet 100 mg, 200 mg</i> | 4 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>ceftazidime injection solution reconstituted 1 gm, 6 gm</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>ceftazidime intravenous solution reconstituted 2 gm</i> | 2 | |
| <i>ceftriaxone sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mg</i> | 2 | |
| <i>ceftriaxone sodium intravenous solution reconstituted 10 gm</i> | 2 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime sodium injection solution reconstituted 750 mg</i> | 2 | |
| <i>cefuroxime sodium intravenous solution reconstituted 1.5 gm</i> | 2 | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>cephalexin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | |
| <i>tazicef injection solution reconstituted 1 gm</i> | 2 | |
| <i>tazicef intravenous solution reconstituted 2 gm</i> | 2 | |
| TAZICEF INTRAVENOUS SOLUTION RECONSTITUTED 6 GM | 2 | |
| TEFLARO INTRAVENOUS SOLUTION RECONSTITUTED 400 MG, 600 MG | 5 | NDS |
| Macrolides | | |
| <i>azithromycin intravenous solution reconstituted 500 mg</i> | 2 | |
| <i>azithromycin oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | 2 | |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack), 500 mg, 500 mg (3 pack), 600 mg</i> | 1 | |
| <i>clarithromycin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| DIFICID ORAL TABLET 200 MG | 5 | NDS; QL (20 per 10 days) |
| <i>erythromycin base oral tablet 250 mg, 500 mg</i> | 4 | |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 200 mg/5ml, 400 mg/5ml</i> | 4 | |
| Miscellaneous B-Lactam Antibiotics | | |
| <i>aztreonam injection solution reconstituted 1 gm, 2 gm</i> | 2 | |
| CAYSTON INHALATION SOLUTION RECONSTITUTED 75 MG | 5 | PA; NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ertapenem sodium injection solution reconstituted 1 gm</i> | 2 | |
| <i>imipenem-cilastatin intravenous solution reconstituted 250 mg, 500 mg</i> | 2 | |
| <i>meropenem intravenous solution reconstituted 1 gm, 500 mg</i> | 2 | |
| Penicillins | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>amoxicillin oral suspension reconstituted 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml</i> | 1 | |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | |
| <i>amoxicillin oral tablet chewable 125 mg, 250 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml, 600-42.9 mg/5ml</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet chewable 200-28.5 mg, 400-57 mg</i> | 4 | |
| <i>ampicillin oral capsule 500 mg</i> | 2 | |
| <i>ampicillin sodium injection solution reconstituted 1 gm, 125 mg</i> | 2 | |
| <i>ampicillin sodium intravenous solution reconstituted 10 gm</i> | 2 | |
| <i>ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm</i> | 2 | |
| <i>ampicillin-sulbactam sodium intravenous solution reconstituted 15 (10-5) gm</i> | 2 | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1200000 UNIT/2ML, 2400000 UNIT/4ML, 600000 UNIT/ML | 4 | |
| <i>dicloxacillin sodium oral capsule 250 mg, 500 mg</i> | 2 | |
| EXTENCILLINE INTRAMUSCULAR SUSPENSION RECONSTITUTED 1200000 UNIT, 2400000 UNIT | 4 | |
| LENTOCILIN INTRAMUSCULAR SUSPENSION RECONSTITUTED 1200000 UNIT | 4 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>nafcillin sodium injection solution reconstituted 1 gm, 2 gm</i> | 2 | |
| <i>nafcillin sodium intravenous solution reconstituted 10 gm</i> | 2 | |
| <i>penicillin g potassium injection solution reconstituted 20000000 unit</i> | 2 | |
| <i>penicillin g procaine intramuscular suspension 600000 unit/ml</i> | 2 | |
| <i>penicillin v potassium oral solution reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>piperacillin sod-tazobactam so intravenous solution reconstituted 2.25 (2-0.25) gm, 3.375 (3-0.375) gm, 4.5 (4-0.5) gm, 40.5 (36-4.5) gm</i> | 2 | |
| Quinolones | | |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>ciprofloxacin in d5w intravenous solution 200 mg/100ml, 400 mg/200ml</i> | 2 | |
| <i>levofloxacin in d5w intravenous solution 250 mg/50ml, 500 mg/100ml, 750 mg/150ml</i> | 2 | |
| <i>levofloxacin oral solution 25 mg/ml</i> | 4 | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| MOXIFLOXACIN HCL IN NAACL INTRAVENOUS SOLUTION 400 MG/250ML | 2 | |
| <i>moxifloxacin hcl oral tablet 400 mg</i> | 2 | |
| Sulfonamides | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 2 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5ml</i> | 2 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | 1 | |
| Tetracyclines | | |
| <i>demeclocycline hcl oral tablet 150 mg, 300 mg</i> | 4 | |
| <i>doxy 100 intravenous solution reconstituted 100 mg</i> | 2 | |
| <i>doxycycline hyclate intravenous solution reconstituted 100 mg</i> | 2 | |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction. 2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>doxycycline hyclate oral tablet 100 mg, 150 mg, 20 mg, 50 mg, 75 mg</i> | 2 | |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | 2 | |
| <i>doxycycline monohydrate oral capsule 150 mg, 75 mg</i> | 2 | QL (60 per 30 days) |
| <i>doxycycline monohydrate oral suspension reconstituted 25 mg/5ml</i> | 2 | |
| <i>doxycycline monohydrate oral tablet 100 mg, 50 mg</i> | 2 | |
| <i>minocycline hcl oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | |
| <i>tetracycline hcl oral capsule 250 mg, 500 mg</i> | 4 | |
| TIGECYCLINE INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | 5 | NDS |

ANTICANCER AGENTS

Anticancer Agents

| | | |
|---|---|-----------------------------------|
| <i>abiraterone acetate oral tablet 250 mg, 500 mg</i> | 5 | PA NSO; NDS; QL (120 per 30 days) |
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180 MG | 5 | PA NSO; NDS |
| <i>anastrozole oral tablet 1 mg</i> | 1 | |
| ANKTIVA INTRAVESICAL SOLUTION 400 MCG/0.4ML | 5 | PA NSO; NDS; QL (1.6 per 28 days) |
| AUGTYRO ORAL CAPSULE 160 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| AUGTYRO ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>azacitidine injection suspension reconstituted 100 mg</i> | 5 | NDS |
| BALVERSA ORAL TABLET 3 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| BALVERSA ORAL TABLET 4 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| BALVERSA ORAL TABLET 5 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| BENDAMUSTINE HCL INTRAVENOUS SOLUTION 100 MG/4ML | 5 | PA NSO; NDS |
| <i>bendamustine hcl intravenous solution reconstituted 100 mg, 25 mg</i> | 5 | PA NSO; NDS |
| BENDEKA INTRAVENOUS SOLUTION 100 MG/4ML | 5 | PA NSO; NDS |
| <i>bexarotene external gel 1 %</i> | 5 | PA NSO; NDS |
| <i>bexarotene oral capsule 75 mg</i> | 5 | PA NSO; NDS |
| <i>bicalutamide oral tablet 50 mg</i> | 2 | |
| <i>bleomycin sulfate injection solution reconstituted 15 unit, 30 unit</i> | 2 | |
| <i>bortezomib injection solution reconstituted 1 mg, 2.5 mg, 3.5 mg</i> | 4 | PA NSO |
| BORUZU INJECTION SOLUTION 3.5 MG/1.4ML | 4 | PA NSO |
| BOSULIF ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| BOSULIF ORAL CAPSULE 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| BOSULIF ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 60 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| CABOMETYX ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CALQUENCE ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CALQUENCE ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 300 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG | 5 | PA NSO; NDS |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG | 5 | PA NSO; NDS; QL (112 per 28 days) |
| COMETRIQ (60 MG DAILY DOSE) ORAL KIT 20 MG | 5 | PA NSO; NDS |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| COTELLIC ORAL TABLET 20 MG | 5 | PA NSO; NDS; QL (63 per 28 days) |
| <i>cyclophosphamide injection solution reconstituted 1 gm, 2 gm, 500 mg</i> | 5 | PA BvD; NDS |
| <i>cyclophosphamide intravenous solution 1 gm/2ml, 2 gm/4ml</i> | 5 | PA BvD; NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| CYCLOPHOSPHAMIDE INTRAVENOUS SOLUTION 1 GM/5ML, 500 MG/2.5ML, 500 MG/5ML, 500 MG/ML | 5 | PA BvD; NDS |
| CYCLOPHOSPHAMIDE ORAL CAPSULE 25 MG | 2 | PA BvD; ST |
| <i>cyclophosphamide oral capsule 50 mg</i> | 2 | PA BvD; ST |
| <i>cyclophosphamide oral tablet 25 mg</i> | 3 | PA BvD; ST |
| CYCLOPHOSPHAMIDE ORAL TABLET 50 MG | 3 | PA BvD; ST |
| DANYELZA INTRAVENOUS SOLUTION 40 MG/10ML | 5 | PA NSO; NDS; QL (120 per 28 days) |
| DANZITEN ORAL TABLET 71 MG, 95 MG | 5 | PA NSO; NDS; QL (112 per 28 days) |
| <i>dasatinib oral tablet 100 mg, 140 mg, 50 mg, 70 mg, 80 mg</i> | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>dasatinib oral tablet 20 mg</i> | 5 | PA NSO; NDS; QL (90 per 30 days) |
| DAURISMO ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| DAURISMO ORAL TABLET 25 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>decitabine intravenous solution reconstituted 50 mg</i> | 5 | NDS |
| <i>doxorubicin hcl liposomal intravenous suspension 2 mg/ml</i> | 5 | PA BvD; NDS |
| ELIGARD SUBCUTANEOUS KIT 22.5 MG, 30 MG, 45 MG, 7.5 MG | 4 | PA NSO |
| ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML | 5 | PA NSO; NDS |
| ELREXFIO SUBCUTANEOUS SOLUTION 76 MG/1.9ML | 5 | PA NSO; NDS; QL (9.5 per 28 days) |
| EMCYT ORAL CAPSULE 140 MG | 5 | NDS |
| EPKINLY SUBCUTANEOUS SOLUTION 4 MG/0.8ML, 48 MG/0.8ML | 5 | PA NSO; NDS |
| ERBITUX INTRAVENOUS SOLUTION 100 MG/50ML, 200 MG/100ML | 5 | PA NSO; NDS |
| ERIVEDGE ORAL CAPSULE 150 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| ERLEADA ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| <i>erlotinib hcl oral tablet 100 mg, 25 mg</i> | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>erlotinib hcl oral tablet 150 mg</i> | 5 | PA NSO; NDS; QL (90 per 30 days) |
| ETOPOPHOS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 4 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>etoposide intravenous solution 100 mg/5ml</i> | 2 | |
| <i>everolimus oral tablet 10 mg</i> | 5 | PA NSO; NDS; QL (56 per 28 days) |
| <i>everolimus oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | 5 | PA NSO; NDS; QL (28 per 28 days) |
| <i>everolimus oral tablet soluble 2 mg, 3 mg, 5 mg</i> | 5 | PA NSO; NDS; QL (112 per 28 days) |
| <i>exemestane oral tablet 25 mg</i> | 2 | |
| EXKIVITY ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| FIRMAGON (240 MG DOSE) SUBCUTANEOUS SOLUTION RECONSTITUTED 120 MG/VIAL | 5 | PA BvD; NDS |
| FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG | 3 | PA BvD |
| <i>floxuridine injection solution reconstituted 0.5 gm</i> | 2 | PA BvD |
| <i>fluorouracil intravenous solution 1 gm/20ml, 5 gm/100ml, 500 mg/10ml</i> | 2 | PA BvD |
| FLUTAMIDE ORAL CAPSULE 125 MG | 2 | |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| FRUZAQLA ORAL CAPSULE 5 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| <i>fulvestrant intramuscular solution prefilled syringe 250 mg/5ml</i> | 5 | NDS |
| FYARRO INTRAVENOUS SUSPENSION RECONSTITUTED 100 MG | 5 | PA NSO; NDS |
| GAVRETO ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> | 5 | PA NSO; NDS; QL (60 per 30 days) |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| GLEOSTINE ORAL CAPSULE 10 MG | 4 | |
| GLEOSTINE ORAL CAPSULE 100 MG, 40 MG | 5 | NDS |
| HERCEPTIN HYLECTA SUBCUTANEOUS SOLUTION 600-10000 MG-UNT/5ML | 5 | PA NSO; NDS; QL (5 per 21 days) |
| HERZUMA INTRAVENOUS SOLUTION RECONSTITUTED 150 MG, 420 MG | 5 | PA NSO; NDS |
| <i>hydroxyurea oral capsule 500 mg</i> | 2 | |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| IDHIFA ORAL TABLET 100 MG, 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>ifosfamide intravenous solution 1 gm/20ml, 3 gm/60ml</i> | 2 | |
| <i>ifosfamide intravenous solution reconstituted 1 gm</i> | 2 | |
| <i>imatinib mesylate oral tablet 100 mg</i> | 2 | PA NSO; QL (180 per 30 days) |
| <i>imatinib mesylate oral tablet 400 mg</i> | 2 | PA NSO; QL (60 per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML | 5 | PA NSO; NDS; QL (216 per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG, 560 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| IMDELLTRA INTRAVENOUS SOLUTION RECONSTITUTED 1 MG, 10 MG | 5 | PA NSO; NDS |
| IMJUDO INTRAVENOUS SOLUTION 25 MG/1.25ML, 300 MG/15ML | 5 | PA NSO; NDS |
| INLYTA ORAL TABLET 1 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| INLYTA ORAL TABLET 5 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| INQOVI ORAL TABLET 35-100 MG | 5 | PA NSO; NDS; QL (5 per 28 days) |
| INREBIC ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ITOVEBI ORAL TABLET 3 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| ITOVEBI ORAL TABLET 9 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| IWILFIN ORAL TABLET 192 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| JEMPERLI INTRAVENOUS SOLUTION 500 MG/10ML | 5 | PA NSO; NDS |
| JYLAMVO ORAL SOLUTION 2 MG/ML | 4 | PA BvD; ST |
| KEYTRUDA INTRAVENOUS SOLUTION 100 MG/4ML | 5 | PA NSO; NDS |
| KIMMTRAK INTRAVENOUS SOLUTION 100 MCG/0.5ML | 5 | PA NSO; NDS; QL (2 per 28 days) |
| KISQALI (200 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| KISQALI (400 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA NSO; NDS; QL (42 per 28 days) |
| KISQALI (600 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA NSO; NDS; QL (63 per 28 days) |
| KISQALI FEMARA (200 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA NSO; NDS; QL (49 per 28 days) |
| KISQALI FEMARA (400 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA NSO; NDS; QL (70 per 28 days) |
| KISQALI FEMARA (600 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA NSO; NDS; QL (91 per 28 days) |
| KOSELUGO ORAL CAPSULE 10 MG | 5 | PA NSO; NDS; QL (300 per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| KRAZATI ORAL TABLET 200 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>lapatinib ditosylate oral tablet 250 mg</i> | 5 | PA NSO; NDS |
| LAZCLUZE ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| LAZCLUZE ORAL TABLET 80 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i> | 5 | PA NSO; NDS; QL (28 per 28 days) |
| LENVIMA (10 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG | 5 | PA NSO; NDS |
| LENVIMA (12 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4 MG | 5 | PA NSO; NDS |
| LENVIMA (14 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4 MG | 5 | PA NSO; NDS |
| LENVIMA (18 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG & 2 X 4 MG | 5 | PA NSO; NDS |
| LENVIMA (20 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG | 5 | PA NSO; NDS |
| LENVIMA (24 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG & 4 MG | 5 | PA NSO; NDS |
| LENVIMA (4 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4 MG | 5 | PA NSO; NDS |
| LENVIMA (8 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4 MG | 5 | PA NSO; NDS |
| <i>letrozole oral tablet 2.5 mg</i> | 2 | |
| LEUKERAN ORAL TABLET 2 MG | 5 | NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------------|
| LEUPROLIDE ACETATE (3 MONTH) INTRAMUSCULAR INJECTABLE 22.5 MG | 4 | PA NSO |
| <i>leuprolide acetate injection kit 1 mg/0.2ml</i> | 2 | PA NSO |
| LONSURF ORAL TABLET 15-6.14 MG | 5 | PA NSO; NDS; QL (100 per 28 days) |
| LONSURF ORAL TABLET 20-8.19 MG | 5 | PA NSO; NDS; QL (80 per 28 days) |
| LOQTORZI INTRAVENOUS SOLUTION 240 MG/6ML | 5 | PA NSO; NDS |
| LORBRENA ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| LUMAKRAS ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| LUMAKRAS ORAL TABLET 320 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| LUNSUMIO INTRAVENOUS SOLUTION 1 MG/ML, 30 MG/30ML | 5 | PA NSO; NDS |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 7.5 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 22.5 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT (4-MONTH) INTRAMUSCULAR KIT 30 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT (6-MONTH) INTRAMUSCULAR KIT 45 MG | 5 | PA NSO; NDS |
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 5 | NDS |
| LYTGOBI (12 MG DAILY DOSE) ORAL TABLET THERAPY PACK 4 MG | 5 | PA NSO; NDS; QL (140 per 28 days) |
| LYTGOBI (16 MG DAILY DOSE) ORAL TABLET THERAPY PACK 4 MG | 5 | PA NSO; NDS; QL (140 per 28 days) |
| LYTGOBI (20 MG DAILY DOSE) ORAL TABLET THERAPY PACK 4 MG | 5 | PA NSO; NDS; QL (140 per 28 days) |
| MARGENZA INTRAVENOUS SOLUTION 250 MG/10ML | 5 | PA NSO; NDS |
| MATULANE ORAL CAPSULE 50 MG | 5 | NDS |
| <i>megestrol acetate oral tablet 20 mg, 40 mg</i> | 2 | |
| MEKINIST ORAL SOLUTION RECONSTITUTED 0.05 MG/ML | 5 | PA NSO; NDS; QL (1260 per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>mercaptopurine oral tablet 50 mg</i> | 2 | |
| <i>methotrexate sodium (pf) injection solution 1 gm/40ml, 250 mg/10ml, 50 mg/2ml</i> | 2 | |
| METHOTREXATE SODIUM INJECTION SOLUTION 50 MG/2ML | 2 | |
| <i>methotrexate sodium injection solution reconstituted 1 gm</i> | 2 | |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 2 | PA BvD; ST |
| <i>mitoxantrone hcl intravenous concentrate 20 mg/10ml</i> | 2 | |
| MVASI INTRAVENOUS SOLUTION 100 MG/4ML, 400 MG/16ML | 5 | PA NSO; NDS |
| NERLYNX ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>nilutamide oral tablet 150 mg</i> | 5 | NDS |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 5 | PA NSO; NDS; QL (3 per 28 days) |
| NUBEQA ORAL TABLET 300 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 5 | PA NSO; NDS |
| OGIVRI INTRAVENOUS SOLUTION RECONSTITUTED 150 MG, 420 MG | 5 | PA NSO; NDS |
| OGSIVEO ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| OGSIVEO ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| OJEMDA ORAL SUSPENSION RECONSTITUTED 25 MG/ML | 5 | PA NSO; NDS; QL (96 per 28 days) |
| OJEMDA ORAL TABLET 100 MG, 100 MG (16 PACK), 100 MG (24 PACK) | 5 | PA NSO; NDS; QL (24 per 28 days) |
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ONTRUZANT INTRAVENOUS SOLUTION RECONSTITUTED 150 MG, 420 MG | 5 | PA NSO; NDS |
| ONUREG ORAL TABLET 200 MG, 300 MG | 5 | PA NSO; NDS; QL (14 per 28 days) |
| OPDIVO INTRAVENOUS SOLUTION 100 MG/10ML, 120 MG/12ML, 240 MG/24ML, 40 MG/4ML | 5 | PA NSO; NDS |
| OPDUALAG INTRAVENOUS SOLUTION 240-80 MG/20ML | 5 | PA NSO; NDS |
| ORSERDU ORAL TABLET 345 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| PACLITAXEL PROTEIN-BOUND PART INTRAVENOUS SUSPENSION RECONSTITUTED 100 MG | 5 | PA BvD; NDS |
| <i>pazopanib hcl oral tablet 200 mg</i> | 5 | PA NSO; NDS; QL (120 per 30 days) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| PEMETREXED DISODIUM INTRAVENOUS SOLUTION 1 GM/40ML, 100 MG/4ML, 500 MG/20ML | 5 | NDS |
| <i>pemetrexed disodium intravenous solution 850 mg/34ml</i> | 5 | NDS |
| <i>pemetrexed disodium intravenous solution reconstituted 1000 mg, 750 mg</i> | 5 | NDS |
| <i>pemetrexed ditromethamine intravenous solution reconstituted 100 mg, 500 mg</i> | 5 | NDS |
| PEMRYDI RTU INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | 5 | NDS |
| PIQRAY (200 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| PIQRAY (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| PIQRAY (300 MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| PURIXAN ORAL SUSPENSION 2000 MG/100ML | 5 | NDS |
| QINLOCK ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| RETEVMO ORAL TABLET 120 MG, 160 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| RETEVMO ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| RETEVMO ORAL TABLET 80 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| REVUFORJ ORAL TABLET 110 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| REVUFORJ ORAL TABLET 160 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| REZLIDHIA ORAL CAPSULE 150 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| RIABNI INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | 5 | PA NSO; NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| RITUXAN HYCELA SUBCUTANEOUS SOLUTION 1400-23400 MG -UT/11.7ML, 1600-26800 MG -UT/13.4ML | 5 | PA NSO; NDS |
| ROZLYTREK ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| ROZLYTREK ORAL PACKET 50 MG | 5 | PA NSO; NDS; QL (360 per 30 days) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| RUXIENCE INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | 5 | PA NSO; NDS |
| RYBREVANT INTRAVENOUS SOLUTION 350 MG/7ML | 5 | PA NSO; NDS |
| RYDAPT ORAL CAPSULE 25 MG | 5 | PA NSO; NDS; QL (224 per 28 days) |
| RYTELO INTRAVENOUS SOLUTION RECONSTITUTED 188 MG, 47 MG | 5 | PA NSO; NDS |
| SCSEMBLIX ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| SCSEMBLIX ORAL TABLET 20 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| SCSEMBLIX ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (300 per 30 days) |
| SOLTAMOX ORAL SOLUTION 10 MG/5ML | 5 | NDS |
| <i>sorafenib tosylate oral tablet 200 mg</i> | 5 | PA NSO; NDS; QL (120 per 30 days) |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 50 MG, 70 MG, 80 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| SPRYCEL ORAL TABLET 20 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | 5 | PA NSO; NDS; QL (28 per 28 days) |
| SYNRIBO SUBCUTANEOUS SOLUTION RECONSTITUTED 3.5 MG | 5 | PA NSO; NDS |
| TABLOID ORAL TABLET 40 MG | 4 | |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5 | PA NSO; NDS; QL (112 per 28 days) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| TAFINLAR ORAL TABLET SOLUBLE 10 MG | 5 | PA NSO; NDS; QL (900 per 30 days) |
| TAGRISSO ORAL TABLET 40 MG, 80 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| TALVEY SUBCUTANEOUS SOLUTION 3 MG/1.5ML, 40 MG/ML | 5 | PA NSO; NDS |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>tamoxifen citrate oral tablet 10 mg, 20 mg</i> | 2 | |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG | 5 | PA NSO; NDS; QL (112 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| TASIGNA ORAL CAPSULE 50 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| TECVAYLI SUBCUTANEOUS SOLUTION 153 MG/1.7ML, 30 MG/3ML | 5 | PA NSO; NDS |
| TEPMETKO ORAL TABLET 225 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| TEVIMBRA INTRAVENOUS SOLUTION 100 MG/10ML | 5 | PA NSO; NDS |
| TIBSOVO ORAL TABLET 250 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| TICE BCG INTRAVESICAL SUSPENSION RECONSTITUTED 50 MG | 4 | |
| TIVDAK INTRAVENOUS SOLUTION RECONSTITUTED 40 MG | 5 | PA NSO; NDS; QL (5 per 21 days) |
| <i>toposar intravenous solution 100 mg/5ml</i> | 2 | |
| <i>toremifene citrate oral tablet 60 mg</i> | 5 | NDS |
| <i>torpenz oral tablet 10 mg</i> | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>torpenz oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | 5 | PA NSO; NDS; QL (30 per 30 days) |
| TRAZIMERA INTRAVENOUS SOLUTION RECONSTITUTED 150 MG, 420 MG | 5 | PA NSO; NDS |
| TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25 MG, 22.5 MG, 3.75 MG | 4 | PA NSO |
| <i>tretinoin oral capsule 10 mg</i> | 5 | NDS |
| TRUQAP ORAL TABLET 160 MG, 200 MG | 5 | PA NSO; NDS; QL (64 per 28 days) |
| TRUSELTIQ (100MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100 MG | 5 | PA NSO; NDS |
| TRUSELTIQ (125MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100 & 25 MG | 5 | PA NSO; NDS |
| TRUSELTIQ (50MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25 MG | 5 | PA NSO; NDS |
| TRUSELTIQ (75MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25 MG | 5 | PA NSO; NDS |
| TRUXIMA INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | 5 | PA NSO; NDS |
| TUKYSA ORAL TABLET 150 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| TUKYSA ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (300 per 30 days) |
| TURALIO ORAL CAPSULE 125 MG, 200 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG | 5 | PA NSO; NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| VEGZELMA INTRAVENOUS SOLUTION 100 MG/4ML, 400 MG/16ML | 5 | PA NSO; NDS |
| VENCLEXTA ORAL TABLET 10 MG | 3 | PA NSO; QL (60 per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100 MG | 5 | PA NSO; NDS |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| <i>vinorelbine tartrate intravenous solution 10 mg/ml, 50 mg/5ml</i> | 2 | |
| VITRAKVI ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 5 | PA NSO; NDS; QL (300 per 30 days) |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| VONJO ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| VORANIGO ORAL TABLET 10 MG, 40 MG | 5 | PA NSO; NDS |
| VYLOY INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 5 | PA NSO; NDS |
| WELIREG ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XALKORI ORAL CAPSULE SPRINKLE 150 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| XALKORI ORAL CAPSULE SPRINKLE 20 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| XALKORI ORAL CAPSULE SPRINKLE 50 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 4 | PA BvD; ST |
| XOSPATA ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG | 5 | PA NSO; NDS; QL (8 per 28 days) |
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA NSO; NDS; QL (4 per 28 days) |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA NSO; NDS; QL (8 per 28 days) |
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG | 5 | PA NSO; NDS; QL (4 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| XPOVIO (60 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA NSO; NDS; QL (24 per 28 days) |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA NSO; NDS; QL (8 per 28 days) |
| XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA NSO; NDS; QL (32 per 28 days) |
| XTANDI ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 80 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| YERVOY INTRAVENOUS SOLUTION 200 MG/40ML, 50 MG/10ML | 5 | PA NSO; NDS |
| YONSA ORAL TABLET 125 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ZEJULA ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| ZIIHERA INTRAVENOUS SOLUTION RECONSTITUTED 300 MG | 5 | PA NSO; NDS |
| ZIRABEV INTRAVENOUS SOLUTION 100 MG/4ML, 400 MG/16ML | 5 | PA NSO; NDS |
| ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG | 4 | PA NSO |
| ZOLINZA ORAL CAPSULE 100 MG | 5 | NDS |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| ZYNLONTA INTRAVENOUS SOLUTION RECONSTITUTED 10 MG | 5 | PA NSO; NDS |
| ZYNYZ INTRAVENOUS SOLUTION 500 MG/20ML | 5 | PA NSO; NDS; QL (20 per 28 days) |
| ANTICONSULSANTS | | |
| <i>Anticonvulsants</i> | | |
| APTIOM ORAL TABLET 200 MG, 400 MG | 5 | ST; NDS; QL (30 per 30 days) |
| APTIOM ORAL TABLET 600 MG, 800 MG | 5 | ST; NDS; QL (60 per 30 days) |
| BRIVIACT INTRAVENOUS SOLUTION 50 MG/5ML | 3 | QL (80 per 30 days) |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 3 | QL (600 per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 3 | QL (60 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>carbamazepine er oral capsule extended release 12 hour 100 mg, 200 mg, 300 mg</i> | 2 | |
| <i>carbamazepine er oral tablet extended release 12 hour 100 mg, 200 mg, 400 mg</i> | 2 | |
| <i>carbamazepine oral suspension 100 mg/5ml</i> | 2 | |
| <i>carbamazepine oral tablet 200 mg</i> | 2 | |
| <i>carbamazepine oral tablet chewable 100 mg, 200 mg</i> | 2 | |
| <i>clobazam oral suspension 2.5 mg/ml</i> | 2 | QL (480 per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg</i> | 2 | QL (60 per 30 days) |
| DIACOMIT ORAL CAPSULE 250 MG | 5 | PA NSO; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL CAPSULE 500 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| DIACOMIT ORAL PACKET 250 MG | 5 | PA NSO; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL PACKET 500 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>diazepam rectal gel 10 mg, 2.5 mg, 20 mg</i> | 4 | |
| <i>divalproex sodium er oral tablet extended release 24 hour 250 mg, 500 mg</i> | 2 | |
| <i>divalproex sodium oral capsule delayed release sprinkle 125 mg</i> | 2 | |
| <i>divalproex sodium oral tablet delayed release 125 mg, 250 mg, 500 mg</i> | 2 | |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 5 | PA NSO; NDS |
| <i>epitol oral tablet 200 mg</i> | 2 | |
| EPRONTIA ORAL SOLUTION 25 MG/ML | 4 | ST |
| <i>ethosuximide oral capsule 250 mg</i> | 2 | |
| <i>ethosuximide oral solution 250 mg/5ml</i> | 2 | |
| <i>felbamate oral suspension 600 mg/5ml</i> | 2 | |
| <i>felbamate oral tablet 400 mg, 600 mg</i> | 2 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 5 | PA NSO; NDS |
| <i>fosphenytoin sodium injection solution 100 mg pe/2ml, 500 mg pe/10ml</i> | 2 | |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 5 | ST; NDS; QL (720 per 30 days) |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 8 MG | 5 | ST; NDS; QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 2 MG | 4 | ST; QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 4 MG, 6 MG | 5 | ST; NDS; QL (60 per 30 days) |
| <i>gabapentin oral capsule 100 mg, 300 mg</i> | 2 | QL (360 per 30 days) |
| <i>gabapentin oral capsule 400 mg</i> | 2 | QL (270 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>gabapentin oral solution 250 mg/5ml</i> | 2 | QL (2160 per 30 days) |
| <i>gabapentin oral tablet 600 mg</i> | 2 | QL (180 per 30 days) |
| <i>gabapentin oral tablet 800 mg</i> | 2 | QL (120 per 30 days) |
| <i>lacosamide intravenous solution 200 mg/20ml</i> | 2 | QL (200 per 5 days) |
| <i>lacosamide oral solution 10 mg/ml</i> | 2 | QL (1200 per 30 days) |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 2 | QL (60 per 30 days) |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | |
| <i>lamotrigine oral tablet chewable 25 mg, 5 mg</i> | 2 | |
| <i>lamotrigine oral tablet dispersible 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | |
| <i>levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg</i> | 2 | |
| <i>levetiracetam intravenous solution 500 mg/5ml</i> | 2 | |
| <i>levetiracetam oral solution 100 mg/ml</i> | 2 | |
| <i>levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg</i> | 2 | |
| LIBERVANT BUCCAL FILM 10 MG, 12.5 MG, 15 MG, 5 MG, 7.5 MG | 4 | QL (10 per 30 days) |
| <i>methsuximide oral capsule 300 mg</i> | 2 | |
| NAYZILAM NASAL SOLUTION 5 MG/0.1ML | 4 | QL (10 per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5ml</i> | 2 | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | 2 | |
| <i>phenobarbital oral elixir 20 mg/5ml</i> | 2 | |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 2 | |
| <i>phenytoin oral suspension 125 mg/5ml</i> | 2 | |
| <i>phenytoin oral tablet chewable 50 mg</i> | 2 | |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg</i> | 2 | |
| <i>phenytoin sodium injection solution 50 mg/ml</i> | 2 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> | 2 | QL (90 per 30 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | 2 | QL (60 per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> | 2 | QL (900 per 30 days) |
| <i>primidone oral tablet 125 mg, 250 mg, 50 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>rufinamide oral suspension 40 mg/ml</i> | 5 | ST; NDS |
| <i>rufinamide oral tablet 200 mg</i> | 2 | ST |
| <i>rufinamide oral tablet 400 mg</i> | 5 | ST; NDS |
| SEZABY INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 5 | PA BvD; NDS |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000 MG, 250 MG, 500 MG, 750 MG | 4 | ST |
| <i>subvenite oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | |
| SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 2 | |
| <i>topiramate oral capsule sprinkle 15 mg, 25 mg</i> | 2 | |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>valproate sodium intravenous solution 100 mg/ml</i> | 2 | |
| <i>valproic acid oral capsule 250 mg</i> | 2 | |
| <i>valproic acid oral solution 250 mg/5ml</i> | 2 | |
| VALTOCO 10 MG DOSE NASAL LIQUID 10 MG/0.1ML | 5 | NDS; QL (10 per 30 days) |
| VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 7.5 MG/0.1ML | 5 | NDS; QL (10 per 30 days) |
| VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 10 MG/0.1ML | 5 | NDS; QL (10 per 30 days) |
| VALTOCO 5 MG DOSE NASAL LIQUID 5 MG/0.1ML | 5 | NDS; QL (10 per 30 days) |
| <i>vigabatrin oral packet 500 mg</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigabatrin oral tablet 500 mg</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigadrone oral packet 500 mg</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigadrone oral tablet 500 mg</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigpoder oral packet 500 mg</i> | 5 | PA NSO; NDS; QL (180 per 30 days) |
| XCOPRI (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 100 & 150 MG | 4 | ST; QL (56 per 28 days) |
| XCOPRI (350 MG DAILY DOSE) ORAL TABLET THERAPY PACK 150 & 200 MG | 4 | ST; QL (56 per 28 days) |
| XCOPRI ORAL TABLET 100 MG, 25 MG, 50 MG | 4 | ST; QL (30 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------------|
| XCOPRI ORAL TABLET 150 MG, 200 MG | 4 | ST; QL (60 per 30 days) |
| XCOPRI ORAL TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG, 14 X 150 MG & 14 X200 MG, 14 X 50 MG & 14 X100 MG | 4 | ST |
| ZONISADE ORAL SUSPENSION 100 MG/5ML | 4 | |
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 5 | PA NSO; NDS; QL (1080 per 30 days) |
| ANTIDEMENTIA AGENTS | | |
| Antidementia Agents | | |
| <i>donepezil hcl oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>donepezil hcl oral tablet 23 mg</i> | 2 | QL (30 per 30 days) |
| <i>donepezil hcl oral tablet dispersible 10 mg</i> | 2 | |
| <i>donepezil hcl oral tablet dispersible 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>ergoloid mesylates oral tablet 1 mg</i> | 2 | |
| <i>galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg, 8 mg</i> | 2 | QL (30 per 30 days) |
| <i>galantamine hydrobromide oral solution 4 mg/ml</i> | 2 | QL (200 per 30 days) |
| <i>galantamine hydrobromide oral tablet 12 mg, 4 mg, 8 mg</i> | 2 | QL (60 per 30 days) |
| <i>memantine hcl er oral capsule extended release 24 hour 14 mg, 21 mg, 28 mg, 7 mg</i> | 2 | ST; QL (30 per 30 days) |
| <i>memantine hcl oral solution 2 mg/ml</i> | 2 | QL (300 per 30 days) |
| <i>memantine hcl oral tablet 10 mg, 5 mg</i> | 2 | QL (60 per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 2 | |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24hr, 4.6 mg/24hr, 9.5 mg/24hr</i> | 2 | QL (30 per 30 days) |
| ANTIDEPRESSANTS | | |
| Antidepressants | | |
| <i>amitriptyline hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 2 | |
| AUVELITY ORAL TABLET EXTENDED RELEASE 45-105 MG | 5 | ST; NDS |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg, 150 mg, 200 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg, 300 mg</i> | 2 | |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | 2 | |
| <i>citalopram hydrobromide oral solution 10 mg/5ml</i> | 2 | |
| <i>citalopram hydrobromide oral tablet 10 mg</i> | 1 | QL (120 per 30 days) |
| <i>citalopram hydrobromide oral tablet 20 mg, 40 mg</i> | 1 | QL (30 per 30 days) |
| <i>clomipramine hcl oral capsule 25 mg, 50 mg, 75 mg</i> | 4 | |
| <i>desipramine hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 4 | |
| <i>desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg</i> | 2 | QL (30 per 30 days) |
| <i>doxepin hcl oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>doxepin hcl oral concentrate 10 mg/ml</i> | 2 | |
| DRIZALMA SPRINKLE ORAL CAPSULE DELAYED RELEASE SPRINKLE 20 MG, 30 MG, 60 MG | 4 | ST; QL (60 per 30 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE DELAYED RELEASE SPRINKLE 40 MG | 4 | ST; QL (30 per 30 days) |
| <i>duloxetine hcl oral capsule delayed release particles 20 mg, 30 mg, 60 mg</i> | 2 | QL (60 per 30 days) |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24HR, 6 MG/24HR, 9 MG/24HR | 5 | ST; NDS; QL (30 per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5ml</i> | 2 | |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| FETZIMA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 20 MG, 40 MG, 80 MG | 4 | ST; QL (30 per 30 days) |
| FETZIMA TITRATION ORAL CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG | 4 | ST |
| <i>fluoxetine hcl oral capsule 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>fluoxetine hcl oral solution 20 mg/5ml</i> | 2 | |
| <i>fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| MARPLAN ORAL TABLET 10 MG | 4 | |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg, 7.5 mg</i> | 2 | |
| <i>mirtazapine oral tablet dispersible 15 mg, 30 mg, 45 mg</i> | 2 | |
| NEFAZODONE HCL ORAL TABLET 100 MG | 2 | |
| <i>nefazodone hcl oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | 2 | |
| <i>nortriptyline hcl oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>nortriptyline hcl oral solution 10 mg/5ml</i> | 4 | |
| <i>paroxetine hcl er oral tablet extended release 24 hour 12.5 mg, 25 mg, 37.5 mg</i> | 4 | |
| <i>paroxetine hcl oral suspension 10 mg/5ml</i> | 4 | |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg</i> | 2 | |
| <i>phenelzine sulfate oral tablet 15 mg</i> | 2 | |
| <i>protriptyline hcl oral tablet 10 mg, 5 mg</i> | 4 | |
| <i>sertraline hcl oral concentrate 20 mg/ml</i> | 2 | |
| <i>sertraline hcl oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| SPRAVATO (56 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE | 5 | PA NSO; NDS |
| SPRAVATO (84 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE | 5 | PA NSO; NDS |
| <i>tranylcypromine sulfate oral tablet 10 mg</i> | 4 | |
| <i>trazodone hcl oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | 1 | |
| <i>trimipramine maleate oral capsule 100 mg, 25 mg, 50 mg</i> | 4 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg</i> | 2 | QL (30 per 30 days) |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 37.5 mg, 75 mg</i> | 2 | QL (90 per 30 days) |
| <i>venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>vilazodone hcl oral tablet 10 mg, 20 mg, 40 mg</i> | 2 | QL (30 per 30 days) |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG | 5 | PA NSO; NDS; QL (28 per 14 days) |
| ZURZUVAE ORAL CAPSULE 30 MG | 5 | PA NSO; NDS; QL (14 per 14 days) |
| ANTIDIABETIC AGENTS | | |
| <i>Antidiabetic Agents, Miscellaneous</i> | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | |
| FARXIGA ORAL TABLET 10 MG, 5 MG | 3 | QL (30 per 30 days) |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG | 3 | QL (30 per 30 days) |
| JANUMET ORAL TABLET 50-1000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG | 3 | QL (30 per 30 days) |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 50-1000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 3 | QL (30 per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 3 | QL (30 per 30 days) |
| JENTADUETO ORAL TABLET 2.5-1000 MG, 2.5-500 MG, 2.5-850 MG | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 5-1000 MG | 3 | QL (30 per 30 days) |
| <i>metformin hcl er oral tablet extended release 24 hour 500 mg</i> | 1 | QL (120 per 30 days) |
| <i>metformin hcl er oral tablet extended release 24 hour 750 mg</i> | 1 | QL (60 per 30 days) |
| <i>metformin hcl oral solution 500 mg/5ml</i> | 4 | QL (765 per 30 days) |
| <i>metformin hcl oral tablet 1000 mg</i> | 1 | QL (75 per 30 days) |
| <i>metformin hcl oral tablet 500 mg</i> | 1 | QL (150 per 30 days) |
| <i>metformin hcl oral tablet 850 mg</i> | 1 | QL (90 per 30 days) |
| <i>mifepristone oral tablet 300 mg</i> | 5 | PA; NDS; QL (112 per 28 days) |
| MOUNJARO SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML, 2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5ML | 3 | PA; QL (2 per 28 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 2 | QL (90 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML, 2 MG/3ML | 3 | PA; QL (3 per 28 days) |
| OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML, 4 MG/3ML | 3 | PA; QL (3 per 28 days) |
| OZEMPIC (2 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 8 MG/3ML | 3 | PA; QL (3 per 28 days) |
| <i>pioglitazone hcl oral tablet 15 mg, 30 mg, 45 mg</i> | 1 | QL (30 per 30 days) |
| <i>pioglitazone hcl-metformin hcl oral tablet 15-500 mg, 15-850 mg</i> | 2 | QL (90 per 30 days) |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | 2 | QL (120 per 30 days) |
| <i>repaglinide oral tablet 2 mg</i> | 2 | QL (240 per 30 days) |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG | 3 | PA; QL (30 per 30 days) |
| SYNJARDY ORAL TABLET 12.5-1000 MG, 12.5-500 MG, 5-1000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 25-1000 MG | 3 | QL (30 per 30 days) |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12.5-1000 MG, 5-1000 MG | 3 | QL (60 per 30 days) |
| TRADJENTA ORAL TABLET 5 MG | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-5-1000 MG, 25-5-1000 MG | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12.5-2.5-1000 MG, 5-2.5-1000 MG | 3 | QL (60 per 30 days) |
| TRULICITY SUBCUTANEOUS SOLUTION PEN-INJECTOR 0.75 MG/0.5ML, 1.5 MG/0.5ML, 3 MG/0.5ML, 4.5 MG/0.5ML | 3 | PA; QL (2 per 28 days) |
| XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 10-500 MG | 3 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG, 5-1000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| <i>Insulins</i> | | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| FIASP FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| FIASP INJECTION SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| FIASP PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| HUMULIN R U-500 (CONCENTRATED) SUBCUTANEOUS SOLUTION 500 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| HUMULIN R U-500 KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 500 UNIT/ML | 3 | max \$35 copay per month supply; QL (24 per 28 days) |
| <i>insulin asp prot & asp flexpen subcutaneous suspension pen-injector (70-30) 100 unit/ml</i> | 2 | max \$35 copay per month supply; QL (30 per 28 days) |
| INSULIN ASPART FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 2 | max \$35 copay per month supply; QL (30 per 28 days) |
| INSULIN ASPART INJECTION SOLUTION 100 UNIT/ML | 2 | max \$35 copay per month supply; QL (40 per 28 days) |
| INSULIN ASPART PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML | 2 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart prot & aspart subcutaneous suspension (70-30) 100 unit/ml</i> | 2 | max \$35 copay per month supply; QL (40 per 28 days) |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | max \$35 copay per month supply |
| LANTUS SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply |
| NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN R FLEXPEN INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN R INJECTION SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--|
| SEMGLEE (YFGN) SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply |
| SEMGLEE (YFGN) SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| SOLQUA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML | 3 | max \$35 copay per month supply; QL (30 per 30 days) |
| TOUJEO MAX SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML | 3 | max \$35 copay per month supply |
| TOUJEO SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML | 3 | max \$35 copay per month supply |
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML | 3 | max \$35 copay per month supply |
| TRESIBA SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply |
| XULTOPHY SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-3.6 UNIT-MG/ML | 3 | max \$35 copay per month supply; QL (15 per 28 days) |
| Sulfonylureas | | |
| <i>glimepiride oral tablet 1 mg, 2 mg</i> | 1 | QL (30 per 30 days) |
| <i>glimepiride oral tablet 4 mg</i> | 1 | QL (60 per 30 days) |
| <i>glipizide er oral tablet extended release 24 hour 10 mg</i> | 1 | QL (60 per 30 days) |
| <i>glipizide er oral tablet extended release 24 hour 2.5 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>glipizide oral tablet 10 mg</i> | 1 | QL (120 per 30 days) |
| <i>glipizide oral tablet 2.5 mg</i> | 1 | QL (60 per 30 days) |
| <i>glipizide oral tablet 5 mg</i> | 1 | QL (240 per 30 days) |
| <i>glipizide-metformin hcl oral tablet 2.5-250 mg</i> | 2 | QL (240 per 30 days) |
| <i>glipizide-metformin hcl oral tablet 2.5-500 mg, 5-500 mg</i> | 2 | QL (120 per 30 days) |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | 1 | |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | |
| ANTIFUNGALS | | |
| Antifungals | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 4 | PA BvD |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>amphotericin b intravenous solution reconstituted 50 mg</i> | 2 | PA BvD |
| <i>amphotericin b liposome intravenous suspension reconstituted 50 mg</i> | 5 | PA BvD; NDS |
| <i>ciclopirox external solution 8 %</i> | 2 | QL (19.8 per 30 days) |
| <i>ciclopirox olamine external cream 0.77 %</i> | 2 | QL (180 per 30 days) |
| <i>ciclopirox olamine external suspension 0.77 %</i> | 4 | QL (180 per 30 days) |
| <i>clotrimazole external cream 1 %</i> | 2 | |
| <i>clotrimazole external solution 1 %</i> | 2 | |
| <i>clotrimazole mouth/throat troche 10 mg</i> | 2 | |
| <i>clotrimazole-betamethasone external cream 1-0.05 %</i> | 2 | QL (90 per 30 days) |
| <i>econazole nitrate external cream 1 %</i> | 2 | QL (170 per 30 days) |
| <i>fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%, 400-0.9 mg/200ml-%</i> | 2 | |
| <i>fluconazole oral suspension reconstituted 10 mg/ml, 40 mg/ml</i> | 2 | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 2 | |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> | 5 | NDS |
| <i>griseofulvin microsize oral suspension 125 mg/5ml</i> | 2 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 4 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | 4 | |
| <i>itraconazole oral capsule 100 mg</i> | 2 | |
| <i>ketoconazole external cream 2 %</i> | 2 | QL (180 per 30 days) |
| <i>ketoconazole external shampoo 2 %</i> | 2 | QL (360 per 30 days) |
| <i>ketoconazole oral tablet 200 mg</i> | 2 | |
| <i>miconazole sodium intravenous solution reconstituted 100 mg, 50 mg</i> | 2 | |
| MICONAZOLE 3 VAGINAL SUPPOSITORY 200 MG | 2 | |
| <i>nyamyc external powder 100000 unit/gm</i> | 2 | QL (60 per 30 days) |
| <i>nystatin external cream 100000 unit/gm</i> | 2 | QL (60 per 30 days) |
| <i>nystatin external ointment 100000 unit/gm</i> | 2 | QL (60 per 30 days) |
| <i>nystatin external powder 100000 unit/gm</i> | 2 | QL (60 per 30 days) |
| <i>nystatin mouth/throat suspension 100000 unit/ml</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>nystatin oral tablet 500000 unit</i> | 2 | |
| <i>nystatin-triamcinolone external cream 100000-0.1 unit/gm-%</i> | 2 | |
| <i>nystop external powder 100000 unit/gm</i> | 2 | QL (60 per 30 days) |
| <i>posaconazole oral tablet delayed release 100 mg</i> | 5 | PA; NDS |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | |
| <i>voriconazole intravenous solution reconstituted 200 mg</i> | 5 | PA BvD; NDS |
| <i>voriconazole oral suspension reconstituted 40 mg/ml</i> | 5 | PA; NDS |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | 4 | |
| ANTIGOUT AGENTS | | |
| <i>Antigout Agents, Other</i> | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | 1 | |
| <i>colchicine oral capsule 0.6 mg</i> | 2 | QL (60 per 30 days) |
| <i>colchicine oral tablet 0.6 mg</i> | 2 | QL (120 per 30 days) |
| <i>colchicine-probenecid oral tablet 0.5-500 mg</i> | 2 | |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | 4 | ST; QL (30 per 30 days) |
| <i>probenecid oral tablet 500 mg</i> | 2 | |
| ANTIHISTAMINES | | |
| <i>Antihistamines</i> | | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |
| <i>levocetirizine dihydrochloride oral tablet 5 mg</i> | 1 | |
| ANTI-INFECTIVES (SKIN AND MUCOUS MEMBRANE) | | |
| <i>Anti-Infectives (Skin And Mucous Membrane)</i> | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> | 4 | |
| <i>metronidazole vaginal gel 0.75 %</i> | 4 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 2 | |
| <i>terconazole vaginal suppository 80 mg</i> | 4 | |
| ANTIMIGRAINE AGENTS | | |
| <i>Antimigraine Agents</i> | | |
| AJOVY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 225 MG/1.5ML | 3 | PA; QL (1.5 per 30 days) |
| AJOVY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 225 MG/1.5ML | 3 | PA; QL (1.5 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>dihydroergotamine mesylate nasal solution 4 mg/ml</i> | 5 | ST; NDS; QL (8 per 28 days) |
| EMGALITY (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML | 3 | PA; QL (3 per 30 days) |
| EMGALITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| EMGALITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| <i>naratriptan hcl oral tablet 1 mg, 2.5 mg</i> | 2 | QL (9 per 30 days) |
| NURTEC ORAL TABLET DISPERSIBLE 75 MG | 3 | PA; QL (18 per 30 days) |
| QULIPTA ORAL TABLET 10 MG, 30 MG, 60 MG | 3 | PA; QL (30 per 30 days) |
| <i>rizatriptan benzoate oral tablet 10 mg, 5 mg</i> | 2 | QL (18 per 30 days) |
| <i>rizatriptan benzoate oral tablet dispersible 10 mg, 5 mg</i> | 2 | QL (18 per 30 days) |
| <i>sumatriptan nasal solution 20 mg/act, 5 mg/act</i> | 2 | QL (12 per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg</i> | 2 | QL (9 per 30 days) |
| <i>sumatriptan succinate oral tablet 25 mg, 50 mg</i> | 2 | QL (18 per 30 days) |
| <i>sumatriptan succinate refill subcutaneous solution cartridge 6 mg/0.5ml</i> | 4 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5ml</i> | 2 | QL (5 per 28 days) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml, 6 mg/0.5ml</i> | 4 | QL (4 per 28 days) |
| UBRELVY ORAL TABLET 100 MG, 50 MG | 3 | PA; QL (16 per 30 days) |
| ANTIMYCOBACTERIALS | | |
| <i>Antimycobacterials</i> | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 2 | |
| <i>ethambutol hcl oral tablet 100 mg, 400 mg</i> | 2 | |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | |
| PRIFTIN ORAL TABLET 150 MG | 4 | |
| <i>pyrazinamide oral tablet 500 mg</i> | 2 | |
| <i>rifabutin oral capsule 150 mg</i> | 4 | |
| <i>rifampin intravenous solution reconstituted 600 mg</i> | 2 | |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| SIRTURO ORAL TABLET 100 MG, 20 MG | 5 | PA; NDS |
| TRECTOR ORAL TABLET 250 MG | 4 | |
| ANTINAUSEA AGENTS | | |
| <i>Antinausea Agents</i> | | |
| <i>aprepitant oral capsule 125 mg</i> | 2 | PA BvD; QL (2 per 28 days) |
| <i>aprepitant oral capsule 40 mg</i> | 2 | PA BvD; QL (1 per 28 days) |
| <i>aprepitant oral capsule 80 & 125 mg</i> | 2 | PA BvD |
| <i>aprepitant oral capsule 80 mg</i> | 2 | PA BvD; QL (4 per 28 days) |
| <i>compro rectal suppository 25 mg</i> | 2 | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> | 4 | PA; QL (60 per 30 days) |
| <i>meclizine hcl oral tablet 12.5 mg, 25 mg</i> | 1 | |
| <i>ondansetron hcl oral tablet 24 mg</i> | 4 | PA BvD |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>ondansetron oral tablet dispersible 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>prochlorperazine edisylate injection solution 10 mg/2ml</i> | 2 | |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>prochlorperazine rectal suppository 25 mg</i> | 2 | |
| <i>promethazine hcl injection solution 25 mg/ml</i> | 2 | |
| <i>promethazine hcl oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>promethegan rectal suppository 12.5 mg, 25 mg</i> | 2 | |
| <i>scopolamine transdermal patch 72 hour 1 mg/3days</i> | 4 | QL (10 per 30 days) |
| ANTIPARASITE AGENTS | | |
| <i>Antiparasite Agents</i> | | |
| <i>albendazole oral tablet 200 mg</i> | 5 | NDS |
| <i>atovaquone oral suspension 750 mg/5ml</i> | 2 | |
| <i>atovaquone-proguanil hcl oral tablet 250-100 mg, 62.5-25 mg</i> | 2 | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 2 | |
| COARTEM ORAL TABLET 20-120 MG | 4 | |
| <i>hydroxychloroquine sulfate oral tablet 100 mg</i> | 2 | QL (180 per 30 days) |
| <i>hydroxychloroquine sulfate oral tablet 200 mg</i> | 2 | QL (90 per 30 days) |
| <i>hydroxychloroquine sulfate oral tablet 300 mg, 400 mg</i> | 2 | QL (60 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| IMPAVIDO ORAL CAPSULE 50 MG | 5 | PA; NDS; QL (84 per 28 days) |
| <i>ivermectin oral tablet 3 mg</i> | 2 | |
| <i>mefloquine hcl oral tablet 250 mg</i> | 2 | |
| <i>nitazoxanide oral tablet 500 mg</i> | 5 | NDS; QL (60 per 30 days) |
| <i>paromomycin sulfate oral capsule 250 mg</i> | 2 | |
| <i>pentamidine isethionate inhalation solution reconstituted 300 mg</i> | 2 | PA BvD |
| <i>pentamidine isethionate injection solution reconstituted 300 mg</i> | 2 | |
| <i>praziquantel oral tablet 600 mg</i> | 2 | |
| PRIMAQUINE PHOSPHATE ORAL TABLET 26.3 (15 BASE) MG | 4 | |
| <i>pyrimethamine oral tablet 25 mg</i> | 5 | PA; NDS |
| <i>quinine sulfate oral capsule 324 mg</i> | 2 | PA |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 2 | |
| ANTIPARKINSONIAN AGENTS | | |
| <i>Antiparkinsonian Agents</i> | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 2 | |
| <i>amantadine hcl oral solution 50 mg/5ml</i> | 2 | |
| <i>amantadine hcl oral tablet 100 mg</i> | 2 | |
| <i>benztropine mesylate oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |
| <i>bromocriptine mesylate oral tablet 2.5 mg</i> | 2 | |
| <i>cabergoline oral tablet 0.5 mg</i> | 2 | |
| <i>carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet dispersible 10-100 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet dispersible 25-100 mg, 25-250 mg</i> | 4 | |
| <i>entacapone oral tablet 200 mg</i> | 2 | |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NDS; QL (150 per 30 days) |
| KYNMOBI TITRATION KIT SUBLINGUAL KIT 10&15&20&25&30 MG | 5 | PA; NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>pramipexole dihydrochloride oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 2 | |
| <i>rasagiline mesylate oral tablet 0.5 mg, 1 mg</i> | 4 | |
| <i>ropinirole hcl er oral tablet extended release 24 hour 2 mg, 4 mg</i> | 2 | |
| <i>ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 2 | |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | |
| <i>selegiline hcl oral tablet 5 mg</i> | 4 | |
| <i>trihexyphenidyl hcl oral tablet 2 mg, 5 mg</i> | 2 | |
| VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML | 5 | PA; NDS; QL (560 per 28 days) |
| ANTIPSYCHOTIC AGENTS | | |
| <i>Antipsychotic Agents</i> | | |
| ABILIFY ASIMTUFII INTRAMUSCULAR PREFILLED SYRINGE 720 MG/2.4ML | 5 | NDS; QL (2.4 per 42 days) |
| ABILIFY ASIMTUFII INTRAMUSCULAR PREFILLED SYRINGE 960 MG/3.2ML | 5 | NDS; QL (3.2 per 42 days) |
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300 MG, 400 MG | 5 | NDS; QL (1 per 26 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300 MG, 400 MG | 5 | NDS; QL (1 per 26 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 2 | |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> | 2 | |
| <i>aripiprazole oral tablet dispersible 10 mg</i> | 4 | ST; QL (90 per 30 days) |
| <i>aripiprazole oral tablet dispersible 15 mg</i> | 4 | ST; QL (60 per 30 days) |
| ARISTADA INITIO INTRAMUSCULAR PREFILLED SYRINGE 675 MG/2.4ML | 5 | NDS; QL (4.8 per 365 days) |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 1064 MG/3.9ML | 5 | NDS; QL (3.9 per 14 days) |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 441 MG/1.6ML | 5 | NDS; QL (1.6 per 14 days) |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 662 MG/2.4ML | 5 | NDS; QL (2.4 per 14 days) |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 882 MG/3.2ML | 5 | NDS; QL (3.2 per 14 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>asenapine maleate sublingual tablet sublingual 10 mg, 2.5 mg, 5 mg</i> | 4 | QL (60 per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 5 | ST; NDS; QL (30 per 30 days) |
| <i>chlorpromazine hcl injection solution 25 mg/ml, 50 mg/2ml</i> | 2 | |
| <i>chlorpromazine hcl oral concentrate 100 mg/ml, 30 mg/ml</i> | 2 | |
| <i>chlorpromazine hcl oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 4 | |
| <i>clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | |
| <i>clozapine oral tablet dispersible 100 mg, 12.5 mg, 25 mg</i> | 4 | ST; QL (90 per 30 days) |
| <i>clozapine oral tablet dispersible 150 mg</i> | 4 | ST; QL (180 per 30 days) |
| <i>clozapine oral tablet dispersible 200 mg</i> | 4 | ST; QL (120 per 30 days) |
| COBENFY ORAL CAPSULE 100-20 MG, 125-30 MG, 50-20 MG | 5 | ST; NDS; QL (60 per 30 days) |
| COBENFY STARTER PACK ORAL CAPSULE THERAPY PACK 50-20 & 100-20 MG | 5 | ST; NDS |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 5 | ST; NDS; QL (60 per 30 days) |
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6 MG | 4 | ST |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 2 | |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 2 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 2 | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5ml</i> | 2 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 4 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml 1 ml, 50 mg/ml, 50 mg/ml(1ml)</i> | 2 | |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 2 | |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1092 MG/3.5ML | 5 | NDS; QL (3.5 per 166 days) |
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1560 MG/5ML | 5 | NDS; QL (5 per 166 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML | 5 | NDS; QL (0.75 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 156 MG/ML | 5 | NDS; QL (1 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 234 MG/1.5ML | 5 | NDS; QL (1.5 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 39 MG/0.25ML | 3 | QL (0.25 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 78 MG/0.5ML | 5 | NDS; QL (0.5 per 21 days) |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML | 5 | NDS; QL (0.88 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 410 MG/1.32ML | 5 | NDS; QL (1.32 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 546 MG/1.75ML | 5 | NDS; QL (1.75 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 819 MG/2.63ML | 5 | NDS; QL (2.63 per 70 days) |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>lurasidone hcl oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i> | 2 | QL (30 per 30 days) |
| <i>lurasidone hcl oral tablet 80 mg</i> | 2 | QL (60 per 30 days) |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| <i>molindone hcl oral tablet 10 mg</i> | 2 | QL (240 per 30 days) |
| <i>molindone hcl oral tablet 25 mg</i> | 2 | QL (270 per 30 days) |
| <i>molindone hcl oral tablet 5 mg</i> | 5 | NDS; QL (120 per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| NUPLAZID ORAL TABLET 10 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>olanzapine intramuscular solution reconstituted 10 mg</i> | 2 | QL (30 per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> | 2 | |
| <i>olanzapine oral tablet dispersible 10 mg, 15 mg, 20 mg, 5 mg</i> | 2 | |
| <i>paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 9 mg</i> | 4 | QL (30 per 30 days) |
| <i>paliperidone er oral tablet extended release 24 hour 6 mg</i> | 4 | QL (60 per 30 days) |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 2 | |
| PERSERIS SUBCUTANEOUS PREFILLED SYRINGE 120 MG, 90 MG | 5 | NDS; QL (1 per 30 days) |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> | 2 | |
| <i>quetiapine fumarate oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | 2 | |
| <i>quetiapine fumarate oral tablet 150 mg</i> | 2 | QL (30 per 30 days) |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 5 | ST; NDS; QL (30 per 30 days) |
| <i>risperidone microspheres er intramuscular suspension reconstituted er 12.5 mg, 25 mg</i> | 2 | QL (2 per 28 days) |
| <i>risperidone microspheres er intramuscular suspension reconstituted er 37.5 mg, 50 mg</i> | 5 | NDS; QL (2 per 28 days) |
| <i>risperidone oral solution 1 mg/ml</i> | 2 | |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 2 | |
| <i>risperidone oral tablet dispersible 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 4 | |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24HR, 5.7 MG/24HR, 7.6 MG/24HR | 5 | ST; NDS; QL (30 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| <i>thioridazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| <i>trifluoperazine hcl oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| UZEDY SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 100 MG/0.28ML | 5 | NDS; QL (0.28 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 125 MG/0.35ML | 5 | NDS; QL (0.35 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 150 MG/0.42ML | 5 | NDS; QL (0.42 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 200 MG/0.56ML | 5 | NDS; QL (0.56 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 250 MG/0.7ML | 5 | NDS; QL (0.7 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 50 MG/0.14ML | 5 | NDS; QL (0.14 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 75 MG/0.21ML | 5 | NDS; QL (0.21 per 28 days) |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 5 | ST; NDS; QL (540 per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG | 5 | ST; NDS; QL (30 per 30 days) |
| VRAYLAR ORAL CAPSULE THERAPY PACK 1.5 & 3 MG | 4 | ST |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | |
| <i>ziprasidone mesylate intramuscular solution reconstituted 20 mg</i> | 2 | QL (6 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 210 MG | 4 | QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 300 MG | 5 | NDS; QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 405 MG | 5 | NDS; QL (1 per 28 days) |
| ANTIVIRALS (SYSTEMIC) | | |
| <i>Antiretrovirals</i> | | |
| <i>abacavir sulfate oral solution 20 mg/ml</i> | 2 | |
| <i>abacavir sulfate oral tablet 300 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>abacavir sulfate-lamivudine oral tablet 600-300 mg</i> | 2 | |
| APRETUDE INTRAMUSCULAR SUSPENSION EXTENDED RELEASE 600 MG/3ML | 5 | NDS; QL (24 per 365 days) |
| APTIVUS ORAL CAPSULE 250 MG | 5 | NDS |
| <i>atazanavir sulfate oral capsule 150 mg, 200 mg, 300 mg</i> | 2 | |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | 5 | NDS; QL (30 per 30 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION EXTENDED RELEASE 400 & 600 MG/2ML, 600 & 900 MG/3ML | 5 | NDS |
| CIMDUO ORAL TABLET 300-300 MG | 5 | NDS |
| COMPLERA ORAL TABLET 200-25-300 MG | 5 | NDS |
| <i>darunavir oral tablet 600 mg, 800 mg</i> | 5 | NDS |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 5 | NDS |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG | 5 | NDS |
| <i>didanosine oral capsule delayed release 250 mg, 400 mg</i> | 2 | |
| DOVATO ORAL TABLET 50-300 MG | 5 | NDS |
| EDURANT ORAL TABLET 25 MG | 5 | NDS |
| <i>efavirenz oral capsule 200 mg, 50 mg</i> | 2 | |
| <i>efavirenz oral tablet 600 mg</i> | 2 | |
| <i>efavirenz-emtricitab-tenofo df oral tablet 600-200-300 mg</i> | 5 | NDS |
| <i>efavirenz-lamivudine-tenofovir oral tablet 400-300-300 mg, 600-300-300 mg</i> | 5 | NDS |
| <i>emtricitabine oral capsule 200 mg</i> | 2 | |
| <i>emtricitabine-tenofovir df oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i> | 5 | NDS |
| <i>emtricitabine-tenofovir df oral tablet 200-300 mg</i> | 2 | |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 4 | |
| EPIVIR HBV ORAL SOLUTION 5 MG/ML | 4 | |
| <i>etravirine oral tablet 100 mg, 200 mg</i> | 5 | NDS |
| EVOTAZ ORAL TABLET 300-150 MG | 5 | NDS |
| <i>fosamprenavir calcium oral tablet 700 mg</i> | 5 | NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90 MG | 5 | NDS |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 5 | NDS |
| INTELENCE ORAL TABLET 25 MG | 4 | |
| ISENTRESS HD ORAL TABLET 600 MG | 5 | NDS |
| ISENTRESS ORAL PACKET 100 MG | 5 | NDS |
| ISENTRESS ORAL TABLET 400 MG | 5 | NDS |
| ISENTRESS ORAL TABLET CHEWABLE 100 MG | 5 | NDS |
| ISENTRESS ORAL TABLET CHEWABLE 25 MG | 3 | |
| JULUCA ORAL TABLET 50-25 MG | 5 | NDS |
| <i>lamivudine oral solution 10 mg/ml</i> | 2 | |
| <i>lamivudine oral tablet 100 mg, 150 mg, 300 mg</i> | 2 | |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 2 | |
| LEXIVA ORAL SUSPENSION 50 MG/ML | 4 | |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5ml</i> | 2 | QL (480 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> | 2 | QL (300 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> | 2 | QL (120 per 30 days) |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> | 5 | NDS |
| <i>nevirapine er oral tablet extended release 24 hour 100 mg</i> | 2 | QL (90 per 30 days) |
| <i>nevirapine er oral tablet extended release 24 hour 400 mg</i> | 2 | QL (30 per 30 days) |
| <i>nevirapine oral suspension 50 mg/5ml</i> | 2 | QL (1200 per 30 days) |
| <i>nevirapine oral tablet 200 mg</i> | 2 | QL (60 per 30 days) |
| NORVIR ORAL PACKET 100 MG | 4 | |
| NORVIR ORAL SOLUTION 80 MG/ML | 4 | |
| ODEFSEY ORAL TABLET 200-25-25 MG | 5 | NDS |
| PIFELTRO ORAL TABLET 100 MG | 5 | NDS |
| PREZCOBIX ORAL TABLET 800-150 MG | 5 | NDS |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 5 | NDS |
| PREZISTA ORAL TABLET 150 MG, 75 MG | 5 | NDS |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML | 4 | |
| REYATAZ ORAL PACKET 50 MG | 5 | NDS |
| <i>ritonavir oral tablet 100 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HOUR 600 MG | 5 | NDS |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 5 | NDS |
| SELZENTRY ORAL TABLET 25 MG | 3 | |
| SELZENTRY ORAL TABLET 75 MG | 5 | NDS |
| <i>stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg</i> | 2 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 5 | NDS |
| SUNLENCA ORAL TABLET THERAPY PACK 4 X 300 MG, 5 X 300 MG | 5 | NDS |
| SUNLENCA SUBCUTANEOUS SOLUTION 463.5 MG/1.5ML | 5 | PA BvD; NDS |
| SYM TUZA ORAL TABLET 800-150-200-10 MG | 5 | NDS |
| TEMIXYS ORAL TABLET 300-300 MG | 5 | NDS |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | 2 | |
| TIVICAY ORAL TABLET 10 MG | 4 | |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5 | NDS |
| TIVICAY PD ORAL TABLET SOLUBLE 5 MG | 5 | NDS |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 5 | NDS; QL (30 per 30 days) |
| TRIUMEQ PD ORAL TABLET SOLUBLE 60-5-30 MG | 4 | |
| TRIZIVIR ORAL TABLET 300-150-300 MG | 5 | NDS |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33ML | 5 | NDS |
| VEMLIDY ORAL TABLET 25 MG | 5 | ST; NDS; QL (30 per 30 days) |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | 5 | NDS |
| VIREAD ORAL POWDER 40 MG/GM | 5 | NDS |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 5 | NDS |
| VOCABRIA ORAL TABLET 30 MG | 4 | |
| <i>zidovudine oral capsule 100 mg</i> | 2 | |
| <i>zidovudine oral syrup 50 mg/5ml</i> | 2 | |
| <i>zidovudine oral tablet 300 mg</i> | 2 | |
| Antivirals, Miscellaneous | | |
| LIVTENCITY ORAL TABLET 200 MG | 5 | PA; NDS |
| <i>oseltamivir phosphate oral capsule 30 mg</i> | 2 | QL (84 per 180 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>oseltamivir phosphate oral capsule 45 mg</i> | 2 | QL (48 per 180 days) |
| <i>oseltamivir phosphate oral capsule 75 mg</i> | 2 | QL (42 per 180 days) |
| <i>oseltamivir phosphate oral suspension reconstituted 6 mg/ml</i> | 2 | QL (540 per 180 days) |
| PAXLOVID (150/100) ORAL TABLET THERAPY PACK 10 X 150 MG & 10 X 100MG | 2 | QL (20 per 5 days) |
| PAXLOVID (300/100) ORAL TABLET THERAPY PACK 20 X 150 MG & 10 X 100MG | 2 | QL (30 per 5 days) |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 5 | PA; NDS; QL (28 per 28 days) |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/ACT | 4 | QL (60 per 180 days) |
| <i>Hcv Antivirals</i> | | |
| EPCLUSA ORAL PACKET 150-37.5 MG | 5 | PA; NDS; QL (28 per 28 days) |
| EPCLUSA ORAL PACKET 200-50 MG | 5 | PA; NDS; QL (56 per 28 days) |
| EPCLUSA ORAL TABLET 200-50 MG, 400-100 MG | 5 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL PACKET 33.75-150 MG | 5 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL PACKET 45-200 MG | 5 | PA; NDS; QL (56 per 28 days) |
| HARVONI ORAL TABLET 45-200 MG, 90-400 MG | 5 | PA; NDS; QL (28 per 28 days) |
| VOSEVI ORAL TABLET 400-100-100 MG | 5 | PA; NDS; QL (28 per 28 days) |
| <i>Interferons</i> | | |
| INTRON A INJECTION SOLUTION RECONSTITUTED 10000000 UNIT, 18000000 UNIT, 50000000 UNIT | 5 | NDS |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5 | PA; NDS |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 180 MCG/0.5ML | 5 | PA; NDS |
| <i>Nucleosides And Nucleotides</i> | | |
| <i>acyclovir oral capsule 200 mg</i> | 1 | |
| <i>acyclovir oral suspension 200 mg/5ml</i> | 4 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 2 | |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 2 | PA BvD |
| <i>adefovir dipivoxil oral tablet 10 mg</i> | 2 | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | 2 | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ribavirin oral tablet 200 mg</i> | 2 | |
| <i>valacyclovir hcl oral tablet 1 gm, 500 mg</i> | 2 | |
| <i>valganciclovir hcl oral solution reconstituted 50 mg/ml</i> | 5 | NDS |
| <i>valganciclovir hcl oral tablet 450 mg</i> | 2 | |
| BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS | | |
| <i>Anticoagulants</i> | | |
| <i>dabigatran etexilate mesylate oral capsule 110 mg, 150 mg, 75 mg</i> | 2 | QL (60 per 30 days) |
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5 MG | 3 | |
| ELIQUIS ORAL TABLET 2.5 MG | 3 | QL (60 per 30 days) |
| ELIQUIS ORAL TABLET 5 MG | 3 | QL (74 per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 100 mg/ml, 150 mg/ml</i> | 2 | QL (60 per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 120 mg/0.8ml, 80 mg/0.8ml</i> | 2 | QL (48 per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 30 mg/0.3ml</i> | 2 | QL (18 per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 40 mg/0.4ml</i> | 2 | QL (24 per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 60 mg/0.6ml</i> | 2 | QL (36 per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 10 mg/0.8ml</i> | 5 | NDS; QL (24 per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 2.5 mg/0.5ml</i> | 2 | QL (15 per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 5 mg/0.4ml</i> | 5 | NDS; QL (12 per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 7.5 mg/0.6ml</i> | 5 | NDS; QL (18 per 30 days) |
| <i>heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml, 5000 unit/ml</i> | 2 | |
| <i>jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| <i>warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | |
| XARELTO ORAL SUSPENSION RECONSTITUTED 1 MG/ML | 3 | QL (600 per 30 days) |
| XARELTO ORAL TABLET 10 MG, 20 MG | 3 | QL (30 per 30 days) |
| XARELTO ORAL TABLET 15 MG, 2.5 MG | 3 | QL (60 per 30 days) |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20 MG | 3 | |
| <i>Blood Formation Modifiers</i> | | |
| ALVAIZ ORAL TABLET 18 MG, 36 MG, 54 MG, 9 MG | 5 | PA; NDS; QL (60 per 30 days) |
| HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT | 5 | PA; NDS; QL (30 per 30 days) |
| HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 3000 UNIT | 5 | PA; NDS; QL (20 per 30 days) |
| NEULASTA ONPRO SUBCUTANEOUS PREFILLED SYRINGE KIT 6 MG/0.6ML | 5 | PA; NDS |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML | 5 | PA; NDS |
| NIVESTYM INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML | 5 | PA; NDS |
| NYVEPRIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML | 5 | PA; NDS |
| PROMACTA ORAL PACKET 12.5 MG | 5 | PA; NDS; QL (90 per 30 days) |
| PROMACTA ORAL PACKET 25 MG | 5 | PA; NDS; QL (180 per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG | 5 | PA; NDS; QL (90 per 30 days) |
| PROMACTA ORAL TABLET 25 MG | 5 | PA; NDS; QL (30 per 30 days) |
| PROMACTA ORAL TABLET 50 MG, 75 MG | 5 | PA; NDS; QL (60 per 30 days) |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML | 3 | PA; QL (12 per 28 days) |
| RETACRIT INJECTION SOLUTION 40000 UNIT/ML | 3 | PA; QL (4 per 28 days) |
| <i>Hematologic Agents, Miscellaneous</i> | | |
| <i>anagrelide hcl oral capsule 0.5 mg, 1 mg</i> | 2 | |
| <i>tranexamic acid oral tablet 650 mg</i> | 2 | |
| <i>Platelet-Aggregation Inhibitors</i> | | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>aspirin-dipyridamole er oral capsule extended release 12 hour 25-200 mg</i> | 2 | |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 3 | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 2 | |
| <i>clopidogrel bisulfate oral tablet 75 mg</i> | 1 | |
| <i>dipyridamole oral tablet 50 mg, 75 mg</i> | 2 | |
| <i>pentoxifylline er oral tablet extended release 400 mg</i> | 2 | |
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i> | 2 | QL (30 per 30 days) |
| CALORIC AGENTS | | |
| <i>Caloric Agents</i> | | |
| CLINIMIX E/DEXTROSE (8/10) INTRAVENOUS SOLUTION 8 % | 4 | PA BvD |
| CLINIMIX E/DEXTROSE (8/14) INTRAVENOUS SOLUTION 8 % | 4 | PA BvD |
| CLINIMIX/DEXTROSE (6/5) INTRAVENOUS SOLUTION 6 % | 4 | PA BvD |
| CLINIMIX/DEXTROSE (8/10) INTRAVENOUS SOLUTION 8 % | 4 | PA BvD |
| CLINIMIX/DEXTROSE (8/14) INTRAVENOUS SOLUTION 8 % | 4 | PA BvD |
| <i>dextrose intravenous solution 5 %</i> | 2 | |
| PROCALAMINE INTRAVENOUS SOLUTION 3 % | 4 | PA BvD |
| CARDIOVASCULAR AGENTS | | |
| <i>Alpha-Adrenergic Agents</i> | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | |
| <i>clonidine transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr</i> | 2 | |
| <i>doxazosin mesylate oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | 1 | |
| <i>droxidopa oral capsule 100 mg, 200 mg, 300 mg</i> | 5 | PA; NDS; QL (180 per 30 days) |
| <i>guanfacine hcl oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>midodrine hcl oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>prazosin hcl oral capsule 1 mg, 2 mg, 5 mg</i> | 2 | |
| <i>Angiotensin II Receptor Antagonists</i> | | |
| <i>candesartan cilexetil oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>candesartan cilexetil-hctz oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | 2 | |
| ENTRESTO ORAL CAPSULE SPRINKLE 15-16 MG, 6-6 MG | 3 | QL (240 per 30 days) |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG | 3 | QL (60 per 30 days) |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | 2 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | 2 | |
| <i>losartan potassium oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>losartan potassium-hctz oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | 1 | |
| <i>olmesartan medoxomil oral tablet 20 mg, 40 mg, 5 mg</i> | 2 | |
| <i>olmesartan medoxomil-hctz oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | 2 | |
| <i>olmesartan-amlodipine-hctz oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 2 | |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | 2 | |
| <i>telmisartan-hctz oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | 2 | |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> | 2 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | 2 | |
| Angiotensin-Converting Enzyme Inhibitors | | |
| <i>benazepril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | 2 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 2 | |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | 1 | |
| <i>fosinopril sodium oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>fosinopril sodium-hctz oral tablet 10-12.5 mg, 20-12.5 mg</i> | 2 | |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 1 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 1 | |
| <i>moexipril hcl oral tablet 15 mg, 7.5 mg</i> | 2 | |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 2 | |
| <i>quinapril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 2 | |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | |
| <i>trandolapril-verapamil hcl er oral tablet extended release 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg</i> | 2 | |
| Antiarrhythmic Agents | | |
| <i>amiodarone hcl oral tablet 100 mg, 200 mg, 400 mg</i> | 2 | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> | 2 | |
| <i>flecainide acetate oral tablet 100 mg, 150 mg, 50 mg</i> | 2 | |
| MULTAQ ORAL TABLET 400 MG | 3 | |
| <i>pacerone oral tablet 100 mg, 200 mg, 400 mg</i> | 2 | |
| <i>propafenone hcl er oral capsule extended release 12 hour 225 mg, 325 mg, 425 mg</i> | 2 | |
| <i>propafenone hcl oral tablet 150 mg, 225 mg, 300 mg</i> | 2 | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 2 | |
| Beta-Adrenergic Blocking Agents | | |
| <i>acebutolol hcl oral capsule 200 mg, 400 mg</i> | 2 | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | 2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 2 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | 1 | |
| <i>labetalol hcl oral tablet 100 mg, 200 mg, 300 mg</i> | 2 | |
| <i>metoprolol succinate er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>nebivolol hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 2 | |
| <i>propranolol hcl er oral capsule extended release 24 hour 120 mg, 160 mg, 60 mg, 80 mg</i> | 2 | |
| <i>propranolol hcl oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | |
| <i>sorine oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 2 | |
| <i>sotalol hcl (af) oral tablet 120 mg, 160 mg, 80 mg</i> | 2 | |
| <i>sotalol hcl oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 2 | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 4 | |
| Calcium-Channel Blocking Agents | | |
| <i>cartia xt oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg</i> | 2 | |
| <i>diltiazem hcl er beads oral capsule extended release 24 hour 360 mg, 420 mg</i> | 2 | |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg</i> | 2 | |
| <i>diltiazem hcl er oral capsule extended release 12 hour 120 mg, 60 mg, 90 mg</i> | 4 | |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | 2 | |
| <i>dilt-xr oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 2 | |
| <i>taztia xt oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>tiadylt er oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 2 | |
| <i>verapamil hcl er oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 2 | |
| <i>verapamil hcl er oral capsule extended release 24 hour 360 mg</i> | 4 | |
| <i>verapamil hcl er oral tablet extended release 120 mg, 180 mg, 240 mg</i> | 2 | |
| <i>verapamil hcl oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | |
| Cardiovascular Agents, Miscellaneous | | |
| CORLANOR ORAL SOLUTION 5 MG/5ML | 3 | QL (600 per 30 days) |
| <i>digoxin oral tablet 125 mcg, 250 mcg, 62.5 mcg</i> | 2 | |
| <i>epinephrine injection solution 0.3 mg/0.3ml</i> | 3 | QL (4 per 30 days) |
| <i>epinephrine injection solution auto-injector 0.15 mg/0.15ml</i> | 3 | QL (4 per 30 days) |
| <i>epinephrine injection solution auto-injector 0.15 mg/0.3ml, 0.3 mg/0.3ml</i> | 2 | QL (4 per 30 days) |
| <i>hydralazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>icatibant acetate subcutaneous solution prefilled syringe 30 mg/3ml</i> | 5 | PA; NDS; QL (18 per 30 days) |
| <i>ivabradine hcl oral tablet 5 mg, 7.5 mg</i> | 3 | QL (60 per 30 days) |
| <i>metyrosine oral capsule 250 mg</i> | 5 | NDS |
| <i>ranolazine er oral tablet extended release 12 hour 1000 mg</i> | 2 | QL (60 per 30 days) |
| <i>ranolazine er oral tablet extended release 12 hour 500 mg</i> | 2 | QL (120 per 30 days) |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG | 4 | PA; QL (30 per 30 days) |
| Dihydropyridines | | |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | 1 | |
| <i>amlodipine besylate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>amlodipine besylate-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> | 2 | |
| <i>amlodipine-valsartan-hctz oral tablet 10-160-25 mg, 10-320-25 mg, 5-160-25 mg</i> | 2 | |
| <i>felodipine er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>nifedipine er oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg</i> | 2 | |
| <i>nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg</i> | 2 | |
| Diuretics | | |
| <i>amiloride hcl oral tablet 5 mg</i> | 1 | |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 2 | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 2 | |
| <i>furosemide injection solution 10 mg/ml</i> | 1 | |
| <i>furosemide oral solution 10 mg/ml, 8 mg/ml</i> | 2 | |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>spironolactone-hctz oral tablet 25-25 mg</i> | 2 | |
| <i>toremide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 1 | |
| <i>triamterene-hctz oral capsule 37.5-25 mg</i> | 1 | |
| <i>triamterene-hctz oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | |
| Dyslipidemics | | |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg</i> | 2 | |
| <i>amlodipine-atorvastatin oral tablet 10-20 mg, 10-40 mg, 10-80 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 2 | QL (30 per 30 days) |
| <i>atorvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 1 | QL (30 per 30 days) |
| <i>cholestyramine light oral packet 4 gm</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>cholestyramine oral packet 4 gm</i> | 2 | |
| <i>colesevelam hcl oral packet 3.75 gm</i> | 4 | |
| <i>colesevelam hcl oral tablet 625 mg</i> | 2 | |
| <i>colestipol hcl oral packet 5 gm</i> | 2 | |
| <i>colestipol hcl oral tablet 1 gm</i> | 2 | |
| <i>ezetimibe oral tablet 10 mg</i> | 2 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg</i> | 2 | QL (30 per 30 days) |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg</i> | 2 | |
| <i>fenofibrate oral tablet 120 mg, 145 mg, 40 mg, 48 mg, 54 mg</i> | 2 | |
| <i>fenofibrate oral tablet 160 mg</i> | 1 | |
| <i>fluvastatin sodium er oral tablet extended release 24 hour 80 mg</i> | 2 | |
| <i>fluvastatin sodium oral capsule 20 mg, 40 mg</i> | 2 | QL (60 per 30 days) |
| <i>gemfibrozil oral tablet 600 mg</i> | 1 | |
| <i>icosapent ethyl oral capsule 0.5 gm</i> | 2 | QL (240 per 30 days) |
| <i>icosapent ethyl oral capsule 1 gm</i> | 2 | QL (120 per 30 days) |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | |
| NEXLETOL ORAL TABLET 180 MG | 3 | ST; QL (30 per 30 days) |
| NEXLIZET ORAL TABLET 180-10 MG | 3 | ST; QL (30 per 30 days) |
| NIACIN (ANTIHYPERLIPIDEMIC) ORAL TABLET 500 MG | 4 | |
| <i>niacin er (antihyperlipidemic) oral tablet extended release 1000 mg, 500 mg, 750 mg</i> | 2 | |
| NIACOR ORAL TABLET 500 MG | 4 | |
| <i>omega-3-acid ethyl esters oral capsule 1 gm</i> | 2 | ST; QL (120 per 30 days) |
| <i>pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg</i> | 2 | QL (30 per 30 days) |
| <i>pravastatin sodium oral tablet 10 mg, 80 mg</i> | 1 | |
| <i>pravastatin sodium oral tablet 20 mg, 40 mg</i> | 1 | QL (30 per 30 days) |
| <i>prevalite oral packet 4 gm</i> | 2 | |
| REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420 MG/3.5ML | 3 | ST; QL (7 per 28 days) |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/ML | 3 | ST; QL (6 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML | 3 | ST; QL (6 per 28 days) |
| <i>rosuvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg</i> | 1 | QL (30 per 30 days) |
| Renin-Angiotensin-Aldosterone System Inhibitors | | |
| <i>aliskiren fumarate oral tablet 150 mg, 300 mg</i> | 2 | |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> | 2 | |
| KERENDIA ORAL TABLET 10 MG, 20 MG | 3 | PA; QL (30 per 30 days) |
| Vasodilators | | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 2 | |
| <i>isosorbide mononitrate er oral tablet extended release 24 hour 120 mg, 30 mg, 60 mg</i> | 1 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>minitran transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 2 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 2 | |
| <i>nitroglycerin sublingual tablet sublingual 0.3 mg, 0.4 mg, 0.6 mg</i> | 2 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 2 | |
| CENTRAL NERVOUS SYSTEM AGENTS | | |
| Central Nervous System Agents | | |
| <i>amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>amphetamine-dextroamphet er oral capsule extended release 24 hour 20 mg, 25 mg, 30 mg</i> | 2 | QL (60 per 30 days) |
| <i>amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> | 2 | QL (60 per 30 days) |
| <i>atomoxetine hcl oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i> | 2 | QL (60 per 30 days) |
| <i>atomoxetine hcl oral capsule 100 mg, 60 mg, 80 mg</i> | 2 | QL (30 per 30 days) |
| AUSTEDO ORAL TABLET 12 MG, 9 MG | 5 | PA; NDS; QL (120 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| AUSTEDO ORAL TABLET 6 MG | 5 | PA; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG | 5 | PA; NDS; QL (90 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 18 MG, 24 MG | 5 | PA; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 30 MG, 36 MG, 42 MG, 48 MG | 5 | PA; NDS; QL (30 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 6 MG | 5 | PA; NDS; QL (210 per 30 days) |
| AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE THERAPY PACK 12 & 18 & 24 & 30 MG, 6 & 12 & 24 MG | 5 | PA; NDS |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30 MCG/0.5ML | 5 | PA; NDS; QL (1 per 28 days) |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30 MCG/0.5ML | 5 | PA; NDS; QL (1 per 28 days) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 5 | PA; NDS; QL (15 per 30 days) |
| <i>dalfampridine er oral tablet extended release 12 hour 10 mg</i> | 2 | PA; QL (60 per 30 days) |
| <i>dimethyl fumarate oral capsule delayed release 120 mg</i> | 5 | PA; NDS; QL (14 per 7 days) |
| <i>dimethyl fumarate oral capsule delayed release 240 mg</i> | 5 | PA; NDS; QL (60 per 30 days) |
| <i>dimethyl fumarate starter pack oral capsule delayed release therapy pack 120 & 240 mg</i> | 5 | PA; NDS |
| <i> fingolimod hcl oral capsule 0.5 mg</i> | 5 | PA; NDS; QL (30 per 30 days) |
| <i> glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml</i> | 5 | PA; NDS; QL (30 per 30 days) |
| <i> glatiramer acetate subcutaneous solution prefilled syringe 40 mg/ml</i> | 5 | PA; NDS; QL (12 per 28 days) |
| <i> glatopa subcutaneous solution prefilled syringe 20 mg/ml</i> | 5 | PA; NDS; QL (30 per 30 days) |
| <i> glatopa subcutaneous solution prefilled syringe 40 mg/ml</i> | 5 | PA; NDS; QL (12 per 28 days) |
| <i> guanfacine hcl er oral tablet extended release 24 hour 1 mg, 2 mg, 3 mg, 4 mg</i> | 2 | |
| INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG | 5 | PA; NDS; QL (30 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| INGREZZA ORAL CAPSULE SPRINKLE 40 MG, 60 MG, 80 MG | 5 | PA; NDS; QL (30 per 30 days) |
| INGREZZA ORAL CAPSULE THERAPY PACK 40 & 80 MG | 5 | PA; NDS |
| KESIMPTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 20 MG/0.4ML | 5 | PA; NDS; QL (1.2 per 28 days) |
| <i>lithium carbonate er oral tablet extended release 300 mg, 450 mg</i> | 2 | |
| <i>lithium carbonate oral capsule 150 mg, 300 mg</i> | 1 | |
| LITHIUM CARBONATE ORAL CAPSULE 600 MG | 1 | |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | |
| <i>lithium oral solution 8 meq/5ml</i> | 2 | |
| MAVENCLAD (10 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; NDS |
| MAVENCLAD (4 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; NDS |
| MAVENCLAD (5 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; NDS |
| MAVENCLAD (6 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; NDS |
| MAVENCLAD (7 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; NDS |
| MAVENCLAD (8 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; NDS |
| MAVENCLAD (9 TABS) ORAL TABLET THERAPY PACK 10 MG | 5 | PA; NDS |
| MAYZENT ORAL TABLET 0.25 MG | 5 | PA; NDS; QL (112 per 28 days) |
| MAYZENT ORAL TABLET 1 MG, 2 MG | 5 | PA; NDS; QL (30 per 30 days) |
| MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 12 X 0.25 MG | 5 | PA; NDS |
| MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 7 X 0.25 MG | 3 | PA |
| <i>methylphenidate hcl oral solution 10 mg/5ml</i> | 2 | QL (900 per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | QL (90 per 30 days) |
| OCREVUS INTRAVENOUS SOLUTION 300 MG/10ML | 5 | PA; NDS; QL (20 per 180 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| OCREVUS ZUNOVO SUBCUTANEOUS SOLUTION 920-23000 MG-UT/23ML | 5 | PA; NDS; QL (23 per 180 days) |
| PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 63 & 94 MCG/0.5ML | 5 | PA; NDS |
| PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 63 & 94 MCG/0.5ML | 5 | PA; NDS |
| PLEGRIDY SUBCUTANEOUS SOLUTION PEN-INJECTOR 125 MCG/0.5ML | 5 | PA; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MCG/0.5ML | 5 | PA; NDS; QL (1 per 28 days) |
| <i>riluzole oral tablet 50 mg</i> | 2 | |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 3 | QL (60 per 30 days) |
| SAVELLA TITRATION PACK ORAL 12.5 & 25 & 50 MG | 3 | |
| <i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> | 5 | PA; NDS; QL (112 per 28 days) |
| VUMERITY ORAL CAPSULE DELAYED RELEASE 231 MG | 5 | PA; NDS; QL (120 per 30 days) |

CONTRACEPTIVES

Contraceptives

| | | |
|---|---|--|
| <i>afirmelle oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>altavera oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>alyacen 1/35 oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>alyacen 7/7/7 oral tablet 0.5/0.75/1-35 mg-mcg</i> | 2 | |
| <i>amethyst oral tablet 90-20 mcg</i> | 2 | |
| <i>apri oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>aubra eq oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>aurovela 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>aurovela 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>aurovela 24 fe oral tablet 1-20 mg-mcg(24)</i> | 2 | |
| <i>aurovela fe 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>aurovela fe 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>aviane oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>ayuna oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>azurette oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | |
| <i>blisovi 24 fe oral tablet 1-20 mg-mcg(24)</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>blisovi fe 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>blisovi fe 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>camila oral tablet 0.35 mg</i> | 2 | |
| <i>chateal eq oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>cryselle-28 oral tablet 0.3-30 mg-mcg</i> | 2 | |
| <i>cyclafem 1/35 oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>cyclafem 7/7/7 oral tablet 0.5/0.75/1-35 mg-mcg</i> | 2 | |
| <i>cyred eq oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>dasetta 1/35 oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>dasetta 7/7/7 oral tablet 0.5/0.75/1-35 mg-mcg</i> | 2 | |
| <i>deblitane oral tablet 0.35 mg</i> | 2 | |
| <i>delyla oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5), 0.15-30 mg-mcg</i> | 2 | |
| <i>dolishale oral tablet 90-20 mcg</i> | 2 | |
| <i>elimest oral tablet 0.3-30 mg-mcg</i> | 2 | |
| <i>eluryng vaginal ring 0.12-0.015 mg/24hr</i> | 2 | QL (1 per 28 days) |
| <i>emoquette oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>emzahh oral tablet 0.35 mg</i> | 2 | |
| <i>enilloring vaginal ring 0.12-0.015 mg/24hr</i> | 4 | QL (1 per 28 days) |
| <i>enpresse-28 oral tablet 50-30/75-40/ 125-30 mcg</i> | 2 | |
| <i>enskyce oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>errin oral tablet 0.35 mg</i> | 2 | |
| <i>estarylla oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | 2 | |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24hr</i> | 2 | QL (1 per 28 days) |
| <i>falmina oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>femynor oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>hailey 24 fe oral tablet 1-20 mg-mcg(24)</i> | 2 | |
| <i>hailey fe 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>hailey fe 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>haloette vaginal ring 0.12-0.015 mg/24hr</i> | 2 | QL (1 per 28 days) |
| <i>heather oral tablet 0.35 mg</i> | 2 | |
| <i>iclevia oral tablet 0.15-0.03 mg</i> | 2 | QL (91 per 84 days) |
| <i>incassia oral tablet 0.35 mg</i> | 2 | |
| <i>introvale oral tablet 0.15-0.03 mg</i> | 2 | QL (91 per 84 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>isibloom oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>jencycla oral tablet 0.35 mg</i> | 2 | |
| <i>jolessa oral tablet 0.15-0.03 mg</i> | 2 | QL (91 per 84 days) |
| <i>juleber oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>junel 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>junel 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>junel fe 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>junel fe 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>junel fe 24 oral tablet 1-20 mg-mcg(24)</i> | 2 | |
| <i>kariva oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | |
| <i>kelnor 1/35 oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>kelnor 1/50 oral tablet 1-50 mg-mcg</i> | 2 | |
| <i>kurvelo oral tablet 0.15-30 mg-mcg</i> | 2 | |
| KYLEENA INTRAUTERINE INTRAUTERINE DEVICE 19.5 MG | 4 | |
| <i>larin 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>larin 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>larin 24 fe oral tablet 1-20 mg-mcg(24)</i> | 2 | |
| <i>larin fe 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>larin fe 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>larissia oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>lessina oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>levonest oral tablet 50-30/75-40/ 125-30 mcg</i> | 2 | |
| <i>levonorgest-eth estrad 91-day oral tablet 0.15-0.03 mg</i> | 2 | QL (91 per 84 days) |
| <i>levonorgest-eth estradiol-iron oral tablet 0.1-20 mg-mcg(21)</i> | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-30 mg-mcg, 90-20 mcg</i> | 2 | |
| <i>levonorg-eth estrad triphasic oral tablet 50-30/75-40/ 125-30 mcg</i> | 2 | |
| <i>levora 0.15/30 (28) oral tablet 0.15-30 mg-mcg</i> | 2 | |
| LILETTA (52 MG) INTRAUTERINE INTRAUTERINE DEVICE 20.1 MCG/DAY | 3 | |
| <i>lillow oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>low-ogestrel oral tablet 0.3-30 mg-mcg</i> | 2 | |
| <i>lutera oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>lyleq oral tablet 0.35 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>lyza oral tablet 0.35 mg</i> | 2 | |
| <i>marlissa oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>microgestin 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>microgestin 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>microgestin 24 fe oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>microgestin fe 1.5/30 oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>microgestin fe 1/20 oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>mili oral tablet 0.25-35 mg-mcg</i> | 2 | |
| MIRENA (52 MG) INTRAUTERINE INTRAUTERINE DEVICE 20 MCG/DAY | 4 | |
| <i>mono-linyah oral tablet 0.25-35 mg-mcg</i> | 2 | |
| NEXPLANON SUBCUTANEOUS IMPLANT 68 MG | 3 | |
| <i>norelgestromin-eth estradiol transdermal patch weekly 150-35 mcg/24hr</i> | 2 | QL (3 per 28 days) |
| <i>norethin ace-eth estrad-fe oral tablet 1-20 mg- mcg, 1.5-30 mg-mcg</i> | 2 | |
| <i>norethindrone oral tablet 0.35 mg</i> | 2 | |
| <i>norethindron-ethinyl estrad-fe oral tablet 1-20/1- 30/1-35 mg-mcg</i> | 2 | |
| <i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-25 mcg, 0.18/0.215/0.25 mg- 35 mcg</i> | 2 | |
| <i>norlyda oral tablet 0.35 mg</i> | 1 | |
| <i>norlyroc oral tablet 0.35 mg</i> | 1 | |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>nortrel 7/7/7 oral tablet 0.5/0.75/1-35 mg-mcg</i> | 2 | |
| <i>nylia 1/35 oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>nylia 7/7/7 oral tablet 0.5/0.75/1-35 mg-mcg</i> | 2 | |
| <i>nymyo oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>pimtrea oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | |
| <i>pirmella 1/35 oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>pirmella 7/7/7 oral tablet 0.5/0.75/1-35 mg-mcg</i> | 2 | |
| <i>portia-28 oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>previfem oral tablet 0.25-35 mg-mcg</i> | 1 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>reclipsen oral tablet 0.15-30 mg-mcg</i> | 2 | |
| <i>setlakin oral tablet 0.15-0.03 mg</i> | 2 | QL (91 per 84 days) |
| <i>sharobel oral tablet 0.35 mg</i> | 2 | |
| <i>simliya oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | |
| SKYLA INTRAUTERINE INTRAUTERINE DEVICE 13.5 MG | 4 | |
| <i>sprintec 28 oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>sronyx oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>tarina 24 fe oral tablet 1-20 mg-mcg(24)</i> | 2 | |
| <i>tarina fe 1/20 eq oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>tilia fe oral tablet 1-20/1-30/1-35 mg-mcg</i> | 2 | |
| <i>tri femynor oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 2 | |
| <i>tri-estarylla oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 2 | |
| <i>tri-legest fe oral tablet 1-20/1-30/1-35 mg-mcg</i> | 2 | |
| <i>tri-linyah oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 2 | |
| <i>tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | |
| <i>tri-lo-marzia oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | |
| <i>tri-lo-mili oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | |
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | |
| <i>tri-mili oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 2 | |
| <i>tri-nymyo oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 2 | |
| <i>tri-previfem oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 1 | |
| <i>tri-sprintec oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 2 | |
| <i>trivora (28) oral tablet 50-30/75-40/ 125-30 mcg</i> | 2 | |
| <i>tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | |
| <i>tri-vylibra oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 2 | |
| <i>turqoz oral tablet 0.3-30 mg-mcg</i> | 2 | |
| <i>vienva oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>viorele oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | |
| <i>volnea oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>vylibra oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>xulane transdermal patch weekly 150-35 mcg/24hr</i> | 2 | QL (3 per 28 days) |
| <i>zafemy transdermal patch weekly 150-35 mcg/24hr</i> | 2 | QL (3 per 28 days) |
| <i>zovia 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | |
| DENTAL AND ORAL AGENTS | | |
| <i>Dental And Oral Agents</i> | | |
| <i>cevimeline hcl oral capsule 30 mg</i> | 2 | |
| <i>chlorhexidine gluconate mouth/throat solution 0.12 %</i> | 1 | |
| <i>denta 5000 plus dental cream 1.1 %</i> | 1 | |
| <i>dentagel dental gel 1.1 %</i> | 1 | |
| <i>perio gard mouth/throat solution 0.12 %</i> | 1 | |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> | 2 | |
| <i>sf 5000 plus dental cream 1.1 %</i> | 1 | |
| SODIUM FLUORIDE 5000 SENSITIVE DENTAL GEL 1.1-5 % | 1 | |
| <i>sodium fluoride mouth/throat solution 0.2 %</i> | 1 | |
| <i>triamcinolone acetonide mouth/throat paste 0.1 %</i> | 2 | |
| DERMATOLOGICAL AGENTS | | |
| <i>Dermatological Agents, Other</i> | | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | 2 | |
| <i>acyclovir external ointment 5 %</i> | 4 | QL (30 per 30 days) |
| <i>ammonium lactate external cream 12 %</i> | 2 | |
| <i>ammonium lactate external lotion 12 %</i> | 2 | |
| <i>calcipotriene external cream 0.005 %</i> | 2 | QL (120 per 30 days) |
| <i>calcipotriene external ointment 0.005 %</i> | 2 | QL (120 per 30 days) |
| <i>calcipotriene external solution 0.005 %</i> | 2 | QL (120 per 30 days) |
| <i>fluorouracil external cream 5 %</i> | 2 | |
| <i>fluorouracil external solution 2 %</i> | 2 | |
| <i>fluorouracil external solution 5 %</i> | 4 | |
| <i>imiquimod external cream 5 %</i> | 2 | QL (24 per 30 days) |
| KLISYRI EXTERNAL OINTMENT 1 % | 3 | QL (5 per 5 days) |
| <i>methoxsalen rapid oral capsule 10 mg</i> | 5 | NDS |
| PANRETIN EXTERNAL GEL 0.1 % | 5 | NDS; QL (60 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>podofilox external solution 0.5 %</i> | 2 | |
| SANTYL EXTERNAL OINTMENT 250 UNIT/GM | 4 | QL (180 per 30 days) |
| VALCHLOR EXTERNAL GEL 0.016 % | 5 | PA NSO; NDS |
| <i>zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 2 | |
| <i>Dermatological Antibacterials</i> | | |
| <i>clindamycin phos-benzoyl perox external gel 1-5 %</i> | 4 | |
| <i>clindamycin phosphate external solution 1 %</i> | 2 | QL (180 per 30 days) |
| <i>clindamycin phosphate external swab 1 %</i> | 2 | |
| <i>erythromycin external solution 2 %</i> | 2 | |
| <i>gentamicin sulfate external cream 0.1 %</i> | 2 | QL (90 per 30 days) |
| <i>gentamicin sulfate external ointment 0.1 %</i> | 2 | QL (120 per 30 days) |
| <i>metronidazole external cream 0.75 %</i> | 2 | |
| <i>metronidazole external gel 0.75 %</i> | 2 | |
| <i>metronidazole external gel 1 %</i> | 4 | |
| <i>mupirocin external ointment 2 %</i> | 1 | QL (220 per 30 days) |
| <i>neuac external gel 1.2-5 %</i> | 1 | |
| <i>rosadan external cream 0.75 %</i> | 2 | |
| <i>selenium sulfide external lotion 2.5 %</i> | 2 | |
| <i>silver sulfadiazine external cream 1 %</i> | 2 | |
| <i>ssd external cream 1 %</i> | 4 | |
| <i>Dermatological Anti-Inflammatory Agents</i> | | |
| <i>ala-cort external cream 1 %</i> | 2 | |
| <i>betamethasone dipropionate aug external cream 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate aug external gel 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate aug external lotion 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate aug external ointment 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate external cream 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate external lotion 0.05 %</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>betamethasone dipropionate external ointment 0.05 %</i> | 2 | |
| <i>betamethasone valerate external cream 0.1 %</i> | 2 | |
| <i>betamethasone valerate external lotion 0.1 %</i> | 2 | |
| <i>betamethasone valerate external ointment 0.1 %</i> | 2 | |
| <i>clobetasol propionate e external cream 0.05 %</i> | 2 | |
| <i>clobetasol propionate emulsion external foam 0.05 %</i> | 4 | |
| <i>clobetasol propionate external cream 0.05 %</i> | 2 | |
| <i>clobetasol propionate external gel 0.05 %</i> | 2 | |
| <i>clobetasol propionate external lotion 0.05 %</i> | 4 | |
| <i>clobetasol propionate external ointment 0.05 %</i> | 2 | |
| <i>clobetasol propionate external shampoo 0.05 %</i> | 2 | |
| <i>clobetasol propionate external solution 0.05 %</i> | 2 | |
| EUCRISA EXTERNAL OINTMENT 2 % | 3 | |
| <i>fluocinolone acetonide external cream 0.01 %, 0.025 %</i> | 2 | |
| <i>fluocinolone acetonide external ointment 0.025 %</i> | 2 | |
| <i>fluocinonide external cream 0.05 %, 0.1 %</i> | 2 | |
| <i>fluocinonide external gel 0.05 %</i> | 2 | |
| <i>fluocinonide external ointment 0.05 %</i> | 2 | |
| <i>fluocinonide external solution 0.05 %</i> | 2 | |
| <i>fluticasone propionate external cream 0.05 %</i> | 2 | |
| <i>halobetasol propionate external cream 0.05 %</i> | 2 | |
| <i>halobetasol propionate external ointment 0.05 %</i> | 2 | |
| <i>hydrocortisone (perianal) external cream 2.5 %</i> | 2 | |
| <i>hydrocortisone external cream 1 %</i> | 2 | |
| <i>hydrocortisone external lotion 2.5 %</i> | 2 | |
| <i>hydrocortisone external ointment 1 %, 2.5 %</i> | 1 | |
| <i>hydrocortisone valerate external cream 0.2 %</i> | 2 | |
| <i>mometasone furoate external cream 0.1 %</i> | 2 | |
| <i>mometasone furoate external ointment 0.1 %</i> | 2 | |
| <i>mometasone furoate external solution 0.1 %</i> | 2 | |
| <i>pimecrolimus external cream 1 %</i> | 4 | QL (100 per 30 days) |
| <i>procto-med hc external cream 2.5 %</i> | 2 | |
| <i>procto-pak external cream 1 %</i> | 2 | |
| <i>proctosol hc external cream 2.5 %</i> | 2 | |
| <i>proctozone-hc external cream 2.5 %</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>tacrolimus external ointment 0.03 %, 0.1 %</i> | 2 | QL (100 per 30 days) |
| <i>triamcinolone acetonide external cream 0.025 %, 0.1 %, 0.5 %</i> | 1 | |
| <i>triamcinolone acetonide external lotion 0.025 %, 0.1 %</i> | 2 | |
| <i>triamcinolone acetonide external ointment 0.025 %, 0.05 %, 0.1 %, 0.5 %</i> | 2 | |
| <i>Dermatological Retinoids</i> | | |
| <i>adapalene external cream 0.1 %</i> | 4 | |
| ALTRENO EXTERNAL LOTION 0.05 % | 4 | PA |
| <i>tazarotene external cream 0.1 %</i> | 2 | |
| <i>tretinoin external cream 0.025 %, 0.05 %, 0.1 %</i> | 2 | PA |
| <i>Scabicides And Pediculicides</i> | | |
| <i>malathion external lotion 0.5 %</i> | 4 | |
| <i>permethrin external cream 5 %</i> | 2 | QL (60 per 30 days) |
| DEVICES | | |
| <i>Devices</i> | | |
| ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML | 2 | PA; ST |
| BD INSULIN SYRINGE 27.5G X 5/8" 2 ML | 2 | PA; ST |
| COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML | 2 | PA; ST |
| CVS GAUZE STERILE PAD 2"X2" | 1 | PA; ST |
| EXEL COMFORT POINT PEN NEEDLE 29G X 12MM | 2 | PA; ST |
| GLOBAL ALCOHOL PREP EASE PAD 70 % | 1 | PA; ST |
| INPEN 100-BLUE-LILLY-HUMALOG DEVICE | 3 | |
| INPEN 100-BLUE-NOVOLOG-FIASP DEVICE | 3 | |
| OMNIPOD 5 DEXG7G6 INTRO GEN 5 KIT | 3 | QL (1 per 365 days) |
| OMNIPOD 5 DEXG7G6 PODS GEN 5 | 3 | QL (10 per 30 days) |
| OMNIPOD 5 G7 INTRO (GEN 5) KIT | 3 | QL (1 per 365 days) |
| OMNIPOD 5 G7 PODS (GEN 5) | 3 | QL (10 per 30 days) |
| OMNIPOD 5 LIBRE2 PLUS G6 KIT | 3 | QL (1 per 365 days) |
| OMNIPOD 5 LIBRE2 PLUS G6 PODS | 3 | QL (10 per 30 days) |
| OMNIPOD CLASSIC PDM (GEN 3) KIT | 3 | QL (1 per 365 days) |
| OMNIPOD CLASSIC PODS (GEN 3) | 3 | QL (10 per 30 days) |
| OMNIPOD DASH INTRO (GEN 4) KIT | 3 | QL (1 per 365 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| OMNIPOD DASH PDM (GEN 4) KIT | 3 | QL (1 per 365 days) |
| OMNIPOD DASH PODS (GEN 4) | 3 | QL (10 per 30 days) |
| PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML | 2 | PA; ST |
| QC ALCOHOL EXTERNAL 70 % | 1 | PA; ST |
| <i>ra isopropyl alcohol wipes external 70 %</i> | 1 | PA; ST |
| RELI-ON INSULIN SYRINGE 29G 0.3 ML | 2 | PA; ST |
| V-GO 20 KIT 20 UNIT/24HR | 3 | QL (30 per 30 days) |
| V-GO 30 KIT 30 UNIT/24HR | 3 | QL (30 per 30 days) |
| V-GO 40 KIT 40 UNIT/24HR | 3 | QL (30 per 30 days) |
| ENZYME COFACTORS/CHAPERONES | | |
| <i>Enzyme Cofactors/Chaperones</i> | | |
| MIPLYFFA ORAL CAPSULE 124 MG, 47 MG, 62 MG, 93 MG | 5 | PA; NDS; QL (90 per 30 days) |
| ENZYME REPLACEMENT/MODIFIERS | | |
| <i>Enzyme Replacement/Modifiers</i> | | |
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000-38000 UNIT, 24000-76000 UNIT, 3000-9500 UNIT, 36000-114000 UNIT, 6000-19000 UNIT | 3 | |
| <i>javygtor oral tablet 100 mg</i> | 5 | PA; NDS |
| <i>nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg</i> | 5 | PA; NDS |
| ORFADIN ORAL SUSPENSION 4 MG/ML | 5 | PA; NDS |
| PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML | 5 | PA BvD; NDS |
| <i>sapropterin dihydrochloride oral tablet 100 mg</i> | 5 | PA; NDS |
| STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45ML, 28 MG/0.7ML, 40 MG/ML, 80 MG/0.8ML | 5 | PA; NDS |
| ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000 UNIT, 15000-47000 UNIT, 20000-63000 UNIT, 25000-79000 UNIT, 3000-10000 UNIT, 40000-126000 UNIT, 5000-24000 UNIT, 60000-189600 UNIT | 3 | |
| EYE, EAR, NOSE, THROAT AGENTS | | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>Eye, Ear, Nose, Throat Agents, Miscellaneous</i> | | |
| <i>atropine sulfate ophthalmic solution 1 %</i> | 2 | |
| <i>azelastine hcl nasal solution 0.1 %</i> | 2 | QL (60 per 30 days) |
| <i>azelastine hcl nasal solution 0.15 %</i> | 2 | QL (30 per 25 days) |
| <i>azelastine hcl ophthalmic solution 0.05 %</i> | 2 | |
| <i>cromolyn sodium ophthalmic solution 4 %</i> | 2 | |
| <i>epinastine hcl ophthalmic solution 0.05 %</i> | 4 | |
| <i>ipratropium bromide nasal solution 0.03 %</i> | 2 | QL (30 per 28 days) |
| <i>ipratropium bromide nasal solution 0.06 %</i> | 2 | QL (15 per 10 days) |
| <i>olopatadine hcl ophthalmic solution 0.1 %, 0.2 %</i> | 2 | |
| <i>Eye, Ear, Nose, Throat Anti-Infectives Agents</i> | | |
| <i>acetic acid otic solution 2 %</i> | 2 | |
| <i>bacitracin ophthalmic ointment 500 unit/gm</i> | 2 | |
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm</i> | 2 | |
| <i>bacitra-neomycin-polymyxin-hc ophthalmic ointment 1 %</i> | 2 | |
| <i>ciprofloxacin hcl ophthalmic solution 0.3 %</i> | 2 | |
| <i>ciprofloxacin-dexamethasone otic suspension 0.3-0.1 %</i> | 2 | QL (7.5 per 7 days) |
| <i>erythromycin ophthalmic ointment 5 mg/gm</i> | 2 | QL (3.5 per 4 days) |
| GENTAK OPHTHALMIC OINTMENT 0.3 % | 2 | |
| <i>gentamicin sulfate ophthalmic solution 0.3 %</i> | 2 | |
| <i>hydrocortisone-acetic acid otic solution 1-2 %</i> | 2 | |
| <i>moxifloxacin hcl ophthalmic solution 0.5 %</i> | 2 | |
| NATACYN OPHTHALMIC SUSPENSION 5 % | 4 | |
| <i>neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000</i> | 2 | |
| <i>neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1</i> | 2 | |
| <i>neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1</i> | 2 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025</i> | 2 | |
| <i>neomycin-polymyxin-hc otic solution 1 %</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>neomycin-polymyxin-hc otic suspension 3.5-10000-1</i> | 2 | |
| <i>neo-polycin hc ophthalmic ointment 1 %</i> | 2 | |
| <i>neo-polycin ophthalmic ointment 3.5-400-10000</i> | 2 | |
| <i>ofloxacin ophthalmic solution 0.3 %</i> | 2 | |
| <i>ofloxacin otic solution 0.3 %</i> | 2 | |
| <i>polycin ophthalmic ointment 500-10000 unit/gm</i> | 2 | |
| <i>polymyxin b-trimethoprim ophthalmic solution 10000-0.1 unit/ml-%</i> | 1 | |
| <i>sulfacetamide sodium ophthalmic ointment 10 %</i> | 2 | |
| <i>sulfacetamide sodium ophthalmic solution 10 %</i> | 2 | |
| <i>sulfacetamide-prednisolone ophthalmic solution 10-0.23 %</i> | 2 | |
| <i>tobramycin ophthalmic solution 0.3 %</i> | 1 | |
| <i>tobramycin-dexamethasone ophthalmic suspension 0.3-0.1 %</i> | 2 | |
| <i>trifluridine ophthalmic solution 1 %</i> | 2 | |
| XDEMVI OPTHALMIC SOLUTION 0.25 % | 5 | PA; NDS; QL (10 per 42 days) |
| ZIRGAN OPTHALMIC GEL 0.15 % | 4 | |
| ZYLET OPTHALMIC SUSPENSION 0.5-0.3 % | 3 | |
| Eye, Ear, Nose, Throat Anti-Inflammatory Agents | | |
| <i>alrex ophthalmic suspension 0.2 %</i> | 3 | ST |
| <i>bromfenac sodium (once-daily) ophthalmic solution 0.09 %</i> | 4 | |
| <i>bromfenac sodium ophthalmic solution 0.07 %, 0.075 %</i> | 2 | |
| <i>cyclosporine ophthalmic emulsion 0.05 %</i> | 2 | QL (60 per 30 days) |
| <i>dexamethasone sodium phosphate ophthalmic solution 0.1 %</i> | 2 | |
| <i>diclofenac sodium ophthalmic solution 0.1 %</i> | 2 | |
| <i>difluprednate ophthalmic emulsion 0.05 %</i> | 4 | |
| EYSUVIS OPTHALMIC SUSPENSION 0.25 % | 3 | QL (8.3 per 14 days) |
| <i>flunisolide nasal solution 25 mcg/act (0.025%)</i> | 4 | QL (50 per 25 days) |
| <i>fluocinolone acetonide otic oil 0.01 %</i> | 2 | |
| <i>fluorometholone ophthalmic suspension 0.1 %</i> | 4 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction. 2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>flurbiprofen sodium ophthalmic solution 0.03 %</i> | 2 | |
| <i>fluticasone propionate nasal suspension 50 mcg/act</i> | 1 | QL (16 per 30 days) |
| ILEVRO OPHTHALMIC SUSPENSION 0.3 % | 3 | |
| INVELTYS OPHTHALMIC SUSPENSION 1 % | 3 | QL (5.6 per 14 days) |
| <i>ketorolac tromethamine ophthalmic solution 0.5 %</i> | 2 | QL (10 per 25 days) |
| LOTEMAX OPHTHALMIC OINTMENT 0.5 % | 3 | QL (3.5 per 14 days) |
| LOTEMAX SM OPHTHALMIC GEL 0.38 % | 3 | QL (5 per 16 days) |
| <i>loteprednol etabonate ophthalmic gel 0.5 %</i> | 4 | QL (10 per 14 days) |
| <i>loteprednol etabonate ophthalmic suspension 0.2 %</i> | 2 | ST |
| <i>loteprednol etabonate ophthalmic suspension 0.5 %</i> | 4 | QL (15 per 19 days) |
| <i>mometasone furoate nasal suspension 50 mcg/act</i> | 4 | QL (34 per 30 days) |
| <i>prednisolone acetate ophthalmic suspension 1 %</i> | 4 | |
| XIIDRA OPHTHALMIC SOLUTION 5 % | 3 | QL (60 per 30 days) |
| GASTROINTESTINAL AGENTS | | |
| <i>Antiulcer Agents And Acid Suppressants</i> | | |
| <i>amoxicill-clarithro-lansopraz oral therapy pack 500 & 500 & 30 mg</i> | 4 | |
| <i>cimetidine hcl oral solution 300 mg/5ml</i> | 2 | |
| <i>esomeprazole magnesium oral capsule delayed release 20 mg</i> | 2 | QL (30 per 30 days) |
| <i>esomeprazole magnesium oral capsule delayed release 40 mg</i> | 2 | QL (60 per 30 days) |
| <i>esomeprazole magnesium oral packet 10 mg, 20 mg</i> | 4 | ST; QL (30 per 30 days) |
| <i>esomeprazole magnesium oral packet 40 mg</i> | 4 | ST; QL (60 per 30 days) |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | 1 | |
| <i>lansoprazole oral capsule delayed release 15 mg</i> | 2 | QL (30 per 30 days) |
| <i>lansoprazole oral capsule delayed release 30 mg</i> | 2 | QL (60 per 30 days) |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | 2 | |
| <i>omeprazole oral capsule delayed release 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>pantoprazole sodium oral tablet delayed release 20 mg</i> | 1 | QL (30 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>pantoprazole sodium oral tablet delayed release 40 mg</i> | 1 | QL (60 per 30 days) |
| <i>rabeprazole sodium oral tablet delayed release 20 mg</i> | 2 | QL (30 per 30 days) |
| <i>sucralfate oral tablet 1 gm</i> | 2 | |
| Gastrointestinal Agents, Other | | |
| <i>carglumic acid oral tablet soluble 200 mg</i> | 5 | PA; NDS |
| <i>constulose oral solution 10 gm/15ml</i> | 2 | |
| <i>cromolyn sodium oral concentrate 100 mg/5ml</i> | 2 | |
| <i>dicyclomine hcl oral capsule 10 mg</i> | 2 | |
| <i>dicyclomine hcl oral solution 10 mg/5ml</i> | 2 | |
| <i>dicyclomine hcl oral tablet 20 mg</i> | 2 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 2 | |
| <i>enulose oral solution 10 gm/15ml</i> | 2 | |
| <i>generlac oral solution 10 gm/15ml</i> | 2 | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>kionex oral suspension 15 gm/60ml</i> | 2 | |
| <i>lactulose oral solution 10 gm/15ml</i> | 2 | |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 3 | QL (30 per 30 days) |
| LOKELMA ORAL PACKET 10 GM, 5 GM | 3 | |
| <i>loperamide hcl oral capsule 2 mg</i> | 2 | |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i> | 2 | QL (60 per 30 days) |
| <i>metoclopramide hcl oral solution 5 mg/5ml</i> | 2 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | 1 | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 3 | QL (30 per 30 days) |
| <i>sodium polystyrene sulfonate oral powder</i> | 2 | |
| <i>sps oral suspension 15 gm/60ml</i> | 2 | |
| URSODIOL ORAL CAPSULE 200 MG, 400 MG | 5 | NDS |
| <i>ursodiol oral capsule 300 mg</i> | 2 | |
| <i>ursodiol oral tablet 250 mg, 500 mg</i> | 2 | |
| VELTASSA ORAL PACKET 1 GM, 16.8 GM, 25.2 GM, 8.4 GM | 3 | |
| XERMELO ORAL TABLET 250 MG | 5 | PA; NDS; QL (84 per 28 days) |
| Laxatives | | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| CLENPIQ ORAL SOLUTION 10-3.5-12 MG-GM -GM/160ML, 10-3.5-12 MG-GM -GM/175ML | 3 | |
| GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240 GM | 2 | |
| <i>gavilyte-g oral solution reconstituted 236 gm</i> | 2 | |
| <i>gavilyte-n with flavor pack oral solution reconstituted 420 gm</i> | 2 | |
| <i>na sulfate-k sulfate-mg sulf oral solution 17.5-3.13-1.6 gm/177ml</i> | 3 | |
| <i>na sulfate-k sulfate-mg sulf oral solution 17.5-3.13-1.6 gm/177ml 2 pack (480ml)</i> | 2 | |
| <i>peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420 gm</i> | 2 | |
| <i>peg-3350/electrolytes oral solution reconstituted 236 gm</i> | 2 | |
| SUTAB ORAL TABLET 1479-225-188 MG | 3 | |
| GENITOURINARY AGENTS | | |
| <i>Antispasmodics, Urinary</i> | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>fesoterodine fumarate er oral tablet extended release 24 hour 4 mg, 8 mg</i> | 2 | |
| <i>flavoxate hcl oral tablet 100 mg</i> | 2 | |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HOUR 25 MG, 50 MG | 2 | |
| <i>oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg, 5 mg</i> | 2 | |
| <i>oxybutynin chloride oral solution 5 mg/5ml</i> | 2 | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 2 | |
| <i>solifenacin succinate oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>tolterodine tartrate er oral capsule extended release 24 hour 2 mg, 4 mg</i> | 2 | |
| <i>tolterodine tartrate oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>tropium chloride er oral capsule extended release 24 hour 60 mg</i> | 4 | |
| <i>tropium chloride oral tablet 20 mg</i> | 2 | |
| <i>Genitourinary Agents, Miscellaneous</i> | | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>alfuzosin hcl er oral tablet extended release 24 hour 10 mg</i> | 2 | QL (30 per 30 days) |
| <i>dutasteride oral capsule 0.5 mg</i> | 2 | |
| <i>finasteride oral tablet 5 mg</i> | 1 | |
| <i>tamsulosin hcl oral capsule 0.4 mg</i> | 1 | |
| <i>terazosin hcl oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |
| HEAVY METAL ANTAGONISTS | | |
| Heavy Metal Antagonists | | |
| <i>deferasirox granules oral packet 180 mg, 360 mg, 90 mg</i> | 5 | PA; NDS |
| <i>deferasirox oral tablet 180 mg, 360 mg, 90 mg</i> | 2 | PA |
| <i>penicillamine oral tablet 250 mg</i> | 5 | PA; NDS |
| <i>trientine hcl oral capsule 250 mg</i> | 5 | PA; NDS; QL (240 per 30 days) |
| HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING | | |
| Androgens | | |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 2 | |
| <i>oxandrolone oral tablet 10 mg, 2.5 mg</i> | 2 | PA |
| <i>testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | 2 | PA |
| <i>testosterone enanthate intramuscular solution 200 mg/ml</i> | 2 | PA; QL (5 per 28 days) |
| <i>testosterone transdermal gel 12.5 mg/act (1%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)</i> | 4 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal gel 20.25 mg/act (1.62%)</i> | 4 | PA; QL (150 per 30 days) |
| XYOSTED SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/0.5ML, 50 MG/0.5ML, 75 MG/0.5ML | 3 | PA; QL (2 per 28 days) |
| Estrogens And Antiestrogens | | |
| DUAVEE ORAL TABLET 0.45-20 MG | 3 | |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>estradiol transdermal patch twice weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 2 | QL (8 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 2 | QL (4 per 28 days) |
| <i>estradiol vaginal cream 0.1 mg/gm</i> | 2 | |
| <i>estradiol vaginal tablet 10 mcg</i> | 4 | QL (18 per 28 days) |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg, 1-0.5 mg</i> | 2 | |
| <i>mimvey oral tablet 1-0.5 mg</i> | 2 | |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG | 3 | |
| PREMARIN VAGINAL CREAM 0.625 MG/GM | 3 | |
| PREMPHASE ORAL TABLET 0.625-5 MG | 3 | |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 3 | |
| <i>raloxifene hcl oral tablet 60 mg</i> | 2 | |
| <i>yuvafem vaginal tablet 10 mcg</i> | 4 | QL (18 per 28 days) |
| Glucocorticoids/Mineralocorticoids | | |
| <i>dexamethasone oral solution 0.5 mg/5ml</i> | 2 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 2 | |
| <i>dexamethasone sodium phosphate injection solution 10 mg/ml, 120 mg/30ml, 4 mg/ml</i> | 1 | |
| <i>fludrocortisone acetate oral tablet 0.1 mg</i> | 2 | |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | |
| <i>methylprednisolone acetate injection suspension 40 mg/ml</i> | 2 | |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 2 | |
| <i>methylprednisolone oral tablet therapy pack 4 mg</i> | 1 | |
| <i>prednisolone oral solution 15 mg/5ml</i> | 2 | PA BvD |
| <i>prednisolone sodium phosphate oral solution 25 mg/5ml, 6.7 (5 base) mg/5ml</i> | 2 | PA BvD |
| <i>prednisone oral solution 5 mg/5ml</i> | 2 | PA BvD |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | PA BvD |
| <i>prednisone oral tablet therapy pack 10 mg (21), 10 mg (48), 5 mg (21), 5 mg (48)</i> | 2 | |
| <i>triamcinolone acetate injection suspension 40 mg/ml</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| Pituitary | | |
| ACTHAR GEL SUBCUTANEOUS AUTO-INJECTOR 40 UNIT/0.5ML | 5 | PA; NDS; QL (15 per 30 days) |
| ACTHAR GEL SUBCUTANEOUS AUTO-INJECTOR 80 UNIT/ML | 5 | PA; NDS; QL (30 per 30 days) |
| ACTHAR INJECTION GEL 80 UNIT/ML | 5 | PA; NDS; QL (35 per 28 days) |
| <i>desmopressin ace spray refrig nasal solution 0.01 %</i> | 2 | |
| <i>desmopressin acetate oral tablet 0.1 mg, 0.2 mg</i> | 2 | |
| INCRELEX SUBCUTANEOUS SOLUTION 40 MG/4ML | 5 | PA; NDS |
| LANREOTIDE ACETATE SUBCUTANEOUS SOLUTION 120 MG/0.5ML | 5 | PA NSO; NDS; QL (0.5 per 28 days) |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT 11.25 MG, 30 MG | 5 | PA; NDS |
| LUPRON DEPOT-PED (6-MONTH) INTRAMUSCULAR KIT 45 MG | 5 | PA; NDS |
| NORDITROPIN FLEXPPO SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MG/1.5ML, 15 MG/1.5ML, 30 MG/3ML, 5 MG/1.5ML | 5 | PA; NDS |
| <i>octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml</i> | 4 | |
| ORGOVYX ORAL TABLET 120 MG | 5 | PA NSO; NDS |
| ORLISSA ORAL TABLET 150 MG | 5 | PA; NDS; QL (28 per 28 days) |
| ORLISSA ORAL TABLET 200 MG | 5 | PA; NDS; QL (56 per 28 days) |
| SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG | 5 | PA; NDS |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML, 0.6 MG/ML, 0.9 MG/ML | 5 | PA; NDS; QL (60 per 30 days) |
| SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 60 MG/0.2ML | 5 | PA NSO; NDS; QL (0.2 per 28 days) |
| SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 90 MG/0.3ML | 5 | PA NSO; NDS; QL (0.3 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NDS |
| Progestins | | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 104 MG/0.65ML | 3 | QL (0.65 per 84 days) |
| <i>gallifrey oral tablet 5 mg</i> | 2 | |
| <i>medroxyprogesterone acetate intramuscular suspension 150 mg/ml</i> | 2 | QL (1 per 84 days) |
| <i>medroxyprogesterone acetate intramuscular suspension prefilled syringe 150 mg/ml</i> | 2 | QL (1 per 84 days) |
| <i>medroxyprogesterone acetate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>megestrol acetate oral suspension 40 mg/ml, 625 mg/5ml</i> | 2 | |
| <i>norethindrone acetate oral tablet 5 mg</i> | 2 | |
| <i>progesterone oral capsule 100 mg, 200 mg</i> | 2 | |
| Thyroid And Antithyroid Agents | | |
| <i>levothyroxine sodium oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | |
| <i>liothyronine sodium oral tablet 25 mcg, 5 mcg, 50 mcg</i> | 2 | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>propylthiouracil oral tablet 50 mg</i> | 2 | |
| IMMUNOLOGICAL AGENTS | | |
| Immunological Agents | | |
| ACTEMRA ACTPEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 162 MG/0.9ML | 5 | PA; NDS |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10ML, 400 MG/20ML, 80 MG/4ML | 5 | PA; NDS |
| ACTEMRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 162 MG/0.9ML | 5 | PA; NDS |
| ARCALYST SUBCUTANEOUS SOLUTION RECONSTITUTED 220 MG | 5 | PA; NDS |
| ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG, 1 MG | 4 | PA BvD |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------|
| ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 5 MG | 5 | PA BvD; NDS |
| <i>azathioprine oral tablet 50 mg</i> | 2 | PA BvD |
| <i>azathioprine sodium injection solution reconstituted 100 mg</i> | 2 | PA BvD |
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML | 5 | PA; NDS; QL (8 per 28 days) |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML | 5 | PA; NDS; QL (8 per 28 days) |
| BESREMI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 500 MCG/ML | 5 | PA NSO; NDS; QL (2 per 28 days) |
| CIMZIA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 200 MG/ML | 5 | PA; NDS |
| CIMZIA SUBCUTANEOUS KIT 2 X 200 MG | 5 | PA; NDS |
| COSENTYX (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML | 5 | PA; NDS |
| COSENTYX SENSOREADY (300 MG) SUBCUTANEOUS SOLUTION AUTO- INJECTOR 150 MG/ML | 5 | PA; NDS |
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML | 5 | PA; NDS |
| COSENTYX UNOREADY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 300 MG/2ML | 5 | PA; NDS |
| <i>cyclosporine intravenous solution 50 mg/ml</i> | 2 | PA BvD |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | PA BvD |
| <i>cyclosporine modified oral solution 100 mg/ml</i> | 2 | PA BvD |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | 2 | PA BvD |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 200 MG/1.14ML, 300 MG/2ML | 5 | PA; NDS |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.67ML, 200 MG/1.14ML, 300 MG/2ML | 5 | PA; NDS |
| ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML | 5 | PA; NDS |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML | 5 | PA; NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML, 50 MG/ML | 5 | PA; NDS |
| ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED 25 MG | 5 | PA; NDS |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML | 5 | PA; NDS |
| <i>everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg</i> | 5 | PA BvD; NDS |
| GAMUNEX-C INJECTION SOLUTION 1 GM/10ML | 5 | PA BvD; NDS |
| <i>gengraf oral capsule 100 mg, 25 mg</i> | 2 | PA BvD |
| <i>gengraf oral solution 100 mg/ml</i> | 2 | PA BvD |
| HUMIRA (2 PEN) SUBCUTANEOUS PEN- INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML, 80 MG/0.8ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.8ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA-PED<40KG CROHNS STARTER SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML & 40MG/0.4ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA-PED>=40KG CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.8ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA-PSORIASIS/UEVIT STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML & 40MG/0.4ML | 5 | PA; NDS; Only NDCs starting with 00074 |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>infliximab intravenous solution reconstituted 100 mg</i> | 5 | PA; NDS |
| KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.67ML | 5 | PA; NDS |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>mycophenolate mofetil hcl intravenous solution reconstituted 500 mg</i> | 2 | PA BvD |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | 2 | PA BvD |
| <i>mycophenolate mofetil oral suspension reconstituted 200 mg/ml</i> | 5 | PA BvD; NDS |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | 2 | PA BvD |
| <i>mycophenolate sodium oral tablet delayed release 180 mg, 360 mg</i> | 4 | PA BvD |
| NULOJIX INTRAVENOUS SOLUTION RECONSTITUTED 250 MG | 5 | PA BvD; NDS |
| ORENCIA CLICKJECT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 125 MG/ML | 5 | PA; NDS |
| ORENCIA INTRAVENOUS SOLUTION RECONSTITUTED 250 MG | 5 | PA; NDS |
| ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MG/ML, 50 MG/0.4ML, 87.5 MG/0.7ML | 5 | PA; NDS |
| OTEZLA ORAL TABLET 20 MG, 30 MG | 5 | PA; NDS |
| OTEZLA ORAL TABLET THERAPY PACK 10 & 20 & 30 MG, 4 X 10 & 51 X20 MG | 5 | PA; NDS |
| PROGRAF INTRAVENOUS SOLUTION 5 MG/ML | 4 | PA BvD |
| PROGRAF ORAL PACKET 0.2 MG, 1 MG | 4 | PA BvD |
| RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML | 4 | ST |
| REZUROCK ORAL TABLET 200 MG | 5 | PA NSO; NDS |
| RINVOQ LQ ORAL SOLUTION 1 MG/ML | 5 | PA; NDS; QL (360 per 30 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 15 MG, 30 MG, 45 MG | 5 | PA; NDS |
| <i>sirolimus oral solution 1 mg/ml</i> | 5 | PA BvD; NDS |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | PA BvD |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| SKYRIZI (150 MG DOSE) SUBCUTANEOUS PREFILLED SYRINGE KIT 75 MG/0.83ML | 5 | PA; NDS |
| SKYRIZI INTRAVENOUS SOLUTION 600 MG/10ML | 5 | PA; NDS |
| SKYRIZI PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML | 5 | PA; NDS |
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180 MG/1.2ML, 360 MG/2.4ML | 5 | PA; NDS |
| SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML | 5 | PA; NDS |
| STELARA INTRAVENOUS SOLUTION 130 MG/26ML | 5 | PA; NDS |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML | 5 | PA; NDS |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML | 5 | PA; NDS |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> | 2 | PA BvD |
| TAVNEOS ORAL CAPSULE 10 MG | 5 | PA; NDS; QL (180 per 30 days) |
| TREMFYA INTRAVENOUS SOLUTION 200 MG/20ML | 5 | PA; NDS |
| TREMFYA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML | 5 | PA; NDS |
| TREMFYA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 MG/ML | 5 | PA; NDS |
| TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 200 MG/2ML | 5 | PA; NDS |
| XELJANZ ORAL SOLUTION 1 MG/ML | 5 | PA; NDS |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 5 | PA; NDS |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HOUR 11 MG, 22 MG | 5 | PA; NDS |
| Vaccines | | |
| ABRYSVO INTRAMUSCULAR SOLUTION RECONSTITUTED 120 MCG/0.5ML | 3 | \$0 copay |
| ACTHIB INTRAMUSCULAR SOLUTION RECONSTITUTED | 3 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 (PREFILLED SYRINGE), 5-2-15.5 LF-MCG/0.5 | 3 | \$0 copay |
| AREXVY INTRAMUSCULAR SUSPENSION RECONSTITUTED 120 MCG/0.5ML | 3 | \$0 copay |
| BCG VACCINE INJECTION SOLUTION RECONSTITUTED 50 MG | 3 | \$0 copay |
| BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 3 | \$0 copay |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 LF-MCG/0.5 | 3 | \$0 copay |
| BOOSTRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 5-2.5-18.5 LF-MCG/0.5 | 3 | \$0 copay |
| DAPTACEL INTRAMUSCULAR SUSPENSION 23-15-5 | 3 | |
| DENGVAXIA SUBCUTANEOUS SUSPENSION RECONSTITUTED | 3 | QL (3 per 365 days) |
| DIPHThERIA-TETANUS TOXOIDS DT INTRAMUSCULAR SUSPENSION 25-5 LFU/0.5ML | 3 | |
| ENGERIX-B INJECTION SUSPENSION 20 MCG/ML | 3 | PA BvD; \$0 copay |
| ENGERIX-B INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/0.5ML, 20 MCG/ML | 3 | PA BvD; \$0 copay |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION | 3 | \$0 copay |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 3 | \$0 copay |
| HAVRIX INTRAMUSCULAR SUSPENSION 1440 EL U/ML | 3 | \$0 copay |
| HAVRIX INTRAMUSCULAR SUSPENSION 720 EL U/0.5ML | 3 | |
| HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 20 MCG/0.5ML | 3 | PA BvD; \$0 copay |
| HIBERIX INJECTION SOLUTION RECONSTITUTED 10 MCG | 3 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| IMOVAX RABIES INTRAMUSCULAR SUSPENSION RECONSTITUTED 2.5 UNIT/ML | 3 | PA BvD; \$0 copay |
| INFANRIX INTRAMUSCULAR SUSPENSION 25-58-10 | 3 | |
| IPOL INJECTION INJECTABLE | 3 | \$0 copay |
| IXCHIQ INTRAMUSCULAR SOLUTION RECONSTITUTED | 3 | \$0 copay |
| IXIARO INTRAMUSCULAR SUSPENSION | 3 | \$0 copay |
| JYNNEOS SUBCUTANEOUS SUSPENSION 0.5 ML | 3 | \$0 copay |
| KINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | 3 | |
| MENACTRA INTRAMUSCULAR SOLUTION | 3 | \$0 copay |
| MENQUADFI INTRAMUSCULAR SOLUTION | 3 | \$0 copay |
| MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED | 3 | \$0 copay |
| M-M-R II INJECTION SOLUTION RECONSTITUTED | 3 | \$0 copay |
| MRESVIA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 50 MCG/0.5ML | 3 | \$0 copay |
| PEDIARIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 3 | |
| PEDVAX HIB INTRAMUSCULAR SUSPENSION 7.5 MCG/0.5ML | 3 | |
| PENBRAYA INTRAMUSCULAR SUSPENSION RECONSTITUTED | 3 | \$0 copay |
| PENTACEL INTRAMUSCULAR SUSPENSION RECONSTITUTED | 3 | |
| PREHEVBRIO INTRAMUSCULAR SUSPENSION 10 MCG/ML | 3 | PA BvD; \$0 copay |
| PRIORIX SUBCUTANEOUS SUSPENSION RECONSTITUTED | 3 | \$0 copay |
| PROQUAD SUBCUTANEOUS SUSPENSION RECONSTITUTED | 3 | |
| QUADRACEL INTRAMUSCULAR SUSPENSION , (58 UNT/ML) | 3 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| QUADRACEL INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | 3 | |
| RABAVERT INTRAMUSCULAR SUSPENSION RECONSTITUTED | 3 | PA BvD; \$0 copay |
| RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5ML | 3 | PA BvD; \$0 copay |
| RECOMBIVAX HB INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/ML, 5 MCG/0.5ML | 3 | PA BvD; \$0 copay |
| ROTARIX ORAL SUSPENSION | 3 | |
| ROTARIX ORAL SUSPENSION RECONSTITUTED | 3 | |
| ROTATEQ ORAL SOLUTION | 3 | |
| SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50 MCG/0.5ML | 3 | \$0 copay; QL (2 per 365 days) |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML | 3 | \$0 copay |
| TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU, 5-2 LFU (INJECTION) | 3 | \$0 copay |
| TICOVAC INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1.2 MCG/0.25ML | 3 | |
| TICOVAC INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 2.4 MCG/0.5ML | 3 | \$0 copay |
| TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 3 | \$0 copay |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720-20 ELU-MCG/ML | 3 | \$0 copay |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5ML | 3 | \$0 copay |
| TYPHIM VI INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 25 MCG/0.5ML | 3 | \$0 copay |
| VAQTA INTRAMUSCULAR SUSPENSION 25 UNIT/0.5ML, 25 UNIT/0.5ML 0.5 ML | 3 | |
| VAQTA INTRAMUSCULAR SUSPENSION 50 UNIT/ML, 50 UNIT/ML 1 ML | 3 | \$0 copay |
| VARIVAX SUBCUTANEOUS INJECTABLE 1350 PFU/0.5ML | 3 | \$0 copay |
| VAXCHORA ORAL SUSPENSION RECONSTITUTED | 3 | \$0 copay |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| YF-VAX SUBCUTANEOUS INJECTABLE , (2.5 ML IN 1 VIAL, MULTI-DOSE) | 3 | \$0 copay |
| INFLAMMATORY BOWEL DISEASE AGENTS | | |
| <i>Inflammatory Bowel Disease Agents</i> | | |
| <i>alosetron hcl oral tablet 0.5 mg, 1 mg</i> | 2 | |
| <i>balsalazide disodium oral capsule 750 mg</i> | 2 | |
| <i>budesonide oral capsule delayed release particles 3 mg</i> | 4 | |
| <i>budesonide rectal foam 2 mg</i> | 2 | |
| <i>hydrocortisone rectal enema 100 mg/60ml</i> | 2 | |
| <i>mesalamine er oral capsule extended release 24 hour 0.375 gm</i> | 4 | |
| <i>mesalamine er oral capsule extended release 500 mg</i> | 2 | |
| <i>mesalamine oral tablet delayed release 1.2 gm</i> | 4 | QL (120 per 30 days) |
| <i>sulfasalazine oral tablet 500 mg</i> | 2 | |
| <i>sulfasalazine oral tablet delayed release 500 mg</i> | 4 | |
| METABOLIC BONE DISEASE AGENTS | | |
| <i>Metabolic Bone Disease Agents</i> | | |
| <i>alendronate sodium oral solution 70 mg/75ml</i> | 4 | QL (300 per 28 days) |
| <i>alendronate sodium oral tablet 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>alendronate sodium oral tablet 35 mg, 70 mg</i> | 1 | QL (4 per 28 days) |
| <i>calcitonin (salmon) nasal solution 200 unit/act</i> | 2 | |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 2 | |
| <i>cinacalcet hcl oral tablet 30 mg, 60 mg</i> | 2 | QL (60 per 30 days) |
| <i>cinacalcet hcl oral tablet 90 mg</i> | 5 | NDS; QL (120 per 30 days) |
| <i>ibandronate sodium oral tablet 150 mg</i> | 2 | QL (1 per 28 days) |
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG, 25 MCG, 50 MCG, 75 MCG | 5 | PA; NDS; QL (2 per 28 days) |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i> | 4 | |
| PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 60 MG/ML | 4 | QL (1 per 180 days) |
| RAYALDEE ORAL CAPSULE EXTENDED RELEASE 30 MCG | 3 | QL (60 per 30 days) |
| TERIPARATIDE SUBCUTANEOUS SOLUTION PEN-INJECTOR 620 MCG/2.48ML | 5 | PA; NDS; QL (2.48 per 28 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| TYMLOS SUBCUTANEOUS SOLUTION PEN-INJECTOR 3120 MCG/1.56ML | 5 | PA; NDS; QL (1.56 per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7ML | 5 | PA; NDS |
| MISCELLANEOUS THERAPEUTIC AGENTS | | |
| <i>Miscellaneous Therapeutic Agents</i> | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5ML | 5 | PA; NDS |
| <i>betaine oral powder</i> | 5 | PA; NDS |
| <i>buspirone hcl oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 2 | |
| COSENTYX INTRAVENOUS SOLUTION 125 MG/5ML | 5 | PA; NDS |
| <i>diazoxide oral suspension 50 mg/ml</i> | 2 | |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS SOLUTION AUTO- INJECTOR 0.5 MG/0.1ML, 1 MG/0.2ML | 3 | |
| GVOKE KIT SUBCUTANEOUS SOLUTION 1 MG/0.2ML | 3 | |
| GVOKE PFS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 0.5 MG/0.1ML, 1 MG/0.2ML | 3 | |
| <i>hydroxyzine pamoate oral capsule 25 mg, 50 mg</i> | 1 | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 2 | |
| <i>l-glutamine oral packet 5 gm</i> | 5 | PA; NDS; QL (180 per 30 days) |
| MESNEX ORAL TABLET 400 MG | 5 | NDS |
| <i>nitroglycerin rectal ointment 0.4 %</i> | 2 | QL (30 per 30 days) |
| <i>pyridostigmine bromide oral tablet 60 mg</i> | 2 | |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| TYBOST ORAL TABLET 150 MG | 3 | QL (30 per 30 days) |
| VEOZAH ORAL TABLET 45 MG | 4 | PA; QL (30 per 30 days) |
| VOWST ORAL CAPSULE | 5 | PA; NDS; QL (12 per 30 days) |
| ZEGALOGUE SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.6 MG/0.6ML | 3 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------|
| ZEGALOGUE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 0.6 MG/0.6ML | 3 | |
| OPHTHALMIC AGENTS | | |
| <i>Antiglaucoma Agents</i> | | |
| <i>acetazolamide er oral capsule extended release 12 hour 500 mg</i> | 2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 2 | |
| <i>acetazolamide sodium injection solution reconstituted 500 mg</i> | 2 | |
| <i>betaxolol hcl ophthalmic solution 0.5 %</i> | 2 | |
| <i>bimatoprost ophthalmic solution 0.03 %</i> | 4 | QL (2.5 per 25 days) |
| <i>brimonidine tartrate ophthalmic solution 0.1 %, 0.15 %, 0.2 %</i> | 2 | |
| <i>brimonidine tartrate-timolol ophthalmic solution 0.2-0.5 %</i> | 4 | |
| <i>brinzolamide ophthalmic suspension 1 %</i> | 2 | |
| <i>carteolol hcl ophthalmic solution 1 %</i> | 2 | |
| <i>dorzolamide hcl ophthalmic solution 2 %</i> | 2 | |
| <i>dorzolamide hcl-timolol mal ophthalmic solution 2-0.5 %</i> | 2 | |
| <i>latanoprost ophthalmic solution 0.005 %</i> | 1 | QL (2.5 per 25 days) |
| <i>levobunolol hcl ophthalmic solution 0.5 %</i> | 2 | |
| LUMIGAN OPHTHALMIC SOLUTION 0.01 % | 3 | QL (2.5 per 25 days) |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 4 | |
| <i>pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 %</i> | 2 | |
| RHOPRESSA OPHTHALMIC SOLUTION 0.02 % | 3 | QL (2.5 per 25 days) |
| ROCKLATAN OPHTHALMIC SOLUTION 0.02-0.005 % | 3 | QL (2.5 per 25 days) |
| SIMBRINZA OPHTHALMIC SUSPENSION 1- 0.2 % | 3 | |
| <i>tafluprost (pf) ophthalmic solution 0.0015 %</i> | 4 | QL (30 per 30 days) |
| <i>timolol maleate ophthalmic solution 0.25 %, 0.5 %</i> | 1 | |
| <i>travoprost (bak free) ophthalmic solution 0.004 %</i> | 4 | QL (2.5 per 25 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| VYZULTA OPHTHALMIC SOLUTION 0.024 % | 4 | QL (5 per 30 days) |
| REPLACEMENT PREPARATIONS | | |
| <i>Replacement Preparations</i> | | |
| <i>dextrose-sodium chloride intravenous solution 5-0.45 %, 5-0.9 %</i> | 2 | |
| <i>klor-con m10 oral tablet extended release 10 meq</i> | 2 | |
| <i>klor-con m15 oral tablet extended release 15 meq</i> | 2 | |
| <i>klor-con m20 oral tablet extended release 20 meq</i> | 2 | |
| <i>magnesium sulfate injection solution 50 %</i> | 4 | |
| <i>magnesium sulfate injection solution 50 % (10ml syringe)</i> | 2 | |
| <i>potassium chloride crys er oral tablet extended release 10 meq, 15 meq, 20 meq</i> | 2 | |
| <i>potassium chloride er oral capsule extended release 10 meq, 8 meq</i> | 2 | |
| <i>potassium chloride er oral tablet extended release 10 meq, 15 meq, 20 meq, 8 meq</i> | 2 | |
| <i>potassium chloride intravenous solution 2 meq/ml</i> | 2 | PA BvD |
| <i>potassium chloride oral solution 20 meq/15ml (10%), 40 meq/15ml (20%)</i> | 4 | |
| <i>potassium citrate er oral tablet extended release 10 meq (1080 mg), 15 meq (1620 mg), 5 meq (540 mg)</i> | 2 | |
| <i>sodium chloride intravenous solution 0.45 %, 0.9 %</i> | 2 | |
| RESPIRATORY TRACT AGENTS | | |
| <i>Anti-Inflammatories, Inhaled</i> | | |
| <i>Corticosteroids</i> | | |
| ADVAIR HFA INHALATION AEROSOL 115-21 MCG/ACT, 230-21 MCG/ACT, 45-21 MCG/ACT | 3 | QL (12 per 30 days) |
| AIRSUPRA INHALATION AEROSOL 90-80 MCG/ACT | 3 | QL (32.1 per 30 days) |
| ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT | 3 | QL (30 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/ACT, 200-25 MCG/ACT, 50-25 MCG/INH | 3 | QL (60 per 30 days) |
| <i>breyna inhalation aerosol 160-4.5 mcg/act, 80-4.5 mcg/act</i> | 2 | QL (30.9 per 30 days) |
| <i>budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml</i> | 2 | PA BvD; QL (120 per 30 days) |
| <i>budesonide inhalation suspension 1 mg/2ml</i> | 2 | PA BvD; QL (60 per 30 days) |
| <i>budesonide-formoterol fumarate inhalation aerosol 160-4.5 mcg/act, 80-4.5 mcg/act</i> | 2 | QL (30.6 per 30 days) |
| <i>fluticasone propionate hfa inhalation aerosol 110 mcg/act</i> | 2 | QL (12 per 30 days) |
| <i>fluticasone propionate hfa inhalation aerosol 220 mcg/act</i> | 2 | QL (24 per 30 days) |
| <i>fluticasone propionate hfa inhalation aerosol 44 mcg/act</i> | 2 | QL (21.2 per 30 days) |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act</i> | 2 | QL (60 per 30 days) |
| <i>wixela inhub inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act</i> | 2 | QL (60 per 30 days) |
| Antileukotrienes | | |
| <i>montelukast sodium oral tablet 10 mg</i> | 1 | |
| <i>montelukast sodium oral tablet chewable 4 mg, 5 mg</i> | 2 | |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | 4 | |
| Bronchodilators | | |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act</i> | 2 | QL (17 per 30 days) |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020503)</i> | 2 | QL (13.4 per 30 days) |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020983)</i> | 2 | QL (36 per 30 days) |
| <i>albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml</i> | 2 | PA BvD |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25 MCG/ACT | 3 | QL (60 per 30 days) |
| ATROVENT HFA INHALATION AEROSOL SOLUTION 17 MCG/ACT | 4 | QL (25.8 per 28 days) |
| BREZTRI AEROSPHERE INHALATION AEROSOL 160-9-4.8 MCG/ACT | 3 | QL (10.7 per 30 days) |
| COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100 MCG/ACT | 3 | QL (8 per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 2 | PA BvD |
| <i>ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml</i> | 2 | PA BvD; QL (540 per 30 days) |
| SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50 MCG/ACT | 3 | QL (60 per 30 days) |
| SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT, 2.5 MCG/ACT | 3 | QL (4 per 30 days) |
| STIOLTO RESPIMAT INHALATION AEROSOL SOLUTION 2.5-2.5 MCG/ACT | 3 | QL (4 per 30 days) |
| STRIVERDI RESPIMAT INHALATION AEROSOL SOLUTION 2.5 MCG/ACT | 3 | QL (4 per 28 days) |
| <i>theophylline er oral tablet extended release 12 hour 100 mg, 200 mg, 300 mg, 450 mg</i> | 4 | |
| <i>theophylline er oral tablet extended release 24 hour 400 mg, 600 mg</i> | 2 | |
| <i>theophylline oral solution 80 mg/15ml</i> | 2 | |
| <i>tiotropium bromide monohydrate inhalation capsule 18 mcg</i> | 2 | QL (30 per 30 days) |
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT, 200-62.5-25 MCG/ACT | 3 | QL (60 per 30 days) |
| <i>Respiratory Tract Agents, Other</i> | | |
| <i>acetylcysteine inhalation solution 10 %, 20 %</i> | 2 | PA BvD |
| BRONCHITOL INHALATION CAPSULE 40 MG | 5 | NDS; QL (560 per 28 days) |
| CINQAIR INTRAVENOUS SOLUTION 100 MG/10ML | 5 | PA; NDS |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>cromolyn sodium inhalation nebulization solution 20 mg/2ml</i> | 2 | PA BvD |
| FASENRA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 30 MG/ML | 5 | PA; NDS; QL (1 per 28 days) |
| FASENRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.5ML, 30 MG/ML | 5 | PA; NDS; QL (1 per 28 days) |
| KALYDECO ORAL PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG | 5 | PA; NDS; QL (56 per 28 days) |
| KALYDECO ORAL TABLET 150 MG | 5 | PA; NDS; QL (56 per 28 days) |
| NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML | 5 | PA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML | 5 | PA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML | 5 | PA; NDS; QL (0.4 per 28 days) |
| NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED 100 MG | 5 | PA; NDS; QL (3 per 28 days) |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5 | PA; NDS; QL (60 per 30 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5 | PA; NDS; QL (112 per 28 days) |
| <i>pirfenidone oral capsule 267 mg</i> | 5 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 267 mg</i> | 5 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 534 mg, 801 mg</i> | 5 | PA; NDS; QL (90 per 30 days) |
| <i>roflumilast oral tablet 250 mcg</i> | 2 | QL (28 per 28 days) |
| <i>roflumilast oral tablet 500 mcg</i> | 2 | QL (30 per 30 days) |
| WINREVAIR SUBCUTANEOUS KIT 2 X 45 MG, 2 X 60 MG, 45 MG, 60 MG | 5 | PA; NDS; QL (1 per 21 days) |
| XOLAIR SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML, 300 MG/2ML, 75 MG/0.5ML | 5 | PA; NDS |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 300 MG/2ML, 75 MG/0.5ML | 5 | PA; NDS |
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150 MG | 5 | PA; NDS |
| SKELLETAL MUSCLE RELAXANTS | | |
| <i>Skeletal Muscle Relaxants</i> | | |
| <i>baclofen oral tablet 10 mg, 15 mg, 20 mg, 5 mg</i> | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>cyclobenzaprine hcl oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>dantrolene sodium oral capsule 100 mg, 25 mg, 50 mg</i> | 4 | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>tizanidine hcl oral tablet 2 mg, 4 mg</i> | 2 | |
| SLEEP DISORDER AGENTS | | |
| <i>Sleep Disorder Agents</i> | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | 2 | PA; QL (30 per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> | 2 | QL (30 per 30 days) |
| <i>modafinil oral tablet 100 mg</i> | 2 | PA; QL (30 per 30 days) |
| <i>modafinil oral tablet 200 mg</i> | 2 | PA; QL (60 per 30 days) |
| <i>sodium oxybate oral solution 500 mg/ml</i> | 5 | PA; NDS; QL (540 per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>zolpidem tartrate er oral tablet extended release 12.5 mg, 6.25 mg</i> | 2 | QL (30 per 30 days) |
| <i>zolpidem tartrate oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| VASODILATING AGENTS | | |
| <i>Vasodilating Agents</i> | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 5 | PA; NDS; QL (90 per 30 days) |
| <i>alyq oral tablet 20 mg</i> | 2 | PA; QL (60 per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | 5 | PA; NDS; QL (60 per 30 days) |
| OPSUMIT ORAL TABLET 10 MG | 5 | PA; NDS; QL (30 per 30 days) |
| <i>sildenafil citrate oral tablet 100 mg, 25 mg, 50 mg</i> | 6 | EX; QL (4 per 30 days) |
| <i>sildenafil citrate oral tablet 20 mg</i> | 2 | PA; QL (360 per 30 days) |
| <i>tadalafil oral tablet 10 mg, 20 mg</i> | 6 | EX; QL (4 per 30 days) |
| <i>tadalafil oral tablet 2.5 mg, 5 mg</i> | 2 | PA; EX Tier 6; QL (4 per 30 days) |
| UPTRAVI INTRAVENOUS SOLUTION RECONSTITUTED 1800 MCG | 5 | PA; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 400 MCG, 600 MCG, 800 MCG | 5 | PA; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 200 MCG | 5 | PA; NDS; QL (240 per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| UPTRAVI TITRATION ORAL TABLET THERAPY PACK 200 & 800 MCG | 5 | PA; NDS |
| <i>ildenafil hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 6 | EX; QL (4 per 30 days) |
| <i>ildenafil hcl oral tablet dispersible 10 mg</i> | 6 | EX; QL (4 per 30 days) |
| VITAMINS AND MINERALS | | |
| <i>Vitamins And Minerals</i> | | |
| PRENATAL ORAL TABLET 27-1 MG | 2 | |

You can find information on the symbols and abbreviations on this table by going to page 11 of the introduction.
2025 Alterwood Advantage Choice Plus, Formulary ID 00025489.

Index of Drugs/Alphabetical Listing

| A | | |
|---|--|--------|
| <i>abacavir sulfate</i> | | 55 |
| <i>abacavir sulfate-lamivudine</i> ... | | 56 |
| ABELCET | | 45 |
| ABILIFY ASIMTUFII..... | | 51 |
| ABILIFY MAINTENA..... | | 51 |
| <i>abiraterone acetate</i> | | 23 |
| ABRYSVO..... | | 94 |
| <i>acamprosate calcium</i> | | 16 |
| <i>acarbose</i> | | 42 |
| <i>acebutolol hcl</i> | | 64 |
| <i>acetaminophen-codeine</i> | | 14 |
| <i>acetazolamide</i> | | 100 |
| <i>acetazolamide er</i> | | 100 |
| <i>acetazolamide sodium</i> | | 100 |
| <i>acetic acid</i> | | 82 |
| <i>acetylcysteine</i> | | 103 |
| <i>acitretin</i> | | 77 |
| ACTEMRA | | 90 |
| ACTEMRA ACTPEN..... | | 90 |
| ACTHAR | | 89 |
| ACTHAR GEL..... | | 89 |
| ACTHIB | | 94 |
| ACTIMMUNE | | 99 |
| <i>acyclovir</i> | | 59, 77 |
| <i>acyclovir sodium</i> | | 59 |
| ADACEL..... | | 95 |
| <i>adapalene</i> | | 80 |
| <i>adefovir dipivoxil</i> | | 59 |
| ADEMPAS..... | | 105 |
| ADVAIR HFA | | 101 |
| <i>afirmelle</i> | | 72 |
| AIRSUPRA | | 101 |
| AJOVY..... | | 47 |
| AKEEGA | | 23 |
| <i>ala-cort</i> | | 78 |
| <i>albendazole</i> | | 49 |
| <i>albuterol sulfate</i> | | 102 |
| <i>albuterol sulfate hfa</i> | | 102 |
| ALECENSA | | 23 |
| <i>alendronate sodium</i> | | 98 |
| <i>alfuzosin hcl er</i> | | 87 |
| <i>aliskiren fumarate</i> | | 69 |
| <i>allopurinol</i> | | 47 |
| <i>alosetron hcl</i> | | 98 |
| <i>aprazolam</i> | | 17 |
| <i>alrex</i> | | 83 |
| <i>altavera</i> | | 72 |
| ALTRENO | | 80 |
| ALUNBRIG | | 23 |
| ALVAIZ | | 61 |
| <i>alyacen 1/35</i> | | 72 |
| <i>alyacen 7/7/7</i> | | 72 |
| <i>alyq</i> | | 105 |
| <i>amantadine hcl</i> | | 50 |
| <i>amethyst</i> | | 72 |
| <i>amikacin sulfate</i> | | 18 |
| <i>amiloride hcl</i> | | 67 |
| <i>amiloride-hydrochlorothiazide</i> | | 67 |
| <i>amiodarone hcl</i> | | 64 |
| <i>amitriptyline hcl</i> | | 39 |
| <i>amlodipine besy-benazepril hcl</i> | | 66 |
| <i>amlodipine besylate</i> | | 66 |
| <i>amlodipine besylate-valsartan</i> | | 66 |
| <i>amlodipine-atorvastatin</i> | | 67 |
| <i>amlodipine-olmesartan</i> | | 67 |
| <i>amlodipine-valsartan-hctz</i> | | 67 |
| <i>ammonium lactate</i> | | 77 |
| <i>amoxapine</i> | | 39 |
| <i>amoxicill-clarithro-lansopraz</i> | | 84 |
| <i>amoxicillin</i> | | 21 |
| <i>amoxicillin-pot clavulanate</i> | | 21 |
| <i>amphetamine-dextroamphet er</i> | | 69 |
| <i>amphetamine-</i> <i>dextroamphetamine</i> | | 69 |
| <i>amphotericin b</i> | | 46 |
| <i>amphotericin b liposome</i> | | 46 |
| <i>ampicillin</i> | | 21 |
| <i>ampicillin sodium</i> | | 21 |
| <i>ampicillin-sulbactam sodium</i> | | 21 |
| <i>anagrelide hcl</i> | | 61 |
| <i>anastrozole</i> | | 23 |
| ANKTIVA..... | | 23 |
| ANORO ELLIPTA..... | | 103 |
| <i>aprepitant</i> | | 49 |
| APRETUDE | | 56 |
| <i>apri</i> | | 72 |
| APTIOM..... | | 35 |
| APTIVUS | | 56 |
| ARCALYST | | 90 |
| AREXVY | | 95 |
| ARIKAYCE | | 18 |
| <i>aripiprazole</i> | | 51 |
| ARISTADA | | 51 |
| ARISTADA INITIO..... | | 51 |
| <i>armodafinil</i> | | 105 |
| ARNUITY ELLIPTA..... | | 101 |
| <i>asenapine maleate</i> | | 52 |
| <i>aspirin-dipyridamole er</i> | | 62 |
| ASSURE ID INSULIN SAFETY SYR | | 80 |
| ASTAGRAF XL..... | | 90, 91 |
| <i>atazanavir sulfate</i> | | 56 |
| <i>atenolol</i> | | 64 |
| <i>atenolol-chlorthalidone</i> | | 65 |
| <i>atomoxetine hcl</i> | | 69 |
| <i>atorvastatin calcium</i> | | 67 |
| <i>atovaquone</i> | | 49 |

| | | | | | |
|---------------------------------------|--------|--|-----|---|---------|
| <i>atovaquone-proguanil hcl</i> | 49 | BENDAMUSTINE HCL | 24 | <i>bromfenac sodium (once-daily)</i> | 83 |
| <i>atropine sulfate</i> | 82 | BENDEKA | 24 | | 83 |
| ATROVENT HFA | 103 | BENLYSTA | 91 | <i>bromocriptine mesylate</i> | 50 |
| <i>aubra eq.</i> | 72 | <i>benztropine mesylate</i> | 50 | BRONCHITOL | 103 |
| AUGTYRO | 23 | BESREMI..... | 91 | BRUKINSA..... | 24 |
| <i>aurovela 1.5/30</i> | 72 | <i>betaine</i> | 99 | <i>budesonide</i> | 98, 102 |
| <i>aurovela 1/20</i> | 72 | <i>betamethasone dipropionate</i> .78, | 79 | <i>budesonide-formoterol fumarate</i> | 102 |
| <i>aurovela 24 fe</i> | 72 | <i>betamethasone dipropionate aug</i> | 78 | | 102 |
| <i>aurovela fe 1.5/30</i> | 72 | | 78 | <i>bumetanide</i> | 67 |
| <i>aurovela fe 1/20</i> | 72 | <i>betamethasone valerate</i> | 79 | <i>buprenorphine</i> | 14 |
| AUSTEDO | 69, 70 | BETASERON | 70 | <i>buprenorphine hcl</i> | 16 |
| AUSTEDO XR..... | 70 | <i>betaxolol hcl</i> | 100 | <i>buprenorphine hcl-naloxone hcl</i> | 16 |
| AUSTEDO XR PATIENT | | <i>bethanechol chloride</i> | 86 | | 16 |
| TITRATION..... | 70 | <i>bexarotene</i> | 24 | <i>bupropion hcl</i> | 40 |
| AUVELITY | 39 | BEXSERO..... | 95 | <i>bupropion hcl er (smoking det)</i> | 16 |
| <i>aviane</i> | 72 | <i>bicalutamide</i> | 24 | | 16 |
| AVONEX PEN | 70 | BICILLIN L-A | 21 | <i>bupropion hcl er (sr)</i> | 39 |
| AVONEX PREFILLED..... | 70 | BIKTARVY | 56 | <i>bupropion hcl er (xl)</i> | 40 |
| <i>ayuna</i> | 72 | <i>bimatoprost</i> | 100 | <i>bupirone hcl</i> | 99 |
| AYVAKIT..... | 23 | <i>bisoprolol fumarate</i> | 65 | <i>butalbital-apap-caff-cod</i> | 14 |
| <i>azacitidine</i> | 23 | <i>bisoprolol-hydrochlorothiazide</i> | 65 | <i>butalbital-apap-caffeine</i> | 14 |
| <i>azathioprine</i> | 91 | | 65 | C | |
| <i>azathioprine sodium</i> | 91 | <i>bleomycin sulfate</i> | 24 | CABENUVA..... | 56 |
| <i>azelastine hcl</i> | 82 | <i>blisovi 24 fe</i> | 72 | <i>cabergoline</i> | 50 |
| <i>azithromycin</i> | 20 | <i>blisovi fe 1.5/30</i> | 73 | CABOMETYX..... | 24 |
| <i>aztreonam</i> | 20 | <i>blisovi fe 1/20</i> | 73 | <i>calcipotriene</i> | 77 |
| <i>azurette</i> | 72 | BOOSTRIX | 95 | <i>calcitonin (salmon)</i> | 98 |
| B | | <i>bortezomib</i> | 24 | <i>calcitriol</i> | 98 |
| <i>bacitracin</i> | 82 | BORUZU..... | 24 | CALQUENCE..... | 24 |
| <i>bacitracin-polymyxin b</i> | 82 | <i>bosentan</i> | 105 | <i>camila</i> | 73 |
| <i>bacitra-neomycin-polymyxin-hc</i> | 82 | BOSULIF | 24 | <i>candesartan cilexetil</i> | 62 |
| | 82 | BRAFTOVI..... | 24 | <i>candesartan cilexetil-hctz</i> | 63 |
| <i>baclofen</i> | 104 | BREO ELLIPTA | 102 | CAPLYTA..... | 52 |
| <i>balsalazide disodium</i> | 98 | <i>breyna</i> | 102 | CAPRELSA..... | 24 |
| BALVERSA..... | 23 | BREZTRI AEROSPHERE... 103 | | <i>captopril</i> | 63 |
| BCG VACCINE..... | 95 | BRILINTA | 62 | <i>carbamazepine</i> | 36 |
| BD INSULIN SYRINGE..... | 80 | <i>brimonidine tartrate</i> | 100 | <i>carbamazepine er</i> | 36 |
| BELSOMRA | 105 | <i>brimonidine tartrate-timolol</i> .100 | | <i>carbidopa-levodopa</i> | 50 |
| <i>benazepril hcl</i> | 63 | <i>brinzolamide</i> | 100 | <i>carbidopa-levodopa er</i> | 50 |
| <i>benazepril-hydrochlorothiazide</i> | 63 | BRIVIACT | 35 | <i>carglumic acid</i> | 85 |
| | 63 | <i>bromfenac sodium</i> | 83 | <i>carteolol hcl</i> | 100 |
| <i>bendamustine hcl</i> | 24 | | | <i>cartia xt</i> | 65 |

| | | | | | |
|--------------------------------------|--------|--|---------|--|-------------|
| <i>carvedilol</i> | 65 | <i>clindamycin phos-benzoyl perox</i> | | COMETRIQ (60 MG DAILY | |
| CAYSTON..... | 20 | | 78 | DOSE) | 24 |
| <i>cefactor</i> | 19 | <i>clindamycin phosphate</i> | 18, 47, | COMFORT ASSIST INSULIN | |
| <i>cefadroxil</i> | 19 | 78 | | SYRINGE..... | 80 |
| <i>cefazolin sodium</i> | 19 | CLINIMIX E/DEXTROSE | | COMPLERA | 56 |
| <i>cefdinir</i> | 19 | (8/10)..... | 62 | <i>compro</i> | 49 |
| <i>cefepime hcl</i> | 19 | CLINIMIX E/DEXTROSE | | <i>constulose</i> | 85 |
| <i>cefixime</i> | 19 | (8/14)..... | 62 | COPIKTRA | 24 |
| <i>cefoxitin sodium</i> | 19 | CLINIMIX/DEXTROSE (6/5) | | CORLANOR | 66 |
| <i>cefpodoxime proxetil</i> | 19 | | 62 | COSENTYX..... | 91, 99 |
| <i>cefprozil</i> | 19 | CLINIMIX/DEXTROSE (8/10) | | COSENTYX (300 MG DOSE) | |
| <i>ceftazidime</i> | 19, 20 | | 62 | | 91 |
| <i>ceftriaxone sodium</i> | 20 | CLINIMIX/DEXTROSE (8/14) | | COSENTYX SENSOREADY | |
| <i>cefuroxime axetil</i> | 20 | | 62 | (300 MG)..... | 91 |
| <i>cefuroxime sodium</i> | 20 | <i>clobazam</i> | 36 | COSENTYX UNOREADY .. | 91 |
| <i>celecoxib</i> | 15 | <i>clobetasol propionate</i> | 79 | COTELLIC..... | 24 |
| <i>cephalexin</i> | 20 | <i>clobetasol propionate e</i> | 79 | CREON..... | 81 |
| <i>cevimeline hcl</i> | 77 | <i>clobetasol propionate emulsion</i> | | <i>cromolyn sodium</i> | 82, 85, 104 |
| <i>chateal eq</i> | 73 | | 79 | <i>cryselle-28</i> | 73 |
| <i>chlordiazepoxide hcl</i> | 17 | <i>clomipramine hcl</i> | 40 | CVS GAUZE STERILE..... | 80 |
| <i>chlorhexidine gluconate</i> | 77 | <i>clonazepam</i> | 17 | <i>cyclafem 1/35</i> | 73 |
| <i>chloroquine phosphate</i> | 49 | <i>clonidine</i> | 62 | <i>cyclafem 7/7/7</i> | 73 |
| <i>chlorpromazine hcl</i> | 52 | <i>clonidine hcl</i> | 62 | <i>cyclobenzaprine hcl</i> | 105 |
| <i>chlorthalidone</i> | 67 | <i>clopidogrel bisulfate</i> | 62 | <i>cyclophosphamide</i> | 24, 25 |
| <i>cholestyramine</i> | 68 | <i>clorazepate dipotassium</i> | 17 | CYCLOPHOSPHAMIDE | 25 |
| <i>cholestyramine light</i> | 67 | <i>clotrimazole</i> | 46 | <i>cyclosporine</i> | 83, 91 |
| <i>ciclopirox</i> | 46 | <i>clotrimazole-betamethasone</i> ... | 46 | <i>cyclosporine modified</i> | 91 |
| <i>ciclopirox olamine</i> | 46 | <i>clozapine</i> | 52 | <i>cyred eq</i> | 73 |
| <i>cilostazol</i> | 62 | COARTEM | 49 | D | |
| CIMDUO..... | 56 | COBENFY | 52 | <i>dabigatran etexilate mesylate</i> . | 60 |
| <i>cimetidine hcl</i> | 84 | COBENFY STARTER PACK | | <i>dalfampridine er</i> | 70 |
| CIMZIA..... | 91 | | 52 | <i>danazol</i> | 87 |
| CIMZIA (2 SYRINGE)..... | 91 | <i>colchicine</i> | 47 | <i>dantrolene sodium</i> | 105 |
| <i>cinacalcet hcl</i> | 98 | <i>colchicine-probenecid</i> | 47 | DANYELZA | 25 |
| CINQAIR | 103 | <i>colesevelam hcl</i> | 68 | DANZITEN | 25 |
| <i>ciprofloxacin hcl</i> | 22, 82 | <i>colestipol hcl</i> | 68 | <i>dapsone</i> | 48 |
| <i>ciprofloxacin in d5w</i> | 22 | <i>colistimethate sodium (cba)</i> ... | 18 | DAPTACEL | 95 |
| <i>ciprofloxacin-dexamethasone</i> . | 82 | COMBIVENT RESPIMAT . | 103 | <i>daptomycin</i> | 18 |
| <i>citalopram hydrobromide</i> | 40 | COMETRIQ (100 MG DAILY | | DAPTOMYCIN | 18 |
| <i>clarithromycin</i> | 20 | DOSE) | 24 | <i>darunavir</i> | 56 |
| CLENPIQ..... | 86 | COMETRIQ (140 MG DAILY | | <i>dasatinib</i> | 25 |
| <i>clindamycin hcl</i> | 18 | DOSE) | 24 | <i>dassetta 1/35</i> | 73 |

| | | | | | |
|---|--------|--|--------|---|--------|
| <i>dasetta 7/7/7</i> | 73 | <i>diltiazem hcl er beads</i> | 65 | ELIQUIS DVT/PE STARTER | |
| DAURISMO..... | 25 | <i>diltiazem hcl er coated beads</i> . | 65 | PACK | 60 |
| <i>deblitane</i> | 73 | <i>dilt-xr</i> | 65 | ELREXFIO..... | 25 |
| <i>decitabine</i> | 25 | <i>dimethyl fumarate</i> | 70 | <i>eluryng</i> | 73 |
| <i>deferasirox</i> | 87 | <i>dimethyl fumarate starter pack</i> | | EMCYT | 25 |
| <i>deferasirox granules</i> | 87 | | 70 | EMGALITY | 48 |
| DELSTRIGO..... | 56 | <i>diphenoxylate-atropine</i> | 85 | EMGALITY (300 MG DOSE) | |
| <i>delyla</i> | 73 | DIPHThERIA-TETANUS | | | 48 |
| <i>demeclocycline hcl</i> | 22 | TOXOIDS DT | 95 | <i>emoquette</i> | 73 |
| DENGVAXIA..... | 95 | <i>dipyridamole</i> | 62 | EMSAM | 40 |
| <i>denta 5000 plus</i> | 77 | <i>disulfiram</i> | 16 | <i>emtricitabine</i> | 56 |
| <i>dentagel</i> | 77 | <i>divalproex sodium</i> | 36 | <i>emtricitabine-tenofovir df</i> | 56 |
| DEPO-SUBQ PROVERA 104 | | <i>divalproex sodium er</i> | 36 | EMTRIVA..... | 56 |
| | 90 | <i>dofetilide</i> | 64 | <i>emzahh</i> | 73 |
| DESCOVY | 56 | <i>dolishale</i> | 73 | <i>enalapril maleate</i> | 63 |
| <i>desipramine hcl</i> | 40 | <i>donepezil hcl</i> | 39 | <i>enalapril-hydrochlorothiazide</i> | 64 |
| <i>desmopressin ace spray refrig</i> | 89 | <i>dorzolamide hcl</i> | 100 | ENBREL..... | 91, 92 |
| <i>desmopressin acetate</i> | 89 | <i>dorzolamide hcl-timolol mal</i> | 100 | ENBREL MINI | 91 |
| <i>desogestrel-ethinyl estradiol</i> .. | 73 | DOVATO | 56 | ENBREL SURECLICK | 92 |
| <i>desvenlafaxine succinate er</i> | 40 | <i>doxazosin mesylate</i> | 62 | <i>endocet</i> | 14 |
| <i>dexamethasone</i> | 88 | <i>doxepin hcl</i> | 40 | ENGERIX-B..... | 95 |
| <i>dexamethasone sodium</i> | | <i>doxorubicin hcl liposomal</i> | 25 | <i>enilloring</i> | 73 |
| <i>phosphate</i> | 83, 88 | <i>doxy 100</i> | 22 | <i>enoxaparin sodium</i> | 60 |
| <i>dextrose</i> | 62 | <i>doxycycline hyclate</i> | 22, 23 | <i>enpresse-28</i> | 73 |
| <i>dextrose-sodium chloride</i> | 101 | <i>doxycycline monohydrate</i> | 23 | <i>enskyce</i> | 73 |
| DIACOMIT..... | 36 | DRIZALMA SPRINKLE..... | 40 | <i>entacapone</i> | 50 |
| <i>diazepam</i> | 17, 36 | <i>dronabinol</i> | 49 | <i>entecavir</i> | 59 |
| <i>diazepam intensol</i> | 17 | <i>droxidopa</i> | 62 | ENTRESTO..... | 63 |
| <i>diazoxide</i> | 99 | DUAVEE..... | 87 | <i>enulose</i> | 85 |
| <i>diclofenac potassium</i> | 15 | <i>duloxetine hcl</i> | 40 | EPCLUSA | 59 |
| <i>diclofenac sodium</i> | 15, 83 | DUPIXENT | 91 | EPIDIOLEX | 36 |
| <i>diclofenac sodium er</i> | 15 | <i>dutasteride</i> | 87 | <i>epinastine hcl</i> | 82 |
| <i>diclofenac-misoprostol</i> | 15 | E | | <i>epinephrine</i> | 66 |
| <i>dicloxacillin sodium</i> | 21 | <i>econazole nitrate</i> | 46 | <i>epitol</i> | 36 |
| <i>dicyclomine hcl</i> | 85 | EDURANT | 56 | EPIVIR HBV | 56 |
| <i>didanosine</i> | 56 | <i>efavirenz</i> | 56 | EPKINLY | 25 |
| DIFICID | 20 | <i>efavirenz-emtricitab-tenofo df</i> | 56 | <i>eplerenone</i> | 69 |
| <i>difluprednate</i> | 83 | <i>efavirenz-lamivudine-tenofovir</i> | | EPRONTIA | 36 |
| <i>digoxin</i> | 66 | | 56 | ERBITUX..... | 25 |
| <i>dihydroergotamine mesylate</i> .. | 48 | ELIGARD | 25 | <i>ergoloid mesylates</i> | 39 |
| <i>diltiazem hcl</i> | 65 | <i>elinest</i> | 73 | ERIVEDGE | 25 |
| <i>diltiazem hcl er</i> | 65 | ELIQUIS | 60 | ERLEADA | 25 |

| | | | | | |
|---|--------|--|--------|---|------------|
| <i>erlotinib hcl</i> | 25 | <i>felbamate</i> | 36 | <i>fluvastatin sodium</i> | 68 |
| <i>errin</i> | 73 | <i>felodipine er</i> | 67 | <i>fluvastatin sodium er</i> | 68 |
| <i>ertapenem sodium</i> | 21 | <i>femynor</i> | 73 | <i>fluvoxamine maleate</i> | 40 |
| <i>erythromycin</i> | 78, 82 | <i>fenofibrate</i> | 68 | <i>fondaparinux sodium</i> | 60 |
| <i>erythromycin base</i> | 20 | <i>fenofibrate micronized</i> | 68 | <i>fosamprenavir calcium</i> | 56 |
| <i>erythromycin ethylsuccinate</i> ... | 20 | <i>fentanyl</i> | 14 | <i>fosinopril sodium</i> | 64 |
| <i>escitalopram oxalate</i> | 40 | <i>fentanyl citrate</i> | 14 | <i>fosinopril sodium-hctz</i> | 64 |
| <i>esomeprazole magnesium</i> | 84 | <i>fesoterodine fumarate er</i> | 86 | <i>fosphenytoin sodium</i> | 36 |
| <i>estarylla</i> | 73 | FETZIMA..... | 40 | FOTIVDA..... | 26 |
| <i>estradiol</i> | 87, 88 | FETZIMA TITRATION | 40 | FRUZAQLA..... | 26 |
| <i>estradiol-norethindrone acet</i> .. | 88 | FIASP | 44 | <i>fulvestrant</i> | 26 |
| <i>eszopiclone</i> | 105 | FIASP FLEXTOUCH | 44 | <i>furosemide</i> | 67 |
| <i>ethambutol hcl</i> | 48 | FIASP PENFILL | 44 | FUZEON | 57 |
| <i>ethosuximide</i> | 36 | <i>finasteride</i> | 87 | FYARRO | 26 |
| <i>ethynodiol diac-eth estradiol</i> .. | 73 | <i>finolimid hcl</i> | 70 | FYCOMPA..... | 36 |
| <i>etodolac</i> | 15 | FINTEPLA | 36 | G | |
| <i>etonogestrel-ethinyl estradiol</i> . | 73 | FIRMAGON..... | 26 | <i>gabapentin</i> | 36, 37 |
| ETOPOPHOS..... | 25 | FIRMAGON (240 MG DOSE) | | <i>galantamine hydrobromide</i> | 39 |
| <i>etoposide</i> | 26 | | 26 | <i>galantamine hydrobromide er</i> | 39 |
| <i>etravirine</i> | 56 | <i>flavoxate hcl</i> | 86 | <i>gallifrey</i> | 90 |
| EUCRISA..... | 79 | <i>flecainide acetate</i> | 64 | GAMUNEX-C..... | 92 |
| <i>everolimus</i> | 26, 92 | <i>floxuridine</i> | 26 | GARDASIL 9..... | 95 |
| EVOTAZ..... | 56 | <i>fluconazole</i> | 46 | GAVILYTE-C..... | 86 |
| EXEL COMFORT POINT PEN | | <i>fluconazole in sodium chloride</i> | | <i>gavilyte-g</i> | 86 |
| NEEDLE | 80 | | 46 | <i>gavilyte-n with flavor pack</i> | 86 |
| <i>exemestane</i> | 26 | <i>flucytosine</i> | 46 | GAVRETO | 26 |
| EXKIVITY..... | 26 | <i>fludrocortisone acetate</i> | 88 | <i>gefitinib</i> | 26 |
| EXTENCILLINE | 21 | <i>flunisolide</i> | 83 | <i>gemfibrozil</i> | 68 |
| EYSUVIS | 83 | <i>fluocinolone acetonide</i> | 79, 83 | <i>generlac</i> | 85 |
| <i>ezetimibe</i> | 68 | <i>fluocinonide</i> | 79 | <i>gengraf</i> | 92 |
| <i>ezetimibe-simvastatin</i> | 68 | <i>fluorometholone</i> | 83 | GENTAK..... | 82 |
| F | | <i>fluorouracil</i> | 26, 77 | <i>gentamicin sulfate</i> | 18, 78, 82 |
| <i>falmina</i> | 73 | <i>fluoxetine hcl</i> | 40 | GENVOYA | 57 |
| <i>famciclovir</i> | 59 | <i>fluphenazine decanoate</i> | 52 | GILOTRIF | 26 |
| <i>famotidine</i> | 84 | <i>fluphenazine hcl</i> | 52 | <i>glatiramer acetate</i> | 70 |
| FANAPT | 52 | <i>flurbiprofen</i> | 15 | <i>glatopa</i> | 70 |
| FANAPT TITRATION PACK | | FLURBIPROFEN | 15 | GLEOSTINE | 26 |
| | 52 | <i>flurbiprofen sodium</i> | 84 | <i>glimepiride</i> | 45 |
| FARXIGA | 42 | FLUTAMIDE..... | 26 | <i>glipizide</i> | 45 |
| FASENRA..... | 104 | <i>fluticasone propionate</i> | 79, 84 | <i>glipizide er</i> | 45 |
| FASENRA PEN | 104 | <i>fluticasone propionate hfa</i> | 102 | <i>glipizide-metformin hcl</i> | 45 |
| <i>febuxostat</i> | 47 | <i>fluticasone-salmeterol</i> | 102 | | |

| | | | |
|--|---|--|---------|
| GLOBAL ALCOHOL PREP | HUMIRA-PED \geq 40KG UC | IMPAVIDO | 50 |
| EASE..... | STARTER | <i>incassia</i> | 73 |
| <i>glyburide</i> | HUMIRA-PS/UV/ADOL HS | INCRELEX | 89 |
| <i>glyburide micronized</i> | STARTER | <i>indapamide</i> | 67 |
| <i>glyburide-metformin</i> | HUMIRA-PSORIASIS/UVEIT | <i>indomethacin</i> | 16 |
| <i>glycopyrrolate</i> | STARTER | INFANRIX..... | 96 |
| <i>glydo</i> | HUMULIN R U-500 | <i>infliximab</i> | 93 |
| GLYXAMBI | (CONCENTRATED) | INGREZZA | 70, 71 |
| <i>griseofulvin microsize</i> | HUMULIN R U-500 | INLYTA | 27 |
| <i>griseofulvin ultramicrosize</i> | KWIKPEN..... | INPEN 100-BLUE-LILLY- | |
| <i>guanfacine hcl</i> | <i>hydralazine hcl</i> | HUMALOG..... | 80 |
| <i>guanfacine hcl er</i> | <i>hydrochlorothiazide</i> | INPEN 100-BLUE- | |
| GVOKE HYPOPEN 2-PACK | <i>hydrocodone-acetaminophen</i> . | NOVOLOG-FIASP | 80 |
| GVOKE KIT | <i>hydrocortisone</i> | INQOVI..... | 27 |
| GVOKE PFS | 79, 88, 98 | INREBIC | 27 |
| H | <i>hydrocortisone (perianal)</i> | <i>insulin asp prot & asp flexpen</i> | 44 |
| HAEGARDA | <i>hydrocortisone valerate</i> | INSULIN ASPART | 44 |
| <i>hailey 24 fe</i> | <i>hydrocortisone-acetic acid</i> | INSULIN ASPART FLEXPEN | |
| <i>hailey fe 1.5/30</i> | <i>hydromorphone hcl</i> | | 44 |
| <i>hailey fe 1/20</i> | <i>hydroxychloroquine sulfate</i> | INSULIN ASPART PENFILL | |
| <i>halobetasol propionate</i> | <i>hydroxyurea</i> | | 44 |
| <i>haloette</i> | <i>hydroxyzine hcl</i> | <i>insulin aspart prot & aspart</i> .. | 44 |
| <i>haloperidol</i> | <i>hydroxyzine pamoate</i> | INTELENCE | 57 |
| <i>haloperidol decanoate</i> | I | INTRON A | 59 |
| <i>haloperidol lactate</i> | <i>ibandronate sodium</i> | <i>introvale</i> | 73 |
| HARVONI | IBRANCE | INVEGA HAFYERA..... | 53 |
| HAVRIX | <i>ibu</i> | INVEGA SUSTENNA..... | 53 |
| <i>heather</i> | <i>ibuprofen</i> | INVEGA TRINZA | 53 |
| <i>heparin sodium (porcine)</i> | <i>icatibant acetate</i> | INVELTYS..... | 84 |
| HEPLISAV-B..... | <i>iclevia</i> | IPOL | 96 |
| HERCEPTIN HYLECTA | ICLUSIG | <i>ipratropium bromide</i> | 82, 103 |
| HERZUMA | <i>icosapent ethyl</i> | <i>ipratropium-albuterol</i> | 103 |
| HIBERIX..... | IDHIFA | <i>irbesartan</i> | 63 |
| HUMIRA (2 PEN) | <i>ifosfamide</i> | <i>irbesartan-hydrochlorothiazide</i> | |
| HUMIRA (2 SYRINGE)..... | ILEVRO | | 63 |
| HUMIRA-CD/UC/HS | <i>imatinib mesylate</i> | ISENTRESS | 57 |
| STARTER | IMBRUVICA | ISENTRESS HD | 57 |
| HUMIRA-PED<40KG | IMDELLTRA | <i>isibloom</i> | 74 |
| CROHNS STARTER..... | <i>imipenem-cilastatin</i> | <i>isoniazid</i> | 48 |
| HUMIRA-PED \geq 40KG | <i>imipramine hcl</i> | <i>isosorbide dinitrate</i> | 69 |
| CROHNS START | <i>imiquimod</i> | <i>isosorbide mononitrate</i> | 69 |
| | IMJUDO | <i>isosorbide mononitrate er</i> | 69 |
| | IMOVAX RABIES | | |

| | | | | | |
|------------------------------------|--------|------------------------------------|-----|---|-----|
| ITOVEBI..... | 27 | KINRIX..... | 96 | LAZCLUZE | 28 |
| <i>itraconazole</i> | 46 | <i>kionex</i> | 85 | <i>leflunomide</i> | 93 |
| <i>ivabradine hcl</i> | 66 | KISQALI (200 MG DOSE) ... | 27 | <i>lenalidomide</i> | 28 |
| <i>ivermectin</i> | 50 | KISQALI (400 MG DOSE) ... | 28 | LENTOCILIN | 21 |
| IWILFIN..... | 27 | KISQALI (600 MG DOSE) ... | 28 | LENVIMA (10 MG DAILY | |
| IXCHIQ..... | 96 | KISQALI FEMARA (200 MG | | DOSE) | 28 |
| IXIARO..... | 96 | DOSE) | 28 | LENVIMA (12 MG DAILY | |
| J | | KISQALI FEMARA (400 MG | | DOSE) | 28 |
| JAKAFI | 27 | DOSE) | 28 | LENVIMA (14 MG DAILY | |
| <i>jantoven</i> | 60 | KISQALI FEMARA (600 MG | | DOSE) | 28 |
| JANUMET | 42 | DOSE) | 28 | LENVIMA (18 MG DAILY | |
| JANUMET XR..... | 42 | KLISYRI | 77 | DOSE) | 28 |
| JANUVIA..... | 42 | <i>klor-con m10</i> | 101 | LENVIMA (20 MG DAILY | |
| JARDIANCE..... | 42 | <i>klor-con m15</i> | 101 | DOSE) | 28 |
| <i>javygtor</i> | 81 | <i>klor-con m20</i> | 101 | LENVIMA (24 MG DAILY | |
| JAYPIRCA..... | 27 | KLOXXADO | 17 | DOSE) | 28 |
| JEMPERLI | 27 | KOSELUGO | 28 | LENVIMA (4 MG DAILY | |
| <i>jencycla</i> | 74 | KRAZATI | 28 | DOSE) | 28 |
| JENTADUETO | 42 | <i>kurvelo</i> | 74 | LENVIMA (8 MG DAILY | |
| JENTADUETO XR..... | 42 | KYLEENA | 74 | DOSE) | 28 |
| <i>jolessa</i> | 74 | KYNMOBI..... | 50 | <i>lessina</i> | 74 |
| <i>juleber</i> | 74 | KYNMOBI TITRATION KIT | | <i>letrozole</i> | 28 |
| JULUCA..... | 57 | | 50 | <i>leucovorin calcium</i> | 99 |
| <i>junel 1.5/30</i> | 74 | L | | LEUKERAN..... | 28 |
| <i>junel 1/20</i> | 74 | <i>labetalol hcl</i> | 65 | <i>leuprolide acetate</i> | 29 |
| <i>junel fe 1.5/30</i> | 74 | <i>lacosamide</i> | 37 | LEUPROLIDE ACETATE (3 | |
| <i>junel fe 1/20</i> | 74 | <i>lactulose</i> | 85 | MONTH) | 29 |
| <i>junel fe 24</i> | 74 | <i>lamivudine</i> | 57 | <i>levetiracetam</i> | 37 |
| JYLAMVO..... | 27 | <i>lamivudine-zidovudine</i> | 57 | <i>levetiracetam er</i> | 37 |
| JYNNEOS | 96 | <i>lamotrigine</i> | 37 | <i>levobunolol hcl</i> | 100 |
| K | | LANREOTIDE ACETATE ... | 89 | <i>levocetirizine dihydrochloride</i> | 47 |
| KALYDECO | 104 | <i>lansoprazole</i> | 84 | <i>levofloxacin</i> | 22 |
| <i>kariva</i> | 74 | LANTUS | 44 | <i>levofloxacin in d5w</i> | 22 |
| <i>kelnor 1/35</i> | 74 | LANTUS SOLOSTAR..... | 44 | <i>levonest</i> | 74 |
| <i>kelnor 1/50</i> | 74 | <i>lapatinib ditosylate</i> | 28 | <i>levonorgest-eth estrad 91-day</i> | 74 |
| KERENDIA | 69 | <i>larin 1.5/30</i> | 74 | <i>levonorgest-eth estradiol-iron</i> | 74 |
| KESIMPTA | 71 | <i>larin 1/20</i> | 74 | <i>levonorgestrel-ethinyl estrad</i> .. | 74 |
| <i>ketoconazole</i> | 46 | <i>larin 24 fe</i> | 74 | <i>levonorg-eth estrad triphasic</i> | 74 |
| <i>ketorolac tromethamine</i> | 16, 84 | <i>larin fe 1.5/30</i> | 74 | <i>levora 0.15/30 (28)</i> | 74 |
| KEYTRUDA..... | 27 | <i>larin fe 1/20</i> | 74 | <i>levothyroxine sodium</i> | 90 |
| KIMMTRAK..... | 27 | <i>larissia</i> | 74 | LEXIVA | 57 |
| KINERET..... | 93 | <i>latanoprost</i> | 100 | <i>l-glutamine</i> | 99 |

| | | | | | |
|---------------------------------------|--------|--------------------------------|--------|--|------------|
| LIBERVANT | 37 | LUPRON DEPOT (3-MONTH) | 29, 89 | <i>medroxyprogesterone acetate</i> | 90 |
| <i>lidocaine</i> | 16 | LUPRON DEPOT (4-MONTH) | 29 | <i>mefloquine hcl</i> | 50 |
| <i>lidocaine hcl urethral/mucosal</i> | 16 | LUPRON DEPOT (6-MONTH) | 29 | <i>megestrol acetate</i> | 29, 90 |
| | 16 | LUPRON DEPOT-PED (3- | 89 | MEKINIST | 29 |
| <i>lidocaine viscous hcl</i> | 16 | MONTH) | 89 | MEKTOVI..... | 29 |
| <i>lidocaine-prilocaine</i> | 16 | LUPRON DEPOT-PED (6- | 89 | <i>meloxicam</i> | 16 |
| <i>lidocan</i> | 16 | MONTH) | 89 | <i>memantine hcl</i> | 39 |
| LILETTA (52 MG) | 74 | <i>lurasidone hcl</i> | 53 | <i>memantine hcl er</i> | 39 |
| <i>lillow</i> | 74 | <i>lutera</i> | 74 | MENACTRA..... | 96 |
| <i>linezolid</i> | 18, 19 | LYBALVI | 53 | MENQUADFI | 96 |
| LINZESS..... | 85 | <i>lyleq</i> | 74 | MENVEO | 96 |
| <i>liothyronine sodium</i> | 90 | LYNPARZA..... | 29 | <i>mercaptopurine</i> | 30 |
| <i>lisinopril</i> | 64 | LYSODREN..... | 29 | <i>meropenem</i> | 21 |
| <i>lisinopril-hydrochlorothiazide</i> | 64 | LYTGOBI (12 MG DAILY | 29 | <i>mesalamine</i> | 98 |
| <i>lithium</i> | 71 | DOSE) | 29 | <i>mesalamine er</i> | 98 |
| <i>lithium carbonate</i> | 71 | LYTGOBI (16 MG DAILY | 29 | MESNEX..... | 99 |
| LITHIUM CARBONATE..... | 71 | DOSE) | 29 | <i>metformin hcl</i> | 42 |
| <i>lithium carbonate er</i> | 71 | LYTGOBI (20 MG DAILY | 29 | <i>metformin hcl er</i> | 42 |
| LIVTENCITY | 58 | DOSE) | 29 | <i>methadone hcl</i> | 14 |
| LOKELMA | 85 | <i>lyza</i> | 75 | <i>methazolamide</i> | 100 |
| LONSURF..... | 29 | M | | <i>methenamine hippurate</i> | 19 |
| <i>loperamide hcl</i> | 85 | <i>magnesium sulfate</i> | 101 | <i>methimazole</i> | 90 |
| <i>lopinavir-ritonavir</i> | 57 | <i>malathion</i> | 80 | <i>methocarbamol</i> | 105 |
| LOQTORZI..... | 29 | <i>maraviroc</i> | 57 | <i>methotrexate sodium</i> | 30 |
| <i>lorazepam</i> | 17, 18 | MARGENZA | 29 | METHOTREXATE SODIUM | |
| <i>lorazepam intensol</i> | 17 | <i>marlissa</i> | 75 | | 30 |
| LORBRENA | 29 | MARPLAN | 41 | <i>methotrexate sodium (pf)</i> | 30 |
| <i>losartan potassium</i> | 63 | MATULANE..... | 29 | <i>methoxsalen rapid</i> | 77 |
| <i>losartan potassium-hetz</i> | 63 | MAVENCLAD (10 TABS).... | 71 | <i>methsuximide</i> | 37 |
| LOTEMAX | 84 | MAVENCLAD (4 TABS)..... | 71 | <i>methylphenidate hcl</i> | 71 |
| LOTEMAX SM..... | 84 | MAVENCLAD (5 TABS)..... | 71 | <i>methylprednisolone</i> | 88 |
| <i>loteprednol etabonate</i> | 84 | MAVENCLAD (6 TABS)..... | 71 | <i>methylprednisolone acetate</i> | 88 |
| <i>lovastatin</i> | 68 | MAVENCLAD (7 TABS)..... | 71 | <i>metoclopramide hcl</i> | 85 |
| <i>low-ogestrel</i> | 74 | MAVENCLAD (8 TABS)..... | 71 | <i>metolazone</i> | 67 |
| <i>loxapine succinate</i> | 53 | MAVENCLAD (9 TABS)..... | 71 | <i>metoprolol succinate er</i> | 65 |
| <i>lubiprostone</i> | 85 | MAYZENT | 71 | <i>metoprolol tartrate</i> | 65 |
| LUMAKRAS | 29 | MAYZENT STARTER PACK | 71 | <i>metronidazole</i> | 19, 47, 78 |
| LUMIGAN..... | 100 | | 71 | <i>metryrosine</i> | 66 |
| LUNSUMIO..... | 29 | <i>meclizine hcl</i> | 49 | <i>micafungin sodium</i> | 46 |
| LUPRON DEPOT (1-MONTH) | 29, 89 | | | MICONAZOLE 3..... | 46 |
| | 29, 89 | | | <i>microgestin 1.5/30</i> | 75 |
| | | | | <i>microgestin 1/20</i> | 75 |

| | | | | | |
|--|--------|---|--------|---|--------|
| <i>microgestin 24 fe</i> | 75 | <i>nafcellin sodium</i> | 22 | <i>nitrofurantoin macrocrystal</i> ... | 19 |
| <i>microgestin fe 1.5/30</i> | 75 | <i>naloxone hcl</i> | 17 | <i>nitrofurantoin monohyd macro</i> | 19 |
| <i>microgestin fe 1/20</i> | 75 | <i>naltrexone hcl</i> | 17 | | 19 |
| <i>midodrine hcl</i> | 62 | <i>naproxen</i> | 16 | <i>nitroglycerin</i> | 69, 99 |
| <i>mifepristone</i> | 42 | <i>naratriptan hcl</i> | 48 | NIVESTYM | 61 |
| <i>mili</i> | 75 | NATACYN | 82 | NORDITROPIN FLEXPRO .. | 89 |
| <i>mimvey</i> | 88 | <i>nateglinide</i> | 42 | <i>norelgestromin-eth estradiol</i> .. | 75 |
| <i>minitran</i> | 69 | NATPARA | 98 | <i>norethin ace-eth estrad-fe</i> | 75 |
| <i>minocycline hcl</i> | 23 | NAYZILAM..... | 37 | <i>norethindrone</i> | 75 |
| <i>minoxidil</i> | 69 | <i>nebivolol hcl</i> | 65 | <i>norethindrone acetate</i> | 90 |
| MIPLYFFA | 81 | <i>nefazodone hcl</i> | 41 | <i>norethindron-ethinyl estrad-fe</i> | 75 |
| MIRENA (52 MG) | 75 | NEFAZODONE HCL | 41 | <i>norgestimate-eth estradiol</i> | 75 |
| <i>mirtazapine</i> | 41 | <i>neomycin sulfate</i> | 18 | <i>norgestim-eth estrad triphasic</i> | 75 |
| <i>misoprostol</i> | 84 | <i>neomycin-bacitracin zn-polymyx</i> | 82 | <i>norlyda</i> | 75 |
| <i>mitoxantrone hcl</i> | 30 | | 82 | <i>norlyroc</i> | 75 |
| M-M-R II..... | 96 | <i>neomycin-polymyxin-dexameth</i> | 82 | <i>nortrel 1/35 (21)</i> | 75 |
| <i>modafinil</i> | 105 | | 82 | <i>nortrel 1/35 (28)</i> | 75 |
| <i>moexipril hcl</i> | 64 | <i>neomycin-polymyxin-gramicidin</i> | 82 | <i>nortrel 7/7/7</i> | 75 |
| <i>molindone hcl</i> | 54 | | 82 | <i>nortriptyline hcl</i> | 41 |
| <i>mometasone furoate</i> | 79, 84 | <i>neomycin-polymyxin-hc</i> | 82, 83 | NORVIR..... | 57 |
| <i>mono-linyah</i> | 75 | <i>neo-polycin</i> | 83 | NOVOLIN 70/30..... | 44 |
| <i>montelukast sodium</i> | 102 | <i>neo-polycin hc</i> | 83 | NOVOLIN 70/30 FLEXPEN .. | 44 |
| MORPHINE SULFATE | 15 | NERLYNX..... | 30 | NOVOLIN N..... | 44 |
| <i>morphine sulfate (concentrate)</i> | 14 | <i>neuac</i> | 78 | NOVOLIN N FLEXPEN | 44 |
| | 14 | NEULASTA ONPRO | 61 | NOVOLIN R | 44 |
| <i>morphine sulfate er</i> | 14 | <i>nevirapine</i> | 57 | NOVOLIN R FLEXPEN..... | 44 |
| MOUNJARO..... | 42 | <i>nevirapine er</i> | 57 | NUBEQA | 30 |
| MOVANTIK | 85 | NEXLETOL | 68 | NUCALA | 104 |
| <i>moxifloxacin hcl</i> | 22, 82 | NEXLIZET..... | 68 | NULOJIX | 93 |
| MOXIFLOXACIN HCL IN | | NEXPLANON..... | 75 | NUPLAZID | 54 |
| NACL | 22 | NIACIN | | NURTEC | 48 |
| MRESVIA | 96 | (ANTIHYPERLIPIDEMIC) | | <i>nyamyc</i> | 46 |
| MULTAQ..... | 64 | | 68 | <i>nylia 1/35</i> | 75 |
| <i>mupirocin</i> | 78 | <i>niacin er (antihyperlipidemic)</i> | 68 | <i>nylia 7/7/7</i> | 75 |
| MVASI..... | 30 | NIACOR..... | 68 | <i>nymyo</i> | 75 |
| <i>mycophenolate mofetil</i> | 93 | NICOTROL NS..... | 17 | <i>nystatin</i> | 46, 47 |
| <i>mycophenolate mofetil hcl</i> | 93 | <i>nifedipine er</i> | 67 | <i>nystatin-triamcinolone</i> | 47 |
| <i>mycophenolate sodium</i> | 93 | <i>nifedipine er osmotic release</i> .. | 67 | <i>nystop</i> | 47 |
| MYRBETRIQ | 86 | <i>nilutamide</i> | 30 | NYVEPRIA | 61 |
| N | | NINLARO | 30 | O | |
| <i>na sulfate-k sulfate-mg sulf</i> | 86 | <i>nitazoxanide</i> | 50 | OCREVUS | 71 |
| <i>nabumetone</i> | 16 | <i>nitisinone</i> | 81 | OCREVUS ZUNOVO..... | 72 |

| | | | | | |
|---|-----|---------------------------------------|--------|---|---------|
| <i>octreotide acetate</i> | 89 | OPDIVO | 30 | <i>pemetrexed disodium</i> | 31 |
| ODEFSEY | 57 | OPDUALAG | 30 | PEMETREXED DISODIUM | 31 |
| ODOMZO | 30 | OPSUMIT | 105 | <i>pemetrexed ditromethamine</i> ... | 31 |
| OFEV | 104 | ORENCIA | 93 | PEMRYDI RTU | 31 |
| <i>ofloxacin</i> | 83 | ORENCIA CLICKJECT | 93 | PENBRAYA | 96 |
| OGIVRI | 30 | ORFADIN | 81 | <i>penicillamine</i> | 87 |
| OGSIVEO | 30 | ORGOVYX | 89 | <i>penicillin g potassium</i> | 22 |
| OJEMDA | 30 | ORLISSA | 89 | <i>penicillin g procaine</i> | 22 |
| OJJAARA | 30 | ORKAMBI | 104 | <i>penicillin v potassium</i> | 22 |
| <i>olanzapine</i> | 54 | ORSERDU | 30 | PENTACEL | 96 |
| <i>olmesartan medoxomil</i> | 63 | <i>oseltamivir phosphate</i> | 58, 59 | <i>pentamidine isethionate</i> | 50 |
| <i>olmesartan medoxomil-hctz</i> | 63 | OTEZLA | 93 | <i>pentoxifylline er</i> | 62 |
| <i>olmesartan-amlodipine-hctz</i> | 63 | <i>oxandrolone</i> | 87 | <i>perindopril erbumine</i> | 64 |
| <i>olopatadine hcl</i> | 82 | <i>oxcarbazepine</i> | 37 | <i>periogard</i> | 77 |
| <i>omega-3-acid ethyl esters</i> | 68 | <i>oxybutynin chloride</i> | 86 | <i>permethrin</i> | 80 |
| <i>omeprazole</i> | 84 | <i>oxybutynin chloride er</i> | 86 | <i>perphenazine</i> | 54 |
| OMNIPOD 5 DEXG7G6 | | <i>oxycodone hcl</i> | 15 | <i>perphenazine-amitriptyline</i> | 41 |
| INTRO GEN 5 | 80 | <i>oxycodone-acetaminophen</i> | 15 | PERSERIS | 54 |
| OMNIPOD 5 DEXG7G6 PODS | | OZEMPIC (0.25 OR 0.5 | | <i>phenelzine sulfate</i> | 41 |
| GEN 5 | 80 | MG/DOSE) | 43 | <i>phenobarbital</i> | 37 |
| OMNIPOD 5 G7 INTRO (GEN | | OZEMPIC (1 MG/DOSE) | 43 | <i>phenytoin</i> | 37 |
| 5) | 80 | OZEMPIC (2 MG/DOSE) | 43 | <i>phenytoin sodium</i> | 37 |
| OMNIPOD 5 G7 PODS (GEN | | P | | <i>phenytoin sodium extended</i> | 37 |
| 5) | 80 | <i>pacerone</i> | 64 | PIFELTRO | 57 |
| OMNIPOD 5 LIBRE2 PLUS | | PACLITAXEL PROTEIN- | | <i>pilocarpine hcl</i> | 77, 100 |
| G6 | 80 | BOUND PART | 31 | <i>pimecrolimus</i> | 79 |
| OMNIPOD 5 LIBRE2 PLUS | | <i>paliperidone er</i> | 54 | <i>pimozide</i> | 54 |
| G6 PODS | 80 | PANRETIN | 77 | <i>pimtreea</i> | 75 |
| OMNIPOD CLASSIC PDM | | <i>pantoprazole sodium</i> | 84, 85 | <i>pioglitazone hcl</i> | 43 |
| (GEN 3) | 80 | <i>paricalcitol</i> | 98 | <i>pioglitazone hcl-metformin hcl</i> | |
| OMNIPOD CLASSIC PODS | | <i>paromomycin sulfate</i> | 50 | | 43 |
| (GEN 3) | 80 | <i>paroxetine hcl</i> | 41 | <i>piperacillin sod-tazobactam so</i> | |
| OMNIPOD DASH INTRO | | <i>paroxetine hcl er</i> | 41 | | 22 |
| (GEN 4) | 80 | PAXLOVID (150/100) | 59 | PIQRAY (200 MG DAILY | |
| OMNIPOD DASH PDM (GEN | | PAXLOVID (300/100) | 59 | DOSE) | 31 |
| 4) | 81 | <i>pazopanib hcl</i> | 31 | PIQRAY (250 MG DAILY | |
| OMNIPOD DASH PODS (GEN | | PEDIARIX | 96 | DOSE) | 31 |
| 4) | 81 | PEDVAX HIB | 96 | PIQRAY (300 MG DAILY | |
| <i>ondansetron</i> | 49 | <i>peg 3350-kcl-na bicarb-nacl</i> .. | 86 | DOSE) | 31 |
| <i>ondansetron hcl</i> | 49 | <i>peg-3350/electrolytes</i> | 86 | <i>pirfenidone</i> | 104 |
| ONTRUZANT | 30 | PEGASYS | 59 | <i>pirmella 1/35</i> | 75 |
| ONUREG | 30 | PEMAZYRE | 31 | <i>pirmella 7/7/7</i> | 75 |

| | | | | | |
|--|-----|---|--------|---------------------------------------|-----|
| <i>pitavastatin calcium</i> | 68 | <i>probenecid</i> | 47 | <i>raloxifene hcl</i> | 88 |
| PLEGRIDY | 72 | PROCALAMINE | 62 | <i>ramipril</i> | 64 |
| PLEGRIDY STARTER PACK | 72 | <i>prochlorperazine</i> | 49 | <i>ranolazine er</i> | 66 |
| <i>podofilox</i> | 78 | <i>prochlorperazine edisylate</i> | 49 | <i>rasagiline mesylate</i> | 51 |
| <i>polycin</i> | 83 | <i>prochlorperazine maleate</i> | 49 | RASUVO | 93 |
| <i>polymyxin b-trimethoprim</i> | 83 | <i>procto-med hc</i> | 79 | RAYALDEE | 98 |
| POMALYST | 31 | <i>procto-pak</i> | 79 | <i>reclipsen</i> | 76 |
| <i>portia-28</i> | 75 | <i>proctosol hc</i> | 79 | RECOMBIVAX HB | 97 |
| <i>posaconazole</i> | 47 | <i>proctozone-hc</i> | 79 | RELENZA DISKHALER | 59 |
| <i>potassium chloride</i> | 101 | <i>progesterone</i> | 90 | RELI-ON INSULIN SYRINGE | 81 |
| <i>potassium chloride crys er</i> ... | 101 | PROGRAF | 93 | <i>repaglinide</i> | 43 |
| <i>potassium chloride er</i> | 101 | PROLIA | 98 | REPATHA | 68 |
| <i>potassium citrate er</i> | 101 | PROMACTA | 61 | REPATHA PUSHTRONEX SYSTEM | 68 |
| <i>pramipexole dihydrochloride</i> . | 51 | <i>promethazine hcl</i> | 49 | REPATHA SURECLICK | 69 |
| <i>prasugrel hcl</i> | 62 | <i>promethegan</i> | 49 | RETACRIT | 61 |
| <i>pravastatin sodium</i> | 68 | <i>propafenone hcl</i> | 64 | RETEVMO | 31 |
| <i>praziquantel</i> | 50 | <i>propafenone hcl er</i> | 64 | RETROVIR | 57 |
| <i>prazosin hcl</i> | 62 | <i>propranolol hcl</i> | 65 | REVUFORJ | 31 |
| <i>prednisolone</i> | 88 | <i>propranolol hcl er</i> | 65 | REXULTI | 54 |
| <i>prednisolone acetate</i> | 84 | <i>propylthiouracil</i> | 90 | REYATAZ | 57 |
| <i>prednisolone sodium phosphate</i> | 88 | PROQUAD | 96 | REZLIDHIA | 31 |
| <i>prednisone</i> | 88 | <i>protriptyline hcl</i> | 41 | REZUROCK | 93 |
| PREFERRED PLUS INSULIN SYRINGE | 81 | PULMOZYME | 81 | RHOPRESSA | 100 |
| <i>pregabalin</i> | 37 | PURIXAN | 31 | RIABNI | 31 |
| PREHEVBRIO | 96 | <i>pyrazinamide</i> | 48 | <i>ribavirin</i> | 60 |
| PREMARIN | 88 | <i>pyridostigmine bromide</i> | 99 | <i>rifabutin</i> | 48 |
| PREMPHASE | 88 | Q | | <i>rifampin</i> | 48 |
| PREMPRO | 88 | QC ALCOHOL | 81 | <i>riluzole</i> | 72 |
| PRENATAL | 106 | QINLOCK | 31 | RINVOQ | 93 |
| <i>prevalite</i> | 68 | QUADRACEL | 96, 97 | RINVOQ LQ | 93 |
| <i>previfem</i> | 75 | <i>quetiapine fumarate</i> | 54 | <i>risperidone</i> | 54 |
| PREVYMIS | 59 | <i>quetiapine fumarate er</i> | 54 | <i>risperidone microspheres er</i> .. | 54 |
| PREZCOBIX | 57 | <i>quinapril hcl</i> | 64 | <i>ritonavir</i> | 57 |
| PREZISTA | 57 | <i>quinapril-hydrochlorothiazide</i> | 64 | RITUXAN HYCELA | 32 |
| PRIFTIN | 48 | <i>quinidine sulfate</i> | 64 | <i>rivastigmine</i> | 39 |
| PRIMAQUINE PHOSPHATE | 50 | <i>quinine sulfate</i> | 50 | <i>rivastigmine tartrate</i> | 39 |
| <i>primidone</i> | 37 | QULIPTA | 48 | <i>rizatriptan benzoate</i> | 48 |
| PRIORIX | 96 | R | | ROCKLATAN | 100 |
| | | <i>ra isopropyl alcohol wipes</i> | 81 | <i>roflumilast</i> | 104 |
| | | RABAVERT | 97 | <i>ropinirole hcl</i> | 51 |
| | | <i>rabeprazole sodium</i> | 85 | | |

| | | | | | |
|---------------------------------------|-----|---------------------------------------|-----|--|--------|
| <i>ropinirole hcl er</i> | 51 | SIRTURO | 49 | <i>sulfacetamide-prednisolone</i> | 83 |
| <i>rosadan</i> | 78 | SKYLA..... | 76 | <i>sulfadiazine</i> | 22 |
| <i>rosuvastatin calcium</i> | 69 | SKYRIZI | 94 | <i>sulfamethoxazole-trimethoprim</i> | |
| ROTARIX | 97 | SKYRIZI (150 MG DOSE).... | 94 | | 22 |
| ROTATEQ | 97 | SKYRIZI PEN..... | 94 | <i>sulfasalazine</i> | 98 |
| ROZLYTREK | 32 | <i>sodium chloride</i> | 101 | <i>sulindac</i> | 16 |
| RUBRACA..... | 32 | <i>sodium fluoride</i> | 77 | <i>sumatriptan</i> | 48 |
| <i>rufinamide</i> | 38 | SODIUM FLUORIDE 5000 | | <i>sumatriptan succinate</i> | 48 |
| RUKOBIA..... | 58 | SENSITIVE..... | 77 | <i>sumatriptan succinate refill</i> | 48 |
| RUXIENCE..... | 32 | <i>sodium oxybate</i> | 105 | <i>sunitinib malate</i> | 32 |
| RYBELSUS | 43 | <i>sodium polystyrene sulfonate</i> . | 85 | SUNLENCA..... | 58 |
| RYBREVANT | 32 | <i>solifenacin succinate</i> | 86 | SUTAB | 86 |
| RYDAPT | 32 | SOLQUA | 45 | SYMPAZAN | 38 |
| RYTELO | 32 | SOLTAMOX..... | 32 | SYMTUZA..... | 58 |
| S | | SOMATULINE DEPOT | 89 | SYNJARDY | 43 |
| SANTYL | 78 | SOMAVERT | 90 | SYNJARDY XR..... | 43 |
| <i>sapropterin dihydrochloride</i> .. | 81 | <i>sorafenib tosylate</i> | 32 | SYNRIBO..... | 32 |
| SAVELLA..... | 72 | <i>sorine</i> | 65 | T | |
| SAVELLA TITRATION PACK | | <i>sotalol hcl</i> | 65 | TABLOID..... | 32 |
| | 72 | <i>sotalol hcl (af)</i> | 65 | TABRECTA | 32 |
| SCEMBLIX..... | 32 | SPIRIVA RESPIMAT..... | 103 | <i>tacrolimus</i> | 80, 94 |
| <i>scopolamine</i> | 49 | <i>spironolactone</i> | 67 | <i>tadalafil</i> | 105 |
| SECUADO | 54 | <i>spironolactone-hctz</i> | 67 | TAFINLAR | 32 |
| <i>selegiline hcl</i> | 51 | SPRAVATO (56 MG DOSE) 41 | | <i>tafluprost (pf)</i> | 100 |
| <i>selenium sulfide</i> | 78 | SPRAVATO (84 MG DOSE) 41 | | TAGRISO..... | 32 |
| SELZENTRY | 58 | <i>sprintec 28</i> | 76 | TALVEY | 32 |
| SEMGLEE (YFGN)..... | 45 | SPRITAM..... | 38 | TALZENNA..... | 32 |
| SEREVENT DISKUS | 103 | SPRYCEL | 32 | <i>tamoxifen citrate</i> | 32 |
| SEROSTIM | 89 | <i>sps</i> | 85 | <i>tamsulosin hcl</i> | 87 |
| <i>sertraline hcl</i> | 41 | <i>sronyx</i> | 76 | <i>tarina 24 fe</i> | 76 |
| <i>setlakin</i> | 76 | <i>ssd</i> | 78 | <i>tarina fe 1/20 eq</i> | 76 |
| SEZABY | 38 | <i>stavudine</i> | 58 | TASIGNA..... | 32, 33 |
| <i>sf 5000 plus</i> | 77 | STELARA | 94 | TAVNEOS | 94 |
| <i>sharobel</i> | 76 | STIOLTO RESPIMAT | 103 | <i>tazarotene</i> | 80 |
| SHINGRIX..... | 97 | STIVARGA..... | 32 | <i>tazicef</i> | 20 |
| SIGNIFOR | 89 | STRENSIQ..... | 81 | TAZICEF..... | 20 |
| <i>sildenafil citrate</i> | 105 | <i>streptomycin sulfate</i> | 18 | <i>taztia xt</i> | 65 |
| <i>silver sulfadiazine</i> | 78 | STRIBILD | 58 | TAZVERIK | 33 |
| SIMBRINZA | 100 | STRIVERDI RESPIMAT ... | 103 | TDVAX | 97 |
| <i>simliya</i> | 76 | <i>subvenite</i> | 38 | TECVAYLI | 33 |
| <i>simvastatin</i> | 69 | <i>sucrafate</i> | 85 | TEFLARO | 20 |
| <i>sirolimus</i> | 93 | <i>sulfacetamide sodium</i> | 83 | <i>telmisartan</i> | 63 |

| | | | | | |
|---|---------|--|------------|-----------------------------------|-----|
| <i>telmisartan-hctz</i> | 63 | <i>tolterodine tartrate er</i> | 86 | <i>trimethoprim</i> | 19 |
| <i>temazepam</i> | 18 | <i>topiramate</i> | 38 | <i>tri-mili</i> | 76 |
| TEMIXYS..... | 58 | <i>toposar</i> | 33 | <i>trimipramine maleate</i> | 41 |
| TENIVAC..... | 97 | <i>toremifene citrate</i> | 33 | TRINTELLIX..... | 41 |
| <i>tenofovir disoproxil fumarate</i> | 58 | <i>torpenz</i> | 33 | <i>tri-nymyo</i> | 76 |
| TEPMETKO..... | 33 | <i>torse mide</i> | 67 | <i>tri-previfem</i> | 76 |
| <i>terazosin hcl</i> | 87 | TOUJEO MAX SOLOSTAR..... | 45 | <i>tri-sprintec</i> | 76 |
| <i>terbinafine hcl</i> | 47 | TOUJEO SOLOSTAR..... | 45 | TRIUMEQ..... | 58 |
| <i>terconazole</i> | 47 | TRADJENTA..... | 43 | TRIUMEQ PD..... | 58 |
| TERIPARATIDE..... | 98 | <i>tramadol hcl</i> | 15 | <i>trivora (28)</i> | 76 |
| <i>testosterone</i> | 87 | <i>tramadol-acetaminophen</i> | 15 | <i>tri-vylibra</i> | 76 |
| <i>testosterone cypionate</i> | 87 | <i>trandolapril</i> | 64 | <i>tri-vylibra lo</i> | 76 |
| <i>testosterone enanthate</i> | 87 | <i>trandolapril-verapamil hcl er</i> | 64 | TRIZIVIR..... | 58 |
| <i>tetrabenazine</i> | 72 | <i>tranexamic acid</i> | 61 | TROGARZO..... | 58 |
| <i>tetracycline hcl</i> | 23 | <i>tranylcypramine sulfate</i> | 41 | <i>tropium chloride</i> | 86 |
| TEVIMBRA..... | 33 | <i>travoprost (bak free)</i> | 100 | <i>tropium chloride er</i> | 86 |
| THALOMID..... | 99 | TRAZIMERA..... | 33 | TRULICITY..... | 43 |
| <i>theophylline</i> | 103 | <i>trazodone hcl</i> | 41 | TRUMENBA..... | 97 |
| <i>theophylline er</i> | 103 | TRECTOR..... | 49 | TRUQAP..... | 33 |
| <i>thioridazine hcl</i> | 55 | TRELEGY ELLIPTA..... | 103 | TRUSELTIQ (100MG DAILY DOSE)..... | 33 |
| <i>thiothixene</i> | 55 | TRELSTAR MIXJECT..... | 33 | TRUSELTIQ (125MG DAILY DOSE)..... | 33 |
| <i>tiadylt er</i> | 66 | TREMFYA..... | 94 | TRUSELTIQ (50MG DAILY DOSE)..... | 33 |
| <i>tiagabine hcl</i> | 38 | TRESIBA..... | 45 | TRUSELTIQ (75MG DAILY DOSE)..... | 33 |
| TIBSOVO..... | 33 | TRESIBA FLEXTOUCH..... | 45 | TRUXIMA..... | 33 |
| TICE BCG..... | 33 | <i>tretinoin</i> | 33, 80 | TUKYSA..... | 33 |
| TICOVAC..... | 97 | <i>tri femynor</i> | 76 | TURALIO..... | 33 |
| TIGECYCLINE..... | 23 | <i>triamcinolone acetonide</i> .. | 77, 80, 88 | <i>turqoz</i> | 76 |
| <i>tilia fe</i> | 76 | <i>triamterene-hctz</i> | 67 | TWINRIX..... | 97 |
| <i>timolol maleate</i> | 65, 100 | <i>triazolam</i> | 18 | TYBOST..... | 99 |
| <i>tinidazole</i> | 50 | <i>trientine hcl</i> | 87 | TYMLOS..... | 99 |
| <i>tiotropium bromide monohydrate</i> | 103 | <i>tri-estarylla</i> | 76 | TYPHIM VI..... | 97 |
| TIVDAK..... | 33 | <i>trifluoperazine hcl</i> | 55 | U | |
| TIVICAY..... | 58 | <i>trifluridine</i> | 83 | UBRELVY..... | 48 |
| TIVICAY PD..... | 58 | <i>trihexyphenidyl hcl</i> | 51 | UPTRAVI..... | 105 |
| <i>tizanidine hcl</i> | 105 | TRIJARDY XR..... | 43 | UPTRAVI TITRATION..... | 106 |
| TOBI PODHALER..... | 18 | <i>tri-legest fe</i> | 76 | <i>ursodiol</i> | 85 |
| <i>tobramycin</i> | 18, 83 | <i>tri-linyah</i> | 76 | URSODIOL..... | 85 |
| <i>tobramycin pak</i> | 18 | <i>tri-lo-estarylla</i> | 76 | UZEDY..... | 55 |
| <i>tobramycin sulfate</i> | 18 | <i>tri-lo-marzia</i> | 76 | | |
| <i>tobramycin-dexamethasone</i> | 83 | <i>tri-lo-mili</i> | 76 | | |
| <i>tolterodine tartrate</i> | 86 | <i>tri-lo-sprintec</i> | 76 | | |

| | | |
|---|---------|--|
| V | | |
| <i>valacyclovir hcl</i> | 60 | |
| VALCHLOR | 78 | |
| <i>valganciclovir hcl</i> | 60 | |
| <i>valproate sodium</i> | 38 | |
| <i>valproic acid</i> | 38 | |
| <i>valsartan</i> | 63 | |
| <i>valsartan-hydrochlorothiazide</i> | 63 | |
| VALTOCO 10 MG DOSE..... | 38 | |
| VALTOCO 15 MG DOSE..... | 38 | |
| VALTOCO 20 MG DOSE..... | 38 | |
| VALTOCO 5 MG DOSE..... | 38 | |
| <i>vancomycin hcl</i> | 19 | |
| VANCOMYCIN HCL | 19 | |
| VANFLYTA | 33 | |
| VAQTA..... | 97 | |
| <i>varденаfil hcl</i> | 106 | |
| <i>varenicline tartrate</i> | 17 | |
| VARENICLINE TARTRATE17 | | |
| <i>varenicline tartrate (starter)</i> .. | 17 | |
| VARIVAX | 97 | |
| VAXCHORA | 97 | |
| VEGZELMA | 34 | |
| VELTASSA | 85 | |
| VEMLIDY | 58 | |
| VENCLEXTA..... | 34 | |
| VENCLEXTA STARTING PACK..... | 34 | |
| <i>venlafaxine hcl</i> | 41 | |
| <i>venlafaxine hcl er</i> | 41 | |
| VEOZAH | 99 | |
| <i>verapamil hcl</i> | 66 | |
| <i>verapamil hcl er</i> | 66 | |
| VERQUVO | 66 | |
| VERSACLOZ | 55 | |
| VERZENIO..... | 34 | |
| V-GO 20..... | 81 | |
| V-GO 30..... | 81 | |
| V-GO 40..... | 81 | |
| <i>vienna</i> | 76 | |
| <i>vigabatrin</i> | 38 | |
| <i>vigadrone</i> | 38 | |
| <i>vigpoder</i> | 38 | |
| <i>vilazodone hcl</i> | 42 | |
| <i>vinorelbine tartrate</i> | 34 | |
| <i>viorele</i> | 76 | |
| VIRACEPT | 58 | |
| VIREAD..... | 58 | |
| VITRAKVI..... | 34 | |
| VIZIMPRO..... | 34 | |
| VOCABRIA | 58 | |
| <i>volnea</i> | 76 | |
| VONJO..... | 34 | |
| VORANIGO..... | 34 | |
| <i>voriconazole</i> | 47 | |
| VOSEVI | 59 | |
| VOWST..... | 99 | |
| VRAYLAR..... | 55 | |
| VUMERITY | 72 | |
| VYALEV..... | 51 | |
| <i>vylibra</i> | 77 | |
| VYLOY | 34 | |
| VYZULTA | 101 | |
| W | | |
| <i>warfarin sodium</i> | 61 | |
| WELIREG | 34 | |
| WINREVAIR | 104 | |
| <i>wixela inhub</i> | 102 | |
| X | | |
| XALKORI..... | 34 | |
| XARELTO | 61 | |
| XARELTO STARTER PACK | 61 | |
| XATMEP..... | 34 | |
| XCOPRI | 38, 39 | |
| XCOPRI (250 MG DAILY DOSE) | 38 | |
| XCOPRI (350 MG DAILY DOSE) | 38 | |
| XDEMVY | 83 | |
| XELJANZ | 94 | |
| XELJANZ XR..... | 94 | |
| XERMELO..... | 85 | |
| XGEVA | 99 | |
| XIFAXAN | 19 | |
| XIGDUO XR..... | 43 | |
| XIIDRA | 84 | |
| XOLAIR..... | 104 | |
| XOSPATA..... | 34 | |
| XPOVIO (100 MG ONCE WEEKLY)..... | 34 | |
| XPOVIO (40 MG ONCE WEEKLY)..... | 34 | |
| XPOVIO (40 MG TWICE WEEKLY)..... | 34 | |
| XPOVIO (60 MG ONCE WEEKLY)..... | 34 | |
| XPOVIO (60 MG TWICE WEEKLY)..... | 35 | |
| XPOVIO (80 MG ONCE WEEKLY)..... | 35 | |
| XPOVIO (80 MG TWICE WEEKLY)..... | 35 | |
| XTANDI..... | 35 | |
| <i>xulane</i> | 77 | |
| XULTOPHY..... | 45 | |
| XYOSTED | 87 | |
| Y | | |
| YERVOY | 35 | |
| YF-VAX..... | 98 | |
| YONSA | 35 | |
| <i>yuvafem</i> | 88 | |
| Z | | |
| <i>zafemy</i> | 77 | |
| <i>zafirlukast</i> | 102 | |
| <i>zaleplon</i> | 105 | |
| ZEGALOGUE..... | 99, 100 | |
| ZEJULA | 35 | |
| ZELBORAF | 35 | |
| <i>zenatane</i> | 78 | |
| ZENPEP | 81 | |
| <i>zidovudine</i> | 58 | |
| ZIIHERA | 35 | |
| <i>ziprasidone hcl</i> | 55 | |
| <i>ziprasidone mesylate</i> | 55 | |

| | | | | | |
|-----------------------------------|-----|------------------------------|----|-----------------------|----|
| ZIRABEV..... | 35 | ZONISADE..... | 39 | ZYDELIG..... | 35 |
| ZIRGAN..... | 83 | <i>zonisamide</i> | 39 | ZYKADIA..... | 35 |
| ZOLADEX..... | 35 | <i>zovia 1/35 (28)</i> | 77 | ZYLET..... | 83 |
| ZOLINZA..... | 35 | ZTALMY..... | 39 | ZYNLONTA..... | 35 |
| <i>zolpidem tartrate</i> | 105 | ZTLIDO..... | 16 | ZYNYZ..... | 35 |
| <i>zolpidem tartrate er</i> | 105 | ZURZUVAE..... | 42 | ZYPREXA RELPREVV..... | 55 |

This formulary was updated on 10/23/2024. For more recent information or other questions, please contact Alterwood Advantage Member Service at 1-866-267-3144 (TTY users should call 711) 24 hours a day, 7 days a week, or visit www.AlterwoodAdvantage.com.



This formulary was updated on 10/23/2024. For more recent information or other questions, please contact Alterwood Advantage Member Services, at 1-866-267-3144 (TTY users should call 711), 24 hours a day, 7 days a week, or visit www.AlterwoodAdvantage.com.

Alterwood Advantage is an HMO and HMO-SNP with a Medicare contract and a State of Maryland Medicaid contract. Enrollment in Alterwood Advantage depends on contract renewal.

The Formulary may change at any time. You will receive notice when necessary.

Benefits, formulary, pharmacy network, provider network, premium and/or copay/coinsurance may change on January 1 of each year. Member premiums, copays, coinsurance, and deductibles may vary based on the level of Extra Help you receive. Please contact the plan for further details.

This information is available for free in other languages. Please call our Member Services number at 1-866-267-3144 or (TTY users should call 711), 24 hours a day, 7 days a week. Member Services also has free language interpreter services available for non-English speakers.

You must generally use network pharmacies to use your prescription drug benefit.